ESCSyncope Guidelines 2018 EHJonlineversion
ESCSyncope Guidelines 2018 EHJonlineversion
net/publication/323856711
CITATIONS READS
146 22,558
Some of the authors of this publication are also working on these related projects:
The effectiveness of thyme honey for the management of treatment-induced xerostomia and oral mucositis in head and neck cancer patients: RCT View project
All content following this page was uploaded by Artur Fedorowski on 20 March 2018.
* Corresponding authors: Michele Brignole, Department of Cardiology, Ospedali Del Tigullio, Via Don Bobbio 25, IT-16033 Lavagna, (GE) Italy. Tel: þ39 0185 329 567,
Fax: þ39 0185 306 506, Email: [email protected]; Angel Moya, Arrhythmia Unit, Hospital Vall d’Hebron, P Vall d’Hebron 119-129, ES-08035 Barcelona, Spain.
Tel: þ34 93 2746166, Fax: þ34 93 2746002, Email: [email protected].
ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers: listed in the Appendix.
1
Representing the European Academy of Neurology (EAN)
2
Representing the European Federation of Internal Medicine (EFIM)
3
Representing the European Society of Emergency Medicine (EuSEM)
ESC entities having participated in the development of this document:
Associations: European Heart Rhythm Association (EHRA)
Councils: Council on Cardiovascular Nursing and Allied Professions, Council for Cardiology Practice, Council on Cardiovascular Primary Care
Working Groups: Myocardial and Pericardial Diseases
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the
ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford
University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC ([email protected]).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available
at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recom-
mendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encour-
aged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or
therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and
accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do
the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent
public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the
health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
C The European Society of Cardiology 2018. All rights reserved. For permissions please email: [email protected]
V
Document Reviewers: Adam Torbicki (CPG Review Coordinator) (Poland), Javier Moreno (CPG Review
Coordinator) (Spain), Victor Aboyans (France), Stefan Agewall (Norway), Riccardo Asteggiano (Italy),
Jean-Jacques Blanc (France), Natan Bornstein1 (Israel), Serge Boveda (France), Héctor Bueno (Spain),
Haran Burri (Switzerland), Antonio Coca (Spain), Jean-Philippe Collet (France), Giorgio Costantino2
(Italy), Ernesto Dıaz-Infante (Spain), Victoria Delgado (The Netherlands), Faas Dolmans
(The Netherlands), Oliver Gaemperli (Switzerland), Jacek Gajek (Poland), Gerhard Hindricks (Germany),
Josef Kautzner (Czech Replublic), Juhani Knuuti (Finland), Piotr Kulakowski (Poland),
Ekaterini Lambrinou (Cyprus), Christophe Leclercq (France), Philippe Mabo (France), Carlos A. Morillo
(Canada), Massimo Francesco Piepoli (Italy), Marco Roffi (Switzerland), Win K. Shen (USA),
Iain A. Simpson (UK), Martin Stockburger (Germany), Peter Vanbrabant3 (Belgium),
Stephan Windecker (Switzerland), and Jose Luis Zamorano (Spain)
The disclosure forms of all experts involved in the development of these Guidelines are available on the
ESC website http://www.escardio.org/guidelines.
...................................................................................................................................................................................................
Keywords Guidelines • Syncope • Transient loss of consciousness • Vasovagal syncope • Reflex
syncope • Orthostatic hypotension • Cardiac syncope • Sudden cardiac death • Electrophysiological
study • Prolonged ECG monitoring • Tilt testing • Carotid sinus massage • Cardiac pacing • Implantable
cardioverter defibrillator • Syncope unit • Emergency department
..
Table of Contents .. 4.2.4.1 In-hospital monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
.. 4.2.4.2 Holter monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
..
1. Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 .. 4.2.4.3 Prospective external event recorders. . . . . . . . . . . . . . 23
2. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 .. 4.2.4.4 Smartphone applications . . . . . . . . . . . . . . . . . . . . . . . . . . 23
..
2.1 What is new in the 2018 version? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 .. 4.2.4.5 External loop recorders. . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3. Definitions, classification, and pathophysiology . . . . . . . . . . . . . . . . . . . . . . 7
.. 4.2.4.6 Remote (at home) telemetry . . . . . . . . . . . . . . . . . . . . . . 23
..
3.1 Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 .. 4.2.4.7 Implantable loop recorders . . . . . . . . . . . . . . . . . . . . . . . 23
3.2 Classification and pathophysiology of syncope and transient
.. 4.2.4.8 Diagnostic criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
..
loss of consciousness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 .. 4.2.5 Video recording in suspected syncope . . . . . . . . . . . . . . . . . . . . 25
3.2.1 Syncope. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
.. 4.2.5.1 In-hospital video recording . . . . . . . . . . . . . . . . . . . . . . . . 25
..
3.2.2 Non-syncopal forms of (real or apparent) transient .. 4.2.5.2 Home video recording . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
loss of consciousness. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
.. 4.2.6 Electrophysiological study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
..
4. Diagnostic evaluation and management according to .. 4.2.6.1 Asymptomatic sinus bradycardia – suspected
..
risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 .. sinus arrest causing syncope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4.1 Initial evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 .. 4.2.6.2 Syncope in bifascicular bundle branch block
..
4.1.1 Diagnosis of syncope. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 .. (impending high-degree atrioventricular block) . . . . . . . . . . . . 25
4.1.2 Management of syncope in the emergency department .. 4.2.6.3 Suspected tachycardia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
..
based on risk stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 .. 4.2.7 Endogenous adenosine and other biomarkers . . . . . . . . . . . . . 27
4.2 Diagnostic tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 .. 4.2.7.1 Adenosine (triphosphate) test and plasma
4.2.1 Carotid sinus massage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 ... concentration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
..
4.2.2 Orthostatic challenge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 .. 4.2.7.2 Cardiovascular biomarkers. . . . . . . . . . . . . . . . . . . . . . . . . 27
4.2.2.1 Active standing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 .. 4.2.7.3 Immunological biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . 27
..
4.2.2.2 Tilt testing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 .. 4.2.8 Echocardiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
4.2.3 Basic autonomic function tests. . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 .. 4.2.8.1 Exercise stress echocardiography . . . . . . . . . . . . . . . . . . 27
..
4.2.3.1 Valsalva manoeuvre. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 .. 4.2.9 Exercise stress testing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.2.3.2 Deep breathing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 .. 4.2.10 Coronary angiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
..
4.2.3.3 Other autonomic function tests . . . . . . . . . . . . . . . . . . . 21 .. 5. Treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
4.2.3.4 Twenty-four-hour ambulatory and home
.. 5.1 General principles of treatment of syncope. . . . . . . . . . . . . . . . . . . . . 28
..
blood pressure monitoring. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 .. 5.2 Treatment of reflex syncope. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
4.2.4 Electrocardiographic monitoring (non-invasive
.. 5.2.1 Education and lifestyle modifications . . . . . . . . . . . . . . . . . . . . . . 29
..
and invasive) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 .. 5.2.2 Discontinuation/reduction of hypotensive therapy . . . . . . . . 31
website and hosted on the EHJ website. The National Societies of the
.. is also the health professional’s responsibility to verify the rules and
..
ESC are encouraged to endorse, translate and implement all ESC .. regulations applicable to drugs and devices at the time of prescription.
Guidelines. Implementation programmes are needed because it has
..
..
been shown that the outcome of disease may be favourably influenced ..
..
by the thorough application of clinical recommendations.
... 2. Introduction
Surveys and registries are needed to verify that real-life daily prac- ..
tice is in keeping with what is recommended in the guidelines, thus .. The first ESC Guidelines for the management of syncope were pub-
..
completing the loop between clinical research, writing of guidelines, .. lished in 2001, with subsequent versions in 2004 and 2009. In March
disseminating them and implementing them into clinical practice. .. 2015, the ESC CPG considered that there were enough new data to
..
Health professionals are encouraged to take the ESC Guidelines fully .. justify the production of new Guidelines.
into account when exercising their clinical judgment, as well as in the .. The most important aspect characterizing this document is the
..
determination and the implementation of preventive, diagnostic, or .. composition of the Task Force, which is truly multidisciplinary.
therapeutic medical strategies. However, the ESC Guidelines do not .. Cardiologists form a minority of the panel; experts in emergency
..
override in any way whatsoever the individual responsibility of health .. medicine, internal medicine and physiology, neurology and auto-
professionals to make appropriate and accurate decisions in consider- .. nomic diseases, geriatric medicine, and nursing cover all aspects of
..
ation of each patient’s health condition and in consultation with that pa- .. management of the various forms of syncope and transient loss of
tient or the patient’s caregiver where appropriate and/or necessary. It .. consciousness (TLOC).
Compared with the previous versions of these Guidelines, the .. The document aims to be patient-orientated and focused on ther-
..
2018 document contains Supplementary Data as an integral part. .. apy, and to reduce the risk of recurrence and the life-threatening
While the print text mainly aims to give formal evidence-based rec-
.. consequences of syncope recurrence. For this purpose, even in the
..
ommendations according to the standardized rules of the ESC, this .. absence of strong evidence from trials, we give as much advice as
new web-only feature allows expansion of the content to practical
.. possible on the most appropriate therapy based on the practical ex-
..
issues, and aims to fill the gap between the best available scientific evi- .. pertise of the members of the Task Force (‘Our patients seek solutions,
dence and the need for dissemination of these concepts into clinical
.. not only explanations’). When possible, we provide therapeutic and
..
practice (‘We have the knowledge, we need to teach it’). Thanks to the .. decision-making algorithms.
..
Supplementary Data further explanation on specific points is given, .. Finally, we recognize that one major challenge in syncope manage-
and thanks to the Web Practical Instructions advice is given on how .. ment is the reduction of inappropriate admissions and inappropriate
..
to evaluate patients with loss of consciousness (LOC), and how to .. use of tests while maintaining the safety of the patient. We give strong
perform and interpret tests properly; whenever possible, we provide .. focus to pathways and organizational issues (‘We have the knowledge;
..
tracings, videos, flow charts, and checklists. .. we need to apply it’). In particular, we propose a care pathway for the
.
Figure 1 What is new in the 2018 syncope Guidelines? AA = antiarrhythmic; AF = atrial fibrillation; ARVC = arrhythmogenic right ventricular car-
diomyopathy; CSM = carotid sinus massage; ECG = electrocardiogram; ED = emergency department; LVEF = left ventricular ejection fraction; EPS =
electrophysiological study; HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;
OH = orthostatic hypotension; PCM = physical counter-pressure manoeuvres; POTS = postural orthostatic tachycardia syndrome; PPS = psycho-
genic pseudosyncope; SNRT = sinus node recovery time; SU = syncope unit; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
Central illustration New/revised concepts in the management of syncope. ECG = electrocardiogram; ED = emergency department; ICD =
implantable cardioverter defibrillator; SCD = sudden cardiac death.
..
management of patients with TLOC from their arrival in the emer- .. • TLOC is defined as a state of real or apparent LOC with loss of
gency department (ED), and give practical instructions on how to set .. awareness, characterized by amnesia for the period of uncon-
.. sciousness, abnormal motor control, loss of responsiveness, and
up outpatient syncope clinics (syncope units) aimed at reducing hos- ..
pitalization, under- and misdiagnoses, and costs. .. a short duration.
..
.. The two main groups of TLOC are ‘TLOC due to head trauma’
..
2.1 What is new in the 2018 version? .. and ‘non-traumatic TLOC’ (Figure 2). Traumatic TLOC will not be
The changes in recommendations made in the 2018 version com-
.. considered further in this document, so TLOC will be used to mean
..
pared with the 2009 version, the new recommendations, and the .. non-traumatic TLOC.
most important new/revised concepts are summarized in Figure 1.
.. The clinical features characterizing TLOC are usually derived from his-
..
.. tory taking from patients and eyewitnesses. Specific characteristics that
.. aid diagnosis are outlined in section 3 of the Web Practical Instructions.
..
.. TLOC groups are defined using pathophysiology: the qualifying cri-
3. Definitions, classification, and .. terion for syncope is cerebral hypoperfusion; for epileptic seizures, it
..
pathophysiology .. is abnormal excessive brain activity; and for psychogenic TLOC it is
.. the psychological process of conversion. The syncope definition rests
..
3.1 Definitions .. on pathophysiology because no set of clinical features encompasses
• Syncope is defined as TLOC due to cerebral hypoperfusion, char- .. all forms of syncope while also excluding all epileptic seizures and
acterized by a rapid onset, short duration, and spontaneous com-
..
.. psychogenic TLOC events.
plete recovery. ..
.. • The adjective presyncope is used to indicate symptoms and signs
Syncope shares many clinical features with other disorders; it
..
.. that occur before unconsciousness in syncope. Note that the
therefore presents in many differential diagnoses. This group of dis- .. noun presyncope is often used to describe a state that resembles
orders is labelled TLOC.
.. the prodrome of syncope, but which is not followed by LOC.
Generalized: Psychogenic
- Tonic pseudosyncope (PPS)
- Clonic Psychogenic non-epileptic
- Tonic-clonic seizures (PNES)
- Atonic
Figure 2 Syncope in the context of transient loss of consciousness. Non-traumatic transient loss of consciousness is classified into one of four
groupings: syncope, epileptic seizures, psychogenic transient loss of consciousness, and a miscellaneous group of rare causes. This order represents
their rate of occurrence. Combinations occur; e.g. non-traumatic transient loss of consciousness causes can cause falls with concussion, in which case
transient loss of consciousness is both traumatic and non-traumatic. TIA = transient ischaemic attack; TLOC = transient loss of consciousness.
..
A variety of terms are used that generally do not match the definitions .. ‘vasodepressive type’ of reflex syncope, seen in the outer ring in
in this document closely enough to be used as synonyms of the defined .. Figure 3. The second is a functional impairment, and the third a struc-
..
terms. For example, a ‘faint’ approximately conforms to syncope but .. tural impairment of the autonomic nervous system, with drug-
emphasizes vasovagal syncope (VVS) over other forms. A glossary of un- .. induced, primary, and secondary autonomic failure in the outer ring.
..
certain terms is shown in section 1 of the Web Practical Instructions. .. In autonomic failure, there is insufficient sympathetic vasoconstriction
.. in response to the upright position.
3.2 Classification and pathophysiology of ..
.. There are four primary causes of low cardiac output. The first is
syncope and transient loss of .. a reflex bradycardia, known as cardioinhibitory reflex syncope.
..
consciousness .. The second concerns cardiovascular causes: arrhythmia, struc-
3.2.1 Syncope
.. tural disease including pulmonary embolism, and pulmonary
..
Table 3 provides a classification of the principal causes of syncope, .. hypertension. The third is inadequate venous return due to vol-
emphasizing groups of disorders with common pathophysiology,
.. ume depletion or venous pooling. Finally, chronotropic and ino-
..
presentation, and risk. Clinical features, epidemiology, prognosis, im- .. tropic incompetence through autonomic failure may impair
.. cardiac output.
pact on quality of life, and economic issues are shown in section 2 of ..
the Web Practical Instructions. .. Note that these primary mechanisms may interact in different
.. ways: firstly, venous pooling and inadequate venous return is also a
The pathophysiological classification centres on a fall in systemic ..
blood pressure (BP) with a decrease in global cerebral blood flow as .. factor that can trigger an inappropriate reflex in orthostatic reflex
.. syncope; secondly, a low total peripheral resistance may cause ven-
the defining characteristic of syncope. Figure 3 shows low BP and glo- ..
bal cerebral hypoperfusion as the central final common pathway of .. ous pooling of blood below the diaphragm, in turn decreasing venous
..
syncope. A sudden cessation of cerebral blood flow for as short as .. return and consequently cardiac output.
6–8 s can cause complete LOC. A systolic BP of 50–60 mmHg at .. The three main groups of syncope, i.e. reflex, cardiovascular, and
..
heart level, i.e. 30–45 mmHg at brain level in the upright position, will .. secondary to orthostatic hypertension (OH), are shown outside the
cause LOC.8,9 .. rings in Figure 3. Both reflex syncope and OH span the two main
..
Systemic BP is the product of cardiac output and total peripheral .. pathophysiological mechanisms.
resistance; a fall in either can cause syncope. However, in syncope, ..
..
both mechanisms often act together to a varying degree. .. 3.2.2 Non-syncopal forms of (real or apparent) transient
There are three primary causes of a low total peripheral resist-
.. loss of consciousness
..
ance. The first is decreased reflex activity causing vasodilatation .. Only those forms of epilepsy in which normal motor control is lost,
through withdrawal of sympathetic vasoconstriction: this is the
.. so patients may fall, are included in Figure 2. These are tonic, clonic,
Vasovagal:
- orthostatic VVS: standing, less common sitting
- emotional: fear, pain (somatic or visceral), instrumentation, blood phobia
Situational:
- micturition
- gastrointestinal stimulation (swallow, defaecation)
- cough, sneeze
- post-exercise
- others (e.g. laughing, brass instrument playing)
Carotid sinus syndrome
Non-classical forms (without prodromes and/or without apparent triggers and/or atypical presentation)
Syncope due to OH
Note that hypotension may be exacerbated by venous pooling during exercise (exercise-induced), after meals (postprandial hypotension), and after prolonged
bed rest
(deconditioning).
Drug-induced OH (most common cause of OH):
- e.g. vasodilators, diuretics, phenothiazine, antidepressants
Volume depletion:
- haemorrhage, diarrhoea, vomiting, etc.
Primary autonomic failure (neurogenic OH):
- pure autonomic failure, multiple system atrophy, Parkinson’s disease, dementia with Lewy bodies
Secondary autonomic failure (neurogenic OH):
- diabetes, amyloidosis, spinal cord injuries, auto-immune autonomic neuropathy, paraneoplastic autonomic neuropathy, kidney failure
Cardiac syncope
Remarks
• All forms of syncope, but mostly reflex syncope and OH, are more likely to occur or are more severe when various factors are present: medica-
tion causing low BP (due to vasodilatation or hypovolaemia), alcohol use, volume depletion (haemorrhage, low fluid intake, diarrhoea, vomiting),
pulmonary diseases causing reduction in brain oxygen supply, environmental factors (thermal stress).
• There are two main pathophysiological mechanisms in reflex syncope. “Vasodepression” refers to conditions in which insufficient sympathetic
vasoconstriction results in hypotension.1,2 “Cardioinhibition” is used when bradycardia or asystole predominates, reflecting a shift towards para-
sympathetic predominance. The haemodynamic pattern, i.e. cardioinhibitory, vasodepressive, or both, is independent of the trigger evoking reflex
syncope. For example, micturition syncope and orthostatic VVS may equally well present as cardioinhibitory or as vasodepressor syncope
• The non-classical form of reflex syncope involves a heterogeneous group of patients. The term is used to describe reflex syncope that occurs
with uncertain or apparently absent triggers and/or atypical presentation. The diagnosis of reflex syncope is probable when other causes of syn-
cope are excluded (absence of structural heart disease) and/or symptoms are reproduced in the tilt test.3 At present, this group also contains
syncope associated with low adenosine plasma levels4,5
• The cardiovascular causes of orthostatic intolerance include classical OH, initial OH, delayed OH, POTS, and VVS, which in this context can be
called orthostatic VVS.6,7 Syndromes of orthostatic intolerance that may cause syncope are presented in Web Practical Instruction section 2.
BP = blood pressure; OH = orthostatic hypotension; POTS = postural orthostatic tachycardia syndrome; VVS = vasovagal syncope.
Figure 4 Flow diagram for the initial evaluation and risk stratification of patients with syncope. BP = blood pressure; ECG = electrocardiogram;
H&P exam = history and physical examination; TLOC = transient loss of consciousness.
VVS is highly probable if syncope is precipitated by pain, fear, or standing, and is associated with typical progressive prodrome
I C
(pallor, sweating, and/or nausea).8,13–17
Situational reflex syncope is highly probable if syncope occurs during or immediately after specific triggers, listed in
13–17 I C
Table 3.8,
Syncope due to OH is confirmed when syncope occurs while standing and there is concomitant significant OH.18–24 I C
In the absence of the above criteria, reflex syncope and OH should be considered likely when the features that suggest reflex
IIa C
syncope or OH are present and the features that suggest cardiac syncope are absent (see Table 5).
Cardiac syncope
Cardiac ischaemia-related syncope is confirmed when syncope presents with evidence of acute myocardial ischaemia with or
I C
without myocardial infarction.25–39
Syncope due to structural cardiopulmonary disorders is highly probable when syncope presents in patients with prolapsing
I C
atrial myxoma, left atrial ball thrombus, severe aortic stenosis, pulmonary embolus, or acute aortic dissection.
AV = atrioventricular; BBB = bundle branch block; b.p.m. = beats per minute; ECG = electrocardiogram; ICD = implantable cardioverter defibrillator; OH = orthostatic hypo-
tension; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VT = ventricular tachycardia; VVS = vasovagal syncope.
a
Class of recommendation.
b
Level of evidence.
..
When a diagnosis is nearly certain or highly likely, no further evalu- .. 4.1.2 Management of syncope in the emergency
ation is needed, and treatment—if any—can be planned. In other .. department based on risk stratification
..
cases, the initial evaluation may suggest a diagnosis when the features .. The management of TLOC of suspected syncopal nature in the ED
listed in Table 5 are present, or otherwise is unable to suggest any .. should answer the following three key questions:
..
diagnosis. ..
.. (1) Is there a serious underlying cause that can be identified?
.. (2) What is the risk of a serious outcome?
Table 5 Clinical features that can suggest a diagnosis ..
on initial evaluation
.. (3) Should the patient be admitted to hospital?
..
.. Figure 5 shows a flow chart for the management and risk stratifica-
..
Reflex syncope .. tion of patients referred to the ED for TLOC suspected to be syn-
• Long history of recurrent syncope, in particular occurring be- .. cope (modified from Casagranda et al.40).
..
fore the age of 40 years ..
• After unpleasant sight, sound, smell, or pain .. Question 1: Is there a serious underlying cause that can be
• Prolonged standing ..
.. identified in the ED?
• During meal .. Normally the presenting complaint of syncope can be established.
• Being in crowded and/or hot places ..
• Autonomic activation before syncope: pallor, sweating, and/ .. The primary aim for an ED clinician is then to establish an underlying
.. diagnosis, especially those associated with the potential for rapid clin-
or nausea/vomiting ..
• With head rotation or pressure on carotid sinus (as in tu- .. ical deterioration.41,42 It is the acute underlying disease that most fre-
.. quently determines short-term adverse events rather than the
mours, shaving, tight collars) ..
• Absence of heart disease .. syncope itself.43 Subsequent management will focus on treating this
.. underlying cause (Figure 5). Many (40–45%) non-cardiovascular and
Syncope due to OH ..
.. some cardiovascular life-threatening underlying conditions are obvi-
• While or after standing ..
.. ous in the ED.44 Table 6 lists high-risk features that suggest the pres-
• Prolonged standing
• Standing after exertion .. ence of a serious underlying cause and low-risk features that suggest
.. a benign underlying cause.
• Post-prandial hypotension ..
• Temporal relationship with start or changes of dosage of vas- ..
odepressive drugs or diuretics leading to hypotension
.. Question 2: What is the risk of a serious outcome?
..
• Presence of autonomic neuropathy or parkinsonism .. High-risk features are shown in Table 6, and how to use this risk pro-
.. file to guide subsequent management and disposition is shown in
Cardiac syncope ..
• During exertion or when supine .. Figure 6.
..
• Sudden onset palpitation immediately followed by syncope .. Risk stratification is important, for two reasons:
• Family history of unexplained sudden death at young age ..
• Presence of structural heart disease or coronary artery .. (1) To recognize patients with a likely low-risk condition able to be dis-
.. charged with adequate patient education.
disease ..
• ECG findings suggesting arrhythmic syncope: .. (2) To recognize patients with a likely high-risk cardiovascular condition
- Bifascicular block (defined as either left or right BBB com-
.. requiring urgent investigation. This may require admission.
..
bined with left anterior or left posterior fascicular block) ..
- Other intraventricular conduction abnormalities (QRS dur- .. High-risk patients are more likely to have cardiac syncope.
ation >_0.12 s)
.. Structural heart disease25–27,31,35,36,45 and primary electrical disease46
..
- Mobitz I second-degree AV block and 1 degree AV block .. are major risk factors for sudden cardiac death (SCD) and overall
with markedly prolonged PR interval .. mortality in patients with syncope. Low-risk patients are more likely
- Asymptomatic mild inappropriate sinus bradycardia (40–50
..
.. to have reflex syncope and have an excellent prognosis.47 OH is
b.p.m.) or slow atrial fibrillation (40–50 b.p.m.) in the ab- .. associated with a two-fold higher risk of death owing to the severity
sence of negatively chronotropic medications ..
- Non-sustained VT
.. of comorbidities compared with the general population.48
..
- Pre-excited QRS complexes ..
- Long or short QT intervals .. Question 3: Should the patient be admitted to hospital?
- Early repolarization
..
.. Approximately 50% of patients who present to the ED with
- ST-segment elevation with type 1 morphology in leads .. syncope are admitted (although the rate varies between 12–86%)
V1-V3 (Brugada pattern) ..
- Negative T waves in right precordial leads, epsilon waves
.. (see Supplementary Data Table 4). The use of clinical decision rules and
.. standardized protocols has not changed this rate significantly. The com-
suggestive of ARVC ..
- Left ventricular hypertrophy suggesting hypertrophic .. posite estimate of outcomes is that in the next 7–30 days, only 0.8%
cardiomyopathy
.. die and 6.9% have a non-fatal severe outcome whilst in the ED, while
..
.. another 3.6% have a post-ED serious outcome (see Supplementary
.. Data Table 4). Unnecessary admission in low-risk patients can be harm-
..
ARVC = arrhythmogenic right ventricular cardiomyopathy; AV = atrioventricular; .. ful.87 Whereas it is crucial to identify these high-risk patients to ensure
BBB = bundle branch block; b.p.m. = beats per minute; ECG = electrocardio- .. early, rapid, and intensive investigation, not all patients at high risk need
gram; OH = orthostatic hypotension; VT = ventricular tachycardia.
..
.. hospitalization.80
.
Figure 5 The management of patients presenting to the emergency department for transient loss of consciousness suspected to be syncope
(modified from Casagranda et al.40). ED = emergency department; TLOC = transient loss of consciousness.
a
For example, this includes pulmonary embolism presenting with shortness of breath, pleuritic chest pain, and syncope, but not trauma
secondary to syncope.
It is recommended that patients with low-risk features, likely to have reflex or situational syncope, or syncope due to OH,
I B
are discharged from the ED.27,35,36,49–54,58,62,69
It is recommended that patients with high-risk features receive an early intensive and prompt evaluation in a syncope unit or
I B
in an ED observation unit (if available), or are hospitalized.26,27,35,36,44–46,50,55–57,59,60,70–76
It is recommended that patients who have neither high- nor low-risk features are observed in the ED or in a syncope unit
I B
instead of being hospitalized.40,63–65,77
Risk stratification scores may be considered for risk stratification in the ED.78–86 IIb B
Table 6 High-risk features (that suggest a serious condition) and low-risk features (that suggest a benign condition) in
patients with syncope at initial evaluation in the emergency department
AF = atrial fibrillation; ARVC = arrhythmogenic right ventricular cardiomyopathy; AV = atrioventricular; BP = blood pressure; b.p.m. = beats per minute; ECG = electrocardio-
gram; ED = emergency department; ICD = implantable cardioverter defibrillator; LQTS = long QT syndrome; LVEF = left ventricular ejection fraction; SCD = sudden cardiac
death; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
a
Some ECG criteria are per se diagnostic of the cause of the syncope (see recommendations: Diagnostic criteria); in such circumstances appropriate therapy is indicated without
further investigations. We strongly suggest the use of standardized criteria to identify ECG abnormalities with the aim of precise diagnosis of ECG-defined cardiac syndromes in
ED practice.61
if
Figure 6 Emergency department risk stratification flow chart. Low- and high-risk features are listed in Table 6. ED = emergency department;
SU = syncope unit.
Patients with low-risk features. These patients do not need further diagnostic tests in the ED as they are likely to have reflex, situational,
or orthostatic syncope. They may benefit from reassurance, or counselling (see Web Practical Instructions section 9.1: ESC information
sheet for patients affected by reflex syncope).
Patients with high-risk features. These patients should be classified as HIGH RISK; they require an intensive diagnostic approach and may
need urgent treatment and admission. These patients should be monitored (although it is unclear for how long this should be, most
studies suggesting up to 6 hours in the ED and up to 24 hours in hospital) in a setting where resuscitation can be performed in case of
deterioration.40,62
Patients that have neither high- nor low-risk features. These patients will require expert syncope opinion, which can probably be safely man-
aged in an outpatient setting.63 There is no direct evidence that admitting patients to hospital changes their outcome, whilst there is evi-
dence that management in an ED observation unit and/or fast-track to a syncope outpatient unit is beneficial.64,65
a
Recent studies have suggested that outcomes in patients presenting with presyncope are similar to those presenting with
syncope.66–68
b
These patients may still require admission to hospital for associated illness, injury or welfare reasons. Low-risk patients can be referred
to the outpatient syncope clinic for therapy purposes, if needed.
..
The diagnostic tests, procedures, and interventions that may re- .. <_48 h coupled with fast-tracking to a syncope unit reduced the ad-
quire admission in patients with high-risk features are listed in Table 7. .. mission rate to 29%.77 Among patients not admitted, 20% were dis-
..
Furthermore, this Task Force believes that the implementation .. charged after a short observation in the ED, 20% were fast-tracked to
of novel care pathways and organizational approaches, such as ED ob- .. the syncope unit, and 31% were discharged directly from the ED.77
..
servation units and syncope in- and outpatient units (Figure 6), ..
offer safe and effective alternatives to admission in the cases .. Risk stratification scores: There are several ED syncope clinical
..
listed in Table 7. Based on a consensus document,40 a single-centre .. decision rules that aim to stratify patients with syncope based on
experience consisting of a short stay in the ED under observation of .. medical history, examination, and ECG findings (see Supplementary
..
Table 7 High-risk syncope patients: criteria favouring a stay in an emergency department observation unit and/or
fast-tracking to a syncope unit vs. requiring admission to hospital
ARVC = arrhythmogenic right ventricular cardiomyopathy; ECG = electrocardiogram; ED = emergency department; SVT = supraventricular tachycardia.
..
Data Table 3).26,34–36,44,88 None of these rules are used widely in EDs .. syndrome (CSS) requires the reproduction of spontaneous symp-
due to poor sensitivity and specificity reported from external valida- .. toms and, in addition, that patients have syncope of unknown ori-
..
tion, or due to a lack of external validation.70,78–85 Syncope clinical .. gin compatible with a reflex mechanism. In such circumstances,
decision rules perform no better than clinician judgment at predicting .. CSM usually shows a period of asystole >6 s.91 The prevalence of
..
short-term serious outcomes.86 Clinical decision rules can predict .. CSS, as defined here, was 8.8% when CSM was performed after
poor outcomes, but most syncope deaths and many poor outcomes .. the initial evaluation in 1855 consecutive patients >40 years of
..
are associated with underlying illness rather than syncope per se,58 .. age with syncope compatible with a reflex mechanism.92,93 In a
particularly in the long term.56 .. multicentre study94 aimed at validation of the 2009 ESC
..
.. Guidelines, CSM was indicated after initial evaluation in 73% of
Even if the quality of evidence is moderate, there is strong con- .. 700 patients and was diagnostic in 12%. The precise methodology
..
sensus from several studies that currently available risk stratifi- .. and results of CSM are shown in section 5 of the Web Practical
cation scores have not shown better sensitivity, specificity, or .. Instructions.
..
prognostic yield compared with clinical judgment in predicting .. The main complications of CSM are neurological. When pooling
short-term serious outcomes after syncope. Therefore, they
.. the data from four studies90,95–97 in which 8720 patients were ana-
..
should not be used alone to perform risk stratification in .. lysed, TIAs or strokes were observed in 21 (0.24%).
the ED.
.. The relationship between abnormal response to CSM and
..
.. spontaneous syncope is a crucial point that has been studied using
..
4.2 Diagnostic tests .. two methods. The first was a pre-post comparison of the recur-
4.2.1 Carotid sinus massage .. rence rate of syncope after pacing. Non-randomized studies dem-
.. onstrated fewer recurrences at follow-up in paced patients than in
A ventricular pause lasting >3 s and/or a fall in systolic BP of >50 ..
mmHg is known as carotid sinus hypersensitivity. Carotid sinus .. those without pacing. These results were confirmed in two
..
hypersensitivity is a common finding in older men without syn- .. randomized trials.98,99 The second method was to analyse the
cope; abnormal responses are frequently observed (<_40%) in .. occurrence of asystolic episodes registered in patients with a car-
..
patients without syncope, especially if they are older and affected .. dioinhibitory response to CSM using an implanted device.
by cardiovascular disease.89 Carotid sinus hypersensitivity is .. Recordings of long pauses were very common in the two trials
..
exceptional in patients <40 years of age.90 The specificity of the .. that employed this method.100,101 These results suggest that a
test increases if spontaneous syncope is reproduced during CSM.
.. positive response to CSM, reproducing symptoms, in patients
..
Syncope was induced in only 5% of asymptomatic persons aged .. with syncope is highly predictive of the occurrence of spontane-
>65 years.89 For the above reasons, the diagnosis of carotid sinus
.. ous asystolic episodes.
Indications
CSM is indicated in patients >40 years of age with syncope of unknown origin compatible with a reflex mechanism.92–94 I B
Diagnostic criteria
CSS is confirmed if CSM causes bradycardia (asystole) and/or hypotension that reproduce spontaneous symptoms, and
I B
patients have clinical features compatible with a reflex mechanism of syncope.89,90,92,93,98–102
BP = blood pressure; CSM = carotid sinus massage; CSS = carotid sinus syndrome; TIA = transient ischaemic attack.
a
Class of recommendation.
b
Level of evidence.
..
4.2.2 Orthostatic challenge .. a disadvantage due to the rapidly falling BP during OH. With a sphyg-
Changing from the supine to the upright position produces a dis- .. momanometer, more than four measurements per minute cannot
..
placement of blood from the thorax to the lower limbs and abdomi- .. be obtained without venous obstruction in the arm. When more fre-
nal cavity that leads to a decrease in venous return and cardiac .. quent readings are required, as for initial OH, continuous beat-to-
..
output. In the absence of compensatory mechanisms, a fall in BP may .. beat non-invasive BP measurement is needed.20,103,104
lead to syncope.20,103,104 The diagnostic criteria for OH have been ..
..
defined by consensus.6 .. Diagnostic criteria: Abnormal BP fall is defined as a progressive
Currently, there are three methods for assessing the response to .. and sustained fall in systolic BP from baseline value >_20 mmHg or
..
change in posture from supine to erect20,103,104: active standing (see .. diastolic BP >_10 mmHg, or a decrease in systolic BP to <90
section 4.2.2.1), head-up tilt (see section 4.2.2.2), and 24-h ambula- .. mmHg. This definition of OH differs from the 2011 consensus6 in
..
tory BP monitoring (ABPM) (see section 4.2.3.4). .. adding the 90 mmHg threshold. This Task Force believes that an
.. absolute threshold of 90 mmHg of systolic BP is useful, especially
..
4.2.2.1 Active standing .. in patients with a supine BP <110 mmHg. An isolated diastolic BP
.. drop is very rare and its clinical relevance for OH diagnosis is lim-
..
Indications: This test is used to diagnose different types of ortho- .. ited. Orthostatic heart rate (HR) increase is blunted or absent
static intolerance (see Web Practical Instructions Web Table 1). A
.. [usually not >10 beats per minute (b.p.m.)] in patients with neuro-
..
sphygmomanometer is adequate for routine clinical testing for classi- .. genic OH, but increases or even exaggerates with anaemia or
cal OH and delayed OH because of its ubiquity and simplicity.
.. hypovolaemia. The probability that syncope and orthostatic com-
..
Automatic arm-cuff devices, which are programmed to repeat and .. plaints are due to OH can be assessed using the information given
confirm measurements when discrepant values are recorded, are at
.. in Table 8.
..
Highly suggestive of OH: syncope and pre- Possibly due to OH: not all of the features
syncope are present during standing, absent highly suggestive of OH are present
while lying, and less severe or absent while sit-
ting; a predilection for the morning; sitting or
lying down must help; complaints may get
worse immediately after exercise, after meals
or in high temperatures; no “autonomic
activation”
Supine and standing Symptomatic abnormal BP fall Syncope is due to OH (Class I) Syncope is likely due to OH (Class IIa)
BP measurement
Asymptomatic abnormal BP fall Syncope is likely due to OH (Class IIa) Syncope may be due to OH (Class IIb)
Active standing
Indications
Intermittent determination by sphygmomanometer of BP and HR while supine and during active standing for 3 min are indi-
I C
cated at initial syncope evaluation.20,103,104
Continuous beat-to-beat non-invasive BP and HR measurement may be preferred when short-lived BP variations are sus-
IIb C
pected, such as in initial OH.20,103,104
Diagnostic criteria
Syncope due to OH is confirmed when there is a fall in systolic BP from baseline value >_20 mmHg or diastolic BP >_10
I C
mmHg, or a decrease in systolic BP to <90 mmHg that reproduces spontaneous symptoms.6,20,103,104
Syncope due to OH should be considered likely when there is an asymptomatic fall in systolic BP from baseline value >_20
mmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg, and symptoms (from history) are consistent IIa C
with OH.6,20,103,104
Syncope due to OH should be considered likely when there is a symptomatic fall in systolic BP from baseline value >_20
mmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg, and not all of the features (from history) are IIa C
suggestive of OH.6,20,103,104
POTS should be considered likely when there is an orthostatic HR increase (>30 b.p.m. or to >120 b.p.m. within 10 min of
IIa C
active standing) in the absence of OH that reproduces spontaneous symptoms.6,20,103,104
Syncope due to OH may be considered possible when there is an asymptomatic fall in systolic BP from baseline value >_20
mmHg or diastolic BP >_10 mmHg, or a decrease in systolic BP to <90 mmHg, and symptoms (from history) are less consis- IIb C
tent with OH.6,20,103,104
BP = blood pressure; b.p.m. = beats per min; OH = orthostatic hypotension; HR = heart rate; POTS = postural orthostatic tachycardia syndrome.
a
Class of recommendation.
b
Level of evidence.
..
4.2.2.2 Tilt testing .. considered: (i) to confirm a diagnosis of reflex syncope in patients in
Since its introduction in 1986,105 many protocols have been reported .. whom this diagnosis was suspected but not confirmed by initial eval-
..
with variations in the initial stabilization phase, duration, tilt angle, .. uation105–109,111, and (ii) for the assessment of autonomic
type of support, and pharmacological provocation. The most com- .. failure, especially for the reproduction of delayed OH (which could not
..
monly used are the trinitroglycerin (TNG) test using 300–400 mg of .. be detected by active standing because of its delayed onset)23,24,112,113
sublingual TNG after a 20-min unmedicated phase,106,107 and the .. and postural orthostatic tachycardia syndrome (POTS).114 Tilt testing
..
low-dose intravenous isoproterenol test, which uses incremental .. may be helpful in separating syncope from PPS.115–117
doses to increase average HR by about 20–25% over baseline (usu- .. Tilt testing has limited value in assessing treatment efficacy.118
..
ally <_3 mg/min).108,109 In a recent systematic literature review,110 the .. However, tilt testing is widely accepted as a useful tool to demon-
overall positivity rate in patients with syncope was 66% for the TNG
.. strate susceptibility of the patient to reflex syncope, especially a
..
protocol and 61% for the isoproterenol protocol; the respective pos- .. hypotensive (vasodepressive) tendency, and thereby to initiate treat-
itivity rate in subjects without syncope (controls) ranged from
.. ment (e.g. physical manoeuvres, see section 5).119–121
..
11–14%; and the test differentiated patients with syncope from con- .. The endpoint of tilt testing is the reproduction of
trols with an odds ratio of 12. The methodology and classification of
.. symptoms along with the characteristic circulatory pattern of
..
responses are described in section 6 of the Web Practical Instructions. .. the indication mentioned above, namely the induction of reflex hypo-
Adding video recording to a tilt table permits objective and repeated
..
.. tension/bradycardia, OH, POTS, or PPS. The typical tilt test result
review of clinical signs in relation to BP and HR, and helps to assess .. patterns are shown in the Web Practical Instructions section 6.
..
the relative contribution of bradycardia and hypotension to syncope ..
(see section 5.2.6.3 and the explanatory video in Web Practical .. Interpretation of tilt testing results in patients with reflex syncope:
..
Instructions section 6.3.15), and to distinguish between VVS and PPS .. Some studies122,123 compared the response to tilt testing with sponta-
(see section 4.2.5). .. neous syncope recorded by an implantable loop recorder (ILR). While
..
The clinical situation corresponding to tilt-induced syncope is that .. a positive cardioinhibitory response to tilt testing predicts, with a high
which is triggered by prolonged standing. The test should be .. probability, an asystolic spontaneous syncope, the presence of a
Tilt testing
Indications
Tilt testing should be considered in patients with suspected reflex syncope, OH, POTS, or PPS.23,24,105–109,111–117 IIa B
119–121
Tilt testing may be considered to educate patients to recognize symptoms and learn physical manoeuvres. IIb B
Diagnostic criteria
Reflex syncope, OH, POTS, or PPS should be considered likely if tilt testing reproduces symptoms along with the charac-
IIa B
teristic circulatory pattern of these conditions.23,24,105–109,111–117
EEG = electroencephalogram; OH = orthostatic hypotension; POTS = postural orthostatic tachycardia syndrome; PPS = psychogenic pseudosyncope; VVS = vasovagal
syncope.
a
Class of recommendation.
b
Level of evidence.
..
.. VVS. This concept has practical implications for therapy (see sec-
.. tions 5.1 and 5.2).
..
..
..
..
.. 4.2.3 Basic autonomic function tests
.. Autonomic function assessment helps to identify autonomic failure as
..
.. the underlying cause of syncope.
..
..
.. 4.2.3.1 Valsalva manoeuvre
.. The methodology of the Valsalva manoeuvre is described in section
..
.. 7.1.1 of the Web Practical Instructions and in Web Video 2. There is
.. strong evidence that the absence of a BP overshoot and an absence
..
.. of a HR increase during the Valsalva is pathognomonic for neurogenic
.. OH, occurring in primary and secondary autonomic failure, and the
..
.. degree of hypotension and/or lack of compensation during forced
.. expiration usually correlate with the degree of autonomic dysfunc-
..
.. tion and related symptoms.138–143 In contrast, a pronounced BP fall
..
.. beyond what is normally expected during forced expiration, but a
.. normal chronotropic response during the manoeuvre, may occur in
..
.. patients with suspected situational syncope, i.e. syncope occurring
Figure 7 Rates of tilt testing positivity in different clinical condi- .. during some forms of situational syncope, e.g. coughing, brass instru-
..
tions. These studies used the Westminster protocol for passive .. ment playing, singing, and weightlifting.144
tilt,125 the Italian protocol for trinitroglycerin tilt,106 and the clo- ..
mipramine protocol,124 for a total of 1453 syncope patients and ..
.. 4.2.3.2 Deep breathing
407 controls without syncope. Studies using other tilt protocols, .. The methodology of the deep-breathing test is described in section
e.g. isoproterenol challenge, were not included. Clom = clomipr- ..
amine; TNG = trinitroglycerin; VVS = vasovagal syncope.
.. 7.1.2 of the Web Practical Instructions. Under physiological conditions,
.. HR rises during inspiration and falls during expiration. HR variability
..
.. during deep breathing (also called the expiratory/inspiratory index or
.. E/I index) is >_15 b.p.m. in healthy individuals aged >50 years.145
..
positive vasodepressor, mixed response, or even a negative response, .. There is strong consensus that blunted or abolished variation is sug-
does not exclude the presence of asystole during spontaneous .. gestive of parasympathetic dysfunction.142,143,146,147
..
syncope.122,123 ..
Tilt testing has an acceptable sensitivity124 and specific- .. 4.2.3.3 Other autonomic function tests
106,124,125 ..
ity when these are calculated in patients with true VVS .. Further tests to evaluate cardiovascular sympathetic function include
or without a history of syncope. However, there is an inability to .. calculation of the 30:15 ratio, the cold pressure test, the sustained
..
apply the test to populations with syncope of uncertain cause .. hand grip test, and mental arithmetic. There is weak evidence that
where it is hoped that tilt testing might prove decisive. In these .. these tests may be useful.13,142,143,147
..
clinical settings, tilt testing fails to deliver (Figure 7). Indeed, tilt ..
testing was positive in 51–56% of patients with atypical clinical fea- .. 4.2.3.4 Twenty-four-hour ambulatory and home blood pressure
..
tures suggesting a reflex mechanism,106,124–128 in 30–36% with .. monitoring
unexplained syncope after full investigation,124,129 and in 45–47% ..
.. Twenty-four-hour ABPM and home BP monitoring (HBPM) are
with true cardiac arrhythmic syncope.130,131 In other words, tilt .. increasingly used to diagnose and monitor the treatment of hyperten-
testing offers little diagnostic value in patients for whom it is most ..
.. sion.148 There is strong evidence that OH is frequently associated with
needed. In these patients, a positive tilt test reveals a susceptibility .. a nocturnal ‘non-dipping’ or even ‘reverse-dipping’ BP pattern in
to orthostatic stress.132 This hypotensive susceptibility plays a role in
..
.. patients with autonomic failure, with relevant therapeutic and prognos-
causing syncope irrespective of the aetiology and mechanism of .. tic implications140,148–151 (see Web Practical Instructions section 7.1.3). In
syncope. For example, in arrhythmic syncope caused by paroxys-
..
.. these patients, ABPM allows the assessment of nocturnal hypertension,
mal atrial tachyarrhythmias, the mechanism is a combination of .. postprandial hypotension, and exercise- and drug-induced hypoten-
onset of the arrhythmia itself and hypotensive susceptibility,
..
.. sion, as well as monitoring for side effects of antihypotensive regimens
corroborated by positive tilt testing.130,131 Similarly, multifactorial .. and pointing to additional disorders such as sleep apnoea.152 There is
mechanisms are likely in other types of cardiac syncope, e.g. aortic
..
.. weak evidence that ABPM may also detect the degree of OH in daily
stenosis,133 hypertrophic cardiomyopathy (HCM),134 and .. life better than single office BP measurements.153
..
sick sinus syndrome.135,136 The presence or absence of suscepti- .. HBPM may be used to investigate the cause of orthostatic intoler-
bility explains the occurrence of syncope in some and not in .. ance, i.e. to clarify whether symptoms are due to OH or to other
..
others affected by the same severity of arrhythmia or structural .. causes, such as vertigo or motor imbalance in Parkinson’s disease or
defect. Tilt testing should now be considered a means of .. multiple system atrophy. The evidence is weak. Finally, HBPM can be
..
exposing a hypotensive tendency rather than being diagnostic of . used to clarify that BP is not low during episodes of PPS.154
Valsalva manoeuvre
Valsalva manoeuvre should be considered for the assessment of autonomic function in patients with suspected neurogenic
IIa B
OH.138–143
Valsalva manoeuvre may be considered for confirming the hypotensive tendency induced by some forms of situational syn-
IIb C
cope, e.g. coughing, brass instrument playing, singing, and weightlifting.144
Deep-breathing test
Deep-breathing tests should be considered for the assessment of autonomic function in patients with suspected neurogenic
IIa B
OH.142,143,146,147
Other autonomic function tests (30:15 ratio, cold pressure test, sustained hand grip test, and mental arithmetic test) may
IIb C
be considered for the assessment of autonomic function in patients with suspected neurogenic OH.13,142,143,147
ABPM
ABPM should be considered to detect and monitor the degree of OH and supine hypertension in daily life in patients with
IIa C
autonomic failure.152,153
ABPM and HBPM may be considered to detect whether BP is abnormally low during episodes suggestive of orthostatic
IIb C
intolerance.
ABPM = ambulatory blood pressure monitoring; BP = blood pressure; HBPM = home blood pressure monitoring; HR = heart rate; OH = orthostatic hypotension.
a
Class of recommendation.
b
Level of evidence.
..
the investigation of palpitations,163 they have a marginal role in the .. There are several areas of interest other than unexplained syn-
evaluation of syncope. .. cope in which ILRs have been investigated:
..
..
4.2.4.4 Smartphone applications .. • Patients with bundle branch block (BBB) in whom paroxysmal
.. atrioventricular (AV) block is likely despite negative complete
Because up to now smartphone applications have recorded real-time .. EPS: an arrhythmia was observed in 41% of these patients (being
ECG, their current role in syncope is limited for the same reason as
..
.. paroxysmal AV block in 70%) under ILR observation, based on
for prospective event recorders.164,165 However, home video .. pooled data from three studies174,187,188 (see Supplementary Data
records are very useful in all forms of TLOC (see section 4.2.5.2).
..
.. Table 6).
.. • Patients in whom epilepsy was suspected but the treatment has
4.2.4.5 External loop recorders
.. proven ineffective: in pooled data, an attack could have
..
In general, external loop recorders have a higher diagnostic yield than .. been documented by ILR in 62% of patients, with an arrhythmic
Holter monitoring.162 External loop recorders can be useful in
.. cause being responsible in 26%137,189–191 (see Supplementary Data
..
patients with relatively frequent syncope episodes.166–168 In a recent .. Table 7).
.. • Patients with unexplained falls: in pooled data, an attack could
multicentre international registry, the diagnostic yield in syncope was .. have been documented by ILR in 70% of patients, with an
24.5%, with the most common finding being bradyarrhythmias; the ..
.. arrhythmic cause being responsible in 14%191–194 (see
stronger predictor for diagnostic findings was early monitoring after .. Supplementary Data Table 8).
the index event.166 ..
.. • Patients with HCM, arrhythmogenic right ventricular cardiomy-
.. opathy (ARVC), or primary electrical diseases (see section 5.4).
4.2.4.6 Remote (at home) telemetry ..
..
Most recently, external and implantable device systems have been .. 4.2.4.8 Diagnostic criteria
developed that provide continuous ECG recording or 24-h loop .. The gold standard for the diagnosis of arrhythmic syncope is when
..
memory with wireless transmission (real time) to a service centre. .. there is a correlation between the symptoms and an ECG record-
Some recent studies have shown that implementing remote monitor- .. ing.195,196 The presence of asymptomatic significant arrhythmias—
..
ing increases the diagnostic yield and achieves diagnosis earlier than .. defined as prolonged asystole (>_3 s), rapid supraventricular
without remote monitoring.169–171 ..
.. tachycardias (SVTs) (i.e. >160 b.p.m. for >32 beats), or ventricular
.. tachycardias (VTs)—has been considered by several authors to be a
4.2.4.7 Implantable loop recorders
..
.. diagnostic finding.185,188,197–199 On the other hand, although the
In a meta-analysis of five randomized controlled trials (RCTs),172–176 .. absence of documentation of an arrhythmia during a syncopal epi-
660 patients with unexplained syncope were randomized to a con-
..
.. sode cannot be considered to be a specific diagnosis, it allows the
ventional strategy consisting of an external loop recorder, tilt testing, .. exclusion of an arrhythmia as the mechanism of the syncope. Most
and an electrophysiological study (EPS), or to prolonged monitoring
..
.. evidence in support of the above diagnostic criteria is indirectly based
with an ILR. The results showed that initial implantation of an ILR in .. on the benefit of specific therapies guided by ECG monitoring in pre-
the workup provided a 3.7 [95% confidence interval (CI) 2.7–5.0]
..
.. venting syncopal recurrences.172,184–186,188,200
increased relative probability of a diagnosis compared with the con- .. Even if the quality of evidence is moderate, there is strong con-
ventional strategy (see Supplementary Data Table 5). ILR was more
..
.. sensus based on evidence from several controlled trials that a
cost-effective than a conventional strategy.172,173,177,178 .. correlation between symptoms and a documented arrhythmia,
..
In pooled data from nine studies179 performed in 506 patients with .. or the presence of some asymptomatic significant arrhythmias
unexplained syncope at the end of complete negative work-up, a cor- .. (defined above), is diagnostic of the cause of syncope and spe-
..
relation between syncope and ECG was found in 176 patients (35%); .. cific treatment must be prescribed.
of these, 56% had asystole (or bradycardia in a few cases) at the time ..
.. The principal limitation of any ECG monitoring device is the
of the recorded event, 11% had tachycardia, and 33% had no arrhyth- .. inability to record BP together with ECG. In reflex syncope, the
mia. Presyncope was much less likely to be associated with an ..
.. documentation of bradycardia/asystole during a syncopal episode
arrhythmia than syncope. Similar findings were subsequently .. does not rule out the possibility that a hidden hypotensive reflex
observed with ILR use expanded in an early phase of evaluation in ..
.. is the principal cause for syncope, and that bradycardia/asystole is
patients with recurrent syncope of uncertain origin, in the absence of .. a secondary late event. This issue has important implications for
high-risk criteria and structural heart disease,176,180–183 and in sus- ..
.. therapy (see section 5). A classification of ECG recordings with
pected reflex syncope.184–186 In particular, an asystolic pause was ..
present during syncope in about 50% of these patients. .. their probable related pathophysiology is available in Web Table 6
.. and Web Practical Instructions section 8.
..
Electrocardiographic monitoring
Indications
Immediate in-hospital monitoring (in bed or by telemetry) is indicated in high-risk patients (defined in Table 6). I C
Holter monitoring should be considered in patients who have frequent syncope or presyncope (>_1 episode per week).161 IIa B
External loop recorders should be considered, early after the index event, in patients who have an inter-symptom interval <_4
IIa B
weeks.162,166,168,201
ILR is indicated in an early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk
criteria (listed in Table 6), and a high likelihood of recurrence within the battery life of the device.175,176,181–184,202, I A
Supplementary Data Table 5
ILR is indicated in patients with high-risk criteria (listed in Table 6) in whom a comprehensive evaluation did not demon-
strate a cause of syncope or lead to a specific treatment, and who do not have conventional indications for primary preven- I A
tion ICD or pacemaker indication.174,180,187,188,195, Supplementary Data Tables 5 and 6
ILR should be considered in patients with suspected or certain reflex syncope presenting with frequent or severe syncopal
IIa B
episodes.184–186
ILR may be considered in patients in whom epilepsy was suspected but the treatment has proven ineffective.137,189–191,
IIb B
Supplementary Data Table 7
ILR may be considered in patients with unexplained falls.191–194, Supplementary Data Table 8 IIb B
Diagnostic criteria
Arrhythmic syncope is confirmed when a correlation between syncope and an arrhythmia (bradyarrhythmia or tachyar-
I B
rhythmia) is detected.172,184–186,188,200
In the absence of syncope, arrhythmic syncope should be considered likely when periods of Mobitz II second- or third-
degree AV block or a ventricular pause >3 s (with the possible exception of young trained persons, during sleep or rate- IIa C
controlled atrial fibrillation), or rapid prolonged paroxysmal SVT or VT are detected.185,188,197–199
AV = atrioventricular; ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
a
Class of recommendation.
b
Level of evidence.
..
4.2.5 Video recording in suspected syncope .. relation to BP and HR objectively and repeatedly, thus helping to dis-
4.2.5.1 In-hospital video recording .. tinguish VVS from PPS. This approach has revealed new pathophysio-
..
For PNES, a video-electroencephalogram (EEG) forms the highest .. logical insights in syncope.9 Attaching the camera to the tilt table
level of diagnostic probability.204 For syncope and PPS, video can play .. allows detailed study of the face and head, which is useful when
..
a similar, probably underused, role (see section 7). Adding video .. assessing the start and end of LOC.9,205 Video recording of tilt-
recording to a tilt table test adds the ability to review clinical signs in .. induced PPS116 ensures that apparent TLOC occurs while BP and HR
..
..
are not low; adding an EEG increases the diagnostic probability of .. sinoatrial block, usually documented by 12-lead ECG or ECG moni-
PPS even further. The method has been proven to show the com- .. toring. The prognostic value of a prolonged sinus node recovery time
..
bined presence of VVS and PPS.117 .. (SNRT) is not well defined. An abnormal response is defined as >_1.6
.. or 2 s for SNRT, or >_525 ms for corrected SNRT.210 One observatio-
..
4.2.5.2 Home video recording .. nal study showed a relationship between the presence of prolonged
Home video records (by means of smartphone technology) are very .. SNRT at EPS and the effect of pacing on symptoms.211 Another small
..
useful in all forms of TLOC to allow signs of an attack to be studied. .. prospective study showed that a corrected SNRT >_800 ms had an
Patients and their relatives should be urged to record attacks, if possi- .. eight-fold higher risk of syncope than a SNRT below this value.212
..
ble, in cases of diagnostic uncertainty. In epilepsy, advances are made ..
towards prolonged video and EEG recording in patients’ .. 4.2.6.2 Syncope in bifascicular bundle branch block (impending high-
..
homes.206,207 For syncope or PPS, experience suggests that the chan- .. degree atrioventricular block)
ces of obtaining a video record are higher for PPS than for syncope, .. Patients with bifascicular block and syncope are at higher risk of devel-
..
which is probably the effect of a high frequency and long duration of .. oping high-degree AV block.213 A prolonged HV interval >_70 ms, or
attacks in PPS. It is rare for the beginning of events to be recorded.206 .. induction of second- or third-degree AV block by pacing or by phar-
..
Home video records allow complex events such as syncope-induced .. macological stress (ajmaline, procainamide, or disopyramide), identi-
epileptic seizures to be diagnosed.208
.. fies a group at higher risk of developing AV block. By combining the
..
.. above-mentioned parts of the electrophysiological protocol, a positive
.. EPS yielded a positive predictive value as high as >_80% for the identifi-
..
Video recording in suspected syncope .. cation of patients who will develop AV block in old studies.214–216
.. This finding has been indirectly confirmed by recent studies that
..
Recommendations Classa Levelb
.. showed a significant reduction in syncopal recurrences in patients
..
.. with prolonged HV implanted with a pacemaker compared with a
Home video recordings of spontaneous .. control group of untreated patients with a negative EPS188, or with a
events should be considered. Physicians ..
.. control group who received an empiric pacemaker.217 These results
should encourage patients and their rel- IIa C .. justify an upgrade of the recommendation for EPS-guided therapy (i.e.
atives to obtain home video recordings ..
.. cardiac pacing) in patients with a positive EPS from class IIa to class I.
of spontaneous events.206,208 ..
..
Adding video recording to tilt testing .. Even if the quality of evidence is moderate, there is strong con-
.. sensus that a positive EPS indicates that the likely mechanism
may be considered in order to increase ..
the reliability of clinical observation of
IIb C .. of syncope is paroxysmal AV block.
9,116,117,205
.. Conversely, approximately one-third of patients with a negative EPS in
induced events. ..
.. whom an ILR was implanted developed intermittent or permanent AV
.. block on follow-up.187 Thus, EPS has a low negative predictive value.
a
Class of recommendation. ..
b
Level of evidence. .. Mortality is high in patients with syncope and BBB. However, neither
.. syncope nor prolonged H-V interval were associated with a higher risk
..
.. of death, and pacemaker therapy did not decrease this risk.213
..
..
4.2.6 Electrophysiological study .. 4.2.6.3 Suspected tachycardia
.. In patients with syncope preceded by a sudden onset of brief palpita-
..
Indications: In an overview of eight studies, including 625 patients .. tions suggesting SVT or VT, an EPS may be indicated to assess the
with syncope undergoing EPS,209 positive results occurred predomi-
.. exact mechanism, especially when a curative catheter ablation proce-
..
nantly in patients with structural heart disease. In recent years, the .. dure is considered to be beneficial.
development of powerful non-invasive methods, i.e. prolonged ECG
.. In patients with a previous myocardial infarction and preserved left
..
monitoring, showing a higher diagnostic value, has decreased the .. ventricular ejection fraction (LVEF), induction of sustained mono-
..
importance of EPS as a diagnostic test. In clinical practice, registry data .. morphic VT is strongly predictive of the cause of syncope,218
show that approximately 3% of patients with unexplained syncope .. whereas the induction of ventricular fibrillation (VF) is considered a
..
evaluated by cardiologists undergo EPS and even fewer if they are .. non-specific finding.37 The absence of induction of ventricular
evaluated by other specialists.71 Nevertheless, EPS remains useful for .. arrhythmias identifies a group at lower risk of arrhythmic syncope.219
..
diagnosis in the following specific clinical situations: asymptomatic .. The role of EPS and the use of pharmacological challenge by
sinus bradycardia (suspected sinus arrest causing syncope), bifascicu- .. class I antiarrhythmic drugs in patients with syncope and sus-
..
lar BBB (impending high-degree AV block), and suspected .. pected Brugada syndrome is controversial. In a recent meta-analy-
tachycardia. .. sis,220 the risk of arrhythmic events was slightly increased in
..
.. patients with a history of unexplained syncope or a spontaneous
Diagnostic criteria: 4.2.6.1 Asymptomatic sinus bradycardia: sus- .. type 1 pattern, and who had induction of VT or VF with one or
..
pected sinus arrest causing syncope .. two extra stimuli. However, the absence of induction in such indi-
The pre-test probability of bradycardia-related syncope is relatively .. viduals does not necessarily preclude arrhythmia risk, particularly
..
high when there is asymptomatic sinus bradycardia (<50 b.p.m.) or . in patients with high-risk features.
Electrophysiological study
Indications
In patients with syncope and previous myocardial infarction, or other scar-related conditions, EPS is indicated when syn-
I B
cope remains unexplained after non-invasive evaluation.218
In patients with syncope and bifascicular BBB, EPS should be considered when syncope remains unexplained after non-inva-
IIa B
sive evaluation.188,214–217,221
In patients with syncope and asymptomatic sinus bradycardia, EPS may be considered in a few instances when non-invasive
IIb B
tests (e.g. ECG monitoring) have failed to show a correlation between syncope and bradycardia.210–212
In patients with syncope preceded by sudden and brief palpitations, EPS may be considered when syncope remains unex-
IIb C
plained after non-invasive evaluation.
EPS-guided therapy
In patients with unexplained syncope and bifascicular BBB, a pacemaker is indicated in the presence of either a baseline H-V
interval of >_70 ms, second- or third-degree His-Purkinje block during incremental atrial pacing, or with pharmacological I B
challenge.188,214–217,221
In patients with unexplained syncope and previous myocardial infarction, or other scar-related conditions, it is recom-
I B
mended that induction of sustained monomorphic VT is managed according to the current ESC Guidelines for VA.46
In patients without structural heart disease with syncope preceded by sudden and brief palpitations, it is recommended that
the induction of rapid SVT or VT, which reproduce hypotensive or spontaneous symptoms, is managed with appropriate I C
therapy according to the current ESC Guidelines.46,222
In patients with syncope and asymptomatic sinus bradycardia, a pacemaker should be considered if a prolonged corrected
IIa B
SNRT is present.210–212
BBB = bundle branch block; DCM = dilated cardiomyopathy; ECG = electrocardiogram; EPS = electrophysiological study; ESC = European Society of Cardiology; SNRT = sinus
node recovery time; SVT = supraventricular tachycardia; VA = ventricular arrhythmia; VF = ventricular fibrillation; VT = ventricular tachycardia.
a
Class of recommendation.
b
Level of evidence.
..
4.2.7 Endogenous adenosine and other biomarkers .. and VVS. In parallel, the adenosine/adenosine triphosphate
Established cardiac biomarkers such as troponin and B-type natriu- .. (ATP) provocation test has been performed to demonstrate the
..
retic peptide have been used to distinguish cardiac from non-cardiac .. utility of adenosine sensitivity and paroxysmal cardioinhibitory
syncope and identify structural heart disease.223–225 .. propensity for the selection of appropriate pacemaker candi-
..
.. dates.4,227,228 The test requires rapid (<2 s) injection of a 20 mg
4.2.7.1 Adenosine (triphosphate) test and plasma concentration .. bolus of ATP/adenosine during ECG monitoring. The induction of
..
The purinergic signalling system, including adenosine and its .. AV block with ventricular asystole lasting >6 s, or the induction
receptors, has been proposed to be involved in unexplained .. of AV block lasting >10 s, is considered abnormal. ATP testing
..
syncope without prodrome.4,226 A low plasma adenosine level is .. was positive in most patients with syncope of unknown origin
associated with paroxysmal AV block or CSS, whereas a high
.. (especially syncope without prodrome and without structural
..
level is seen in those with a hypotensive/vasodepressive tendency . heart disease4) but not in controls, suggesting that paroxysmal AV
..
block could be the cause of unexplained syncope. Although car- .. 4.2.7.3 Immunological biomarkers
diac pacing may lead to substantial reduction of syncopal attacks .. Autoantibodies against adrenergic receptors in OH and POTS have
..
in elderly patients with unexplained syncope and a positive ATP .. been reported, but further studies are needed.232–234
test,229 previous studies showed no correlation between ..
..
AV block induced by ATP and ECG findings (documented by ILR) .. 4.2.8 Echocardiography
during spontaneous syncope.122,123,227 Thus, the low predictive ..
.. For patients with suspected heart disease, echocardiography serves
value of the test does not support its routine use in selecting ..
patients for cardiac pacing, but rather its positivity suggests that .. to confirm or refute the suspicions in equal proportions and plays an
.. important role in risk stratification.235,236 Echocardiography identifies
it can be used to confirm the suspicion of asystolic syncope ..
by means of prolonged ECG monitoring. The role of endogenous .. the cause of syncope in very few patients when no more tests are
.. needed (i.e. severe aortic stenosis, obstructive cardiac tumours or
adenosine release in triggering a special form of asystolic ..
.. thrombi, pericardial tamponade, or aortic dissection).237–239 In a lit-
syncope (so-called adenosine-sensitive syncope) remains under .. erature review, right and left atrial myxoma presented with syncope
investigation. ..
.. in <20% of cases.240–244
..
4.2.7.2 Cardiovascular biomarkers ..
Some cardiovascular biomarkers are increased in autonomic dysfunc-
.. 4.2.8.1 Exercise stress echocardiography
.. Upright or semi-supine exercise stress echocardiography to detect
tion underlying syncope, such as elevated copeptin (vasopressin), ..
endothelin-1, and N-terminal pro-B-type natriuretic peptide in
.. provocable left ventricular outflow tract obstruction should be con-
.. sidered in patients with HCM that complain of exertional or postural
OH,113,230,231 whereas atrial natriuretic peptide may be reduced in ..
POTS.113 At present, the use of cardiovascular biomarkers in the
.. syncope, particularly when it recurs during similar circumstances (e.g.
.. when rushing upstairs or straining). A gradient of >_50 mmHg is usu-
diagnosis of syncope awaits more evidence and verification in inde- ..
.. ally considered to be the threshold at which left ventricular outflow
pendent cohorts. .. tract obstruction becomes haemodynamically important.245–249
Echocardiography
Indications
Echocardiography is indicated for diagnosis and risk stratification in patients with suspected structural heart disease.235,236 I B
Two-dimensional and Doppler echocardiography during exercise in the standing, sitting, or semi-supine position to detect
provocable left ventricular outflow tract obstruction is indicated in patients with HCM, a history of syncope, and a resting I B
or provoked peak instantaneous left ventricular outflow tract gradient <50 mmHg.245–249
Diagnostic criteria
Aortic stenosis, obstructive cardiac tumours or thrombi, pericardial tamponade, and aortic dissection are the most prob-
I C
able causes of syncope when the ECG shows the typical features of these conditions.237–244
Figure 8 General framework of treatment is based on risk stratification and the identification of specific mechanisms when possible. ARVC =
arrhythmogenic right ventricular cardiomyopathy; CAD = coronary artery disease; DCM = dilated cardiomyopathy; ECG = electrocardiographic;
HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; LQTS = long QT syndrome; SCD = sudden cardiac death.
Table 9 Expected syncope recurrence rates with a permanent pacemaker in different clinical settings (for more
details see Supplementary Data Table 9).
Syncope due to established bradycardia and absence of hypotensive mechanism High efficacy (<_5% recurrence rate)
Syncope due to established bradycardia and associated hypotensive mechanism Moderate efficacy (5–25% recurrence rate)
Syncope due to suspected bradycardia and associated hypotensive mechanism Low efficacy (>25% recurrence rate)
patients is non-pharmacological treatment, including education, .. 5.2.1 Education and lifestyle modifications
..
lifestyle modification, and reassurance regarding the benign nature of .. Education and lifestyle modifications have not been evaluated in
the condition. .. randomized studies, but there is a consensus for implementing them
..
Additional treatment may be necessary in patients with severe forms, .. as first-line therapy in all cases. These comprise reassurance about
as defined in Web Practical Instructions section 2.3, in particular: when
.. the benign nature of the disease, education regarding awareness and the
..
very frequent syncope alters quality of life; when recurrent syncope .. possible avoidance of triggers and situations (e.g. dehydration and/or
without, or with a very short, prodrome exposes the patient to a risk of
.. hot crowded environments), and the early recognition of prodromal
..
trauma; and when syncope occurs during a high-risk activity (e.g. driving, .. symptoms in order to sit or lie down and activate counter-pressure
machine operation, flying, or competitive athletics, etc.). Only 14% of
.. manoeuvres without delay. If possible, triggers should be addressed
..
the highly selected population with reflex syncope who are referred to .. directly, such as cough suppression in cough syncope, micturition in the
specialized syncope units may need such additional treatment.186 In gen-
..
.. sitting position, etc. Increased intake of oral fluids is also advised. Salt
eral, no therapy is appropriate for every form of reflex syncope. The .. supplementation at a dose of 120 mmol/day of sodium chloride has
..
most important discriminant for the choice of therapy is age. A decision .. been proposed.259 In general, >50% of patients with recurrent syncopal
pathway for the selection of a specific therapy according to age, severity .. episodes in the 1 or 2 years before evaluation do not have syncopal
..
of syncope, and clinical forms is summarized in Figure 9. . recurrences in the following 1 or 2 years and, in those with recurrences,
Figure 9 Schematic practical decision pathway for the first-line management of reflex syncope (based on patient’s history and tests) according to
age, severity of syncope, and clinical forms. Younger patients are those aged <40 years while older patients are >60 years, with an overlap between 40
and 60 years. Severity of reflex syncope is defined in the text. The duration of prodrome is largely subjective and imprecise. A value of <_5 s distinguishes
arrhythmic from reflex syncope49; in patients without structural heart disease, a duration >10 s can distinguish reflex syncope from cardiac syncope.38
In practice, the prodrome is ‘absent or very short’ if it does not allow patients enough time to act, such as to sit or lie down. The heading’ low BP phe-
notype’ identifies patients with chronic low BP values (in general, systolic around 110 mmHg, who have a clear history of orthostatic intolerance and
orthostatic VVS). The group ‘dominant cardioinhibition‘ identifies patients in whom clinical features and results of tests suggest that sudden cardioinhibi-
tion is mainly responsible for syncope. One such clue is lack of prodrome, so patients without prodromes may, after analysis, fall into this category.
Remark:
Overlap between subgroups is expected.
In selected cases, pacing may be used in patients aged <40 years. This Task Force cannot give recommendations due to the lack of
sufficient evidence from studies.
In selected cases, fludrocortisone may be used in patients aged >60 years. This Task Force cannot give recommendations due to
the lack of sufficient evidence from studies.
Midodrine can be used at any age even if existing studies were performed in young patients.
Patients with short or no prodrome should continue investigations to identify the underlying mechanism and guide subsequent
therapy.
Sometimes an ILR strategy should also be considered in patients aged <40 years.
BP = blood pressure; ILR = implantable loop recorder; VVS = vasovagal syncope.
a
Spontaneous or provoked by, sequentially, carotid sinus massage, tilt testing, or ILR.
..
the burden of syncope decreases by >70% compared with the .. Despite the lack of controlled studies, there is strong consensus
preceding period. The effect of education and reassurance is .. that education and lifestyle modifications have a high impact
..
probably the most likely reason for the decrease in syncope .. in reducing recurrence of syncope.
(see Supplementary Data Table 10). An example of a patient instruction ..
..
sheet can be found in the Web Practical Instructions section 9.1: European .. 5.2.2 Discontinuation/reduction of hypotensive therapy
Society of Cardiology information sheet for patients affected by reflex .. Careful avoidance of agents that lower BP, i.e. any antihyperten-
..
syncope. . sive agents, nitrates, diuretics, neuroleptic antidepressants, or
..
dopaminergic drugs, is key in the prevention of recurrence of syn- .. There is sufficient evidence from multiple trials that tilt train-
cope. In a small randomized trial260 performed in 58 patients .. ing has little efficacy in reducing recurrence of syncope in
..
(mean age 74 ± 11 years) affected by vasodepressor reflex syn- .. young patients with long-lasting recognizable prodromal symp-
cope diagnosed by tilt testing or CSM, who were taking on average .. toms. Further research is unlikely to have an important impact
..
2.5 hypotensive drugs, discontinuation or reduction of the vasoac- .. on our confidence in the estimate.
tive therapy caused a reduction of the rate of the primary com- ..
..
bined endpoint of syncope, presyncope, and adverse events from ..
50 to 19% (hazard ratio 0.37) compared with a control group who .. 5.2.5 Pharmacological therapy
..
continued hypotensive therapy during a follow-up of 9 months. In .. Pharmacological therapy may be considered in patients who have
the Systolic Blood Pressure Intervention Trial,261 patients at high .. recurrent syncope despite education and lifestyle modifications
..
cardiovascular risk who were already using antihypertensive drugs .. including training in PCM. Many drugs have been tested in the treat-
targeting a systolic BP of 120 mmHg had an approximately two- .. ment of reflex syncope, for the most part with disappointing results.
..
fold risk of syncope vs. the control group targeting a systolic BP of .. While results have been satisfactory in uncontrolled trials or short-
140 mmHg. In a short-term randomized trial262 conducted in 32 .. term controlled trials, several long-term placebo-controlled prospec-
..
patients affected by CSS, withdrawal of vasodilator therapy .. tive trials have not shown a benefit of the active drug over placebo,
reduced the magnitude of the vasodepressor reflex induced by
.. with some exceptions.
..
CSM. ..
..
.. 5.2.5.1 Fludrocortisone
There is moderate evidence that discontinuation/reduction of .. Fludrocortisone, by increasing renal sodium reabsorption and
hypotensive therapy targeting a systolic BP of 140 mmHg
..
.. expanding plasma volume, may counteract the physiological cascade
should be effective in reducing syncopal recurrences in patients .. leading to the orthostatic vasovagal reflex.273 The mechanism of
..
with hypotensive susceptibility. Further research is likely to .. action can be compared with that of saline infusion, which has also
have an important impact on our confidence in the estimate. .. proved effective in acute tilt test studies.274 The Prevention of
..
.. Syncope Trial (POST) 2275 enrolled 210 young (median age 30 years)
.. patients with low–normal values of arterial BP and without comor-
5.2.3 Physical counter-pressure manoeuvres ..
Isometric muscle contractions increase cardiac output and arterial BP
.. bidities, and randomized them to receive fludrocortisone (titrated at
.. a dosage of 0.05–0.2 mg once per day) or placebo. The primary end-
during the phase of impending reflex syncope. Three clinical stud- ..
ies119,120,263 and one prospective multicentre randomized trial121
.. point showed only a marginal non-significant reduction in syncope in
.. the fludrocortisone group compared with the placebo group (hazard
assessed the effectiveness of physical counter-pressure manoeuvres ..
(PCM) of the legs or arms and showed that they allowed the patient
.. ratio 0.69, 95% CI 0.46–1.03; P=0.069), which became more signifi-
.. cant when the analysis was restricted to patients who achieved 0.2
to avoid or delay losing consciousness in most cases. In the Physical ..
.. mg/day dose stabilization at 2 weeks. The clinical benefit of fludrocor-
Counterpressure Manoeuvres Trial (PC-Trial),121 223 patients aged ..
.. tisone therapy was modest: at 12 months, 44% of patients in the flu-
38 ± 15 years with recurrent reflex syncope and recognizable pro-
.. drocortisone arm continued to suffer syncope, a rate only slightly
dromal symptoms were randomized to receive standardized conven- .. lower than the 60.5% rate observed in the placebo arm. In the mean-
tional therapy alone or conventional therapy plus training in PCM. ..
.. time, a similar number of patients discontinued fludrocortisone ther-
Actuarial recurrence-free survival was better in the PCM group .. apy owing to side effects, thus equating the benefit/risk ratio.
(log-rank P=0.018), resulting in a relative risk reduction of 39% (95% ..
.. Fludrocortisone should not be used in patients with hypertension or
CI 11–53). No adverse events were reported. A limitation of this .. heart failure. Fludrocortisone was ineffective in a small randomized
treatment is that it cannot be used in patients with short or absent ..
.. double-blind trial in children.276
prodrome and that PCM are less effective in patients older than 60 ..
years.264 An instruction sheet on how to perform PCM can be found ..
.. There is moderate evidence that fludrocortisone may be effec-
in the Web Practical Instructions section 9.2. ..
.. tive in reducing syncopal recurrences in young patients with
.. lownormal values of arterial BP and without comorbidities.
There is moderate evidence that PCM is effective in reducing ..
syncopal recurrences in patients <60 years old with long- .. Further research is likely to have an important impact on our
.. confidence in the estimate of effect.
lasting recognizable prodromal symptoms. ..
..
.. 5.2.5.2 Alpha-agonists
..
5.2.4 Tilt training .. As failure to achieve proper vasoconstriction of the peripheral ves-
In highly motivated young patients with recurrent vasovagal symp- .. sels is common in reflex syncope, alpha-agonist vasoconstrictors (eti-
..
toms triggered by orthostatic stress, the prescription of progressively .. lefrine and midodrine) have been used. Etilefrine has been studied in
prolonged periods of enforced upright posture (so-called tilt training) .. a large randomized placebo-controlled double-blind trial.277 During
..
has been proposed to reduce syncope recurrence.265 While some .. follow-up, patients treated twice daily with etilefrine 25 mg or pla-
studies suggested modest benefit with outpatient tilt training,266,267 .. cebo showed no difference in the frequency of syncope or the time
..
most controlled trials reported no significant effect.268–272 .. to recurrence. Midodrine [usually 2.5–10 mg, three times daily (t.i.d)]
Moreover, this treatment is hampered by the low compliance of
.. has proved effective in small studies but none satisfied the criteria of
..
patients in continuing the training programme for a long period. . a pivotal clinical trial. A recent systematic review of these trials278
..
showed that the confidence in estimates was moderate because of .. orthostatic VVS.287 Norepinephrine transport inhibitors (reboxetine
imprecision and publication bias. The most frequent side effects that .. and sibutramine) lead to a selective increase in sympathetic tone dur-
..
led to discontinuation of midodrine were supine hypertension, pilo- .. ing stress by inhibiting the reuptake of norepinephrine in sympathetic
motor reactions, and urinary problems (urinary retention, hesitancy, .. neuronal synapses. In double-blind, randomized, crossover fashion,
..
or urgency). The major limitation of midodrine is frequent dosing, .. reboxetine and sibutramine block or attenuate the vasovagal reflex
which limits long-term compliance. Overall, these data suggest that .. during tilt testing.288 In an open-label prospective clinical study in
..
chronic pharmacological treatment with alpha-agonists alone may be .. seven very symptomatic patients who had not responded to any pre-
of little use in reflex syncope and that long-term treatment cannot be .. vious treatment, sibutramine achieved 94% suppression of syncopal
..
advised for occasional symptoms. .. episodes at 6 months.289
.. Ganglionic plexus ablation. Radiofrequency ablation of vagal ganglia
..
There are contrasting results from multiple trials that alpha- .. located close to the sinus node and AV node was reported to abolish
agonists may be effective in reducing syncopal recurrences in .. the vagal efferent output during VVS in some observational studies
..
patients with the orthostatic form of VVS. Further research is .. and case reports.290,291 However, owing to a weak rationale, small
likely to have an important impact on our confidence in the .. populations, weak documentation of follow-up results, procedural
..
estimate. .. risks, and lack of control groups, the current evidence is insufficient
.. to confirm the efficacy of vagal ganglia ablation.
..
5.2.5.3 Beta-blockers ..
Beta-blockers have been presumed to lessen the degree of ventricu-
..
..
lar mechanoreceptor activation owing to their negative inotropic .. 5.2.6 Cardiac pacing
effect in reflex syncope. This theory has not been supported by the
..
.. Permanent pacemaker therapy may be effective if asystole is a domi-
outcome of clinical trials. Beta-blockers failed to be effective in VVS .. nant feature of reflex syncope. Establishing a relationship between
..
in two randomized double-blind controlled trials.279,280 A rationale .. symptoms and bradycardia should be the goal of the clinical evalua-
for the use of beta-blockers in other forms of neutrally-mediated syn- .. tion of patients with syncope and a normal baseline ECG. The efficacy
..
cope is lacking. It should be emphasized that beta-blockers may .. of pacing depends on the clinical setting. A comparative table of
enhance bradycardia in CSS. .. results in different settings is reported in the Supplementary Data
..
.. Table 9. Figure 10 summarizes the recommended indication for
There is sufficient evidence from multiple trials that beta- .. pacing.
..
blockers are not appropriate in reducing syncopal recurrences. ..
Desirable and undesirable effects are closely balanced. .. 5.2.6.1 Evidence from trials in suspected or certain reflex syncope and
..
.. electrocardiogram-documented asystole
5.2.5.4 Other drugs .. In two observational studies, cardiac pacing reduced syncope burden
..
Paroxetine, a selective serotonin reuptake inhibitor, was effective in .. in patients with documented asystolic syncope by 92184 and 83%,200
one placebo-controlled trial, which included highly symptomatic .. but did not prevent all syncopal events. In the randomized
..
patients from one institution.281 This finding has not been confirmed .. double-blind Third International Study on Syncope of Uncertain
in other studies and has no experimental support. Conversely, .. Etiology (ISSUE)-3 trial,185 77 patients who had documentation, by
..
human studies with different subtypes of serotonin-receptor antago- .. means of ILR, of syncope with >_3-s asystole or >_6-s asystole without
nists demonstrated a decreased tolerance to tilt.1,282 In a small
.. syncope were randomly assigned to receive either dual-chamber pac-
..
randomized trial, benzodiazepine was as effective as metoprolol.283 .. ing with rate drop response or sensing only. During follow-up, the 2-
A somatostatin analogue (octreotide)284 was used in a few patients
.. year estimated rate of syncope recurrence was 57% with pacemaker
..
affected by orthostatic intolerance and its effect cannot be properly .. off and 25% with pacemaker on (log-rank P¼0.039). The risk of
evaluated.
..
.. recurrence was reduced by 57%. In the ILR subgroup of the multi-
.. centre Syncope Unit Project (SUP) 2 study,292 the estimated rates of
5.2.5.5 Emerging new therapies in specific subgroups
..
.. syncope recurrence with pacing were 11% at 1 year, 24% at 2 years,
Low-adenosine phenotype. In a series of case reports, theophylline .. and 24% at 3 years, and were significantly lower than the correspond-
..
appeared effective in patients with recurrent sudden onset (pre)syn- .. ing rates observed in untreated control patients. The above evidence
cope who presented with the common biological characteristic of .. supports a class IIa recommendation
..
low circulating adenosine levels.285,286 Theophylline is a non-selective ..
adenosine receptor antagonist that is potentially effective when .. There is sufficient evidence that dual-chamber cardiac pacing
..
adenosine is suspected to be involved in the mechanism of syncope. .. should be considered to reduce recurrence of syncope when
An intra-patient comparison between a period with and a period .. the correlation between symptoms and ECG is established in
..
without theophylline therapy, with the support of prolonged ECG .. patients 40 years of age with the clinical features of those in
monitoring, showed that symptoms disappeared and the number of .. the ISSUE studies.
..
prolonged asystolic pauses was impressively reduced from a median ..
of 1.11 per month during 13 months of no treatment to 0 per month .. 5.2.6.2 Evidence from trials in patients with carotid sinus syndrome
..
during 20 months of theophylline treatment. .. The evidence supporting the benefit of cardiac pacing in patients
Low-norepinephrine phenotype. A mismatch between sympathetic .. affected by cardioinhibitory CSS is limited to a few small controlled
..
nerve activity and norepinephrine spillover is present in patients with . trials and retrospective observational studies. In a review293 including
Figure 10 Summary of indications for pacing in patients with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome.
12 studies for a total of 601 paced and 305 unpaced patients, the syn-
.. 5.2.6.3 Evidence from trials in patients with tilt-induced vasovagal
..
copal recurrence rate during follow-up ranged from 0–20% with pac- .. syncope
..
ing, whereas the recurrence of syncope was always higher in .. Effectiveness of pacing in patients with tilt-induced VVS has been
untreated patients, who showed a rate between 20–60%. In a meta- .. studied in five multicentre RCTs.296–300 When combining the results
..
analysis of the three studies293 with a control group of untreated .. of these trials, 318 patients were evaluated; syncope recurred in 21%
patients, syncope recurred in 9% of 85 paced patients and in 38% of .. of the paced patients and in 44% of unpaced patients (P < 0.001). A
..
91 controls (relative risk 0.24, 95% CI 0.12–0.48). In a single-centre .. meta-analysis of all studies suggested a non-significant 17% reduction
registry of 169 consecutive patients treated with pacemakers, the .. in syncope from the double-blind studies, and an 84% reduction in
..
actuarial estimate of syncopal recurrence was 7% at 1 year, 16% at .. the studies where the control group did not receive a pacemaker.301
3 years, and 20% at 5 years.90 In the CSS subgroup of the multicentre .. In general, pacing was ineffective in trials that enrolled patients with-
..
SUP 2 study,292 the estimated syncope recurrence rates with pacing .. out an asystolic tilt response.299,300 All of these studies have limita-
were 9% at 1 year, 18% at 2 years, and 20% at 3 years, and were signif- .. tions, and a direct comparison is somewhat difficult because of
..
icantly lower than the corresponding rates observed in untreated .. important differences in study design, largely focused on patient
controls, which were 21%, 33%, and 43%, respectively. Given the .. selection. Overall, in typical vasovagal populations, pacing seems to
..
similar outcome of patients with reflex spontaneous asystolic pauses .. have marginal efficacy.
and those with CSS, this Task Force voted to downgrade the recom-
.. The rationale for the efficacy of cardiac pacing is that the cardioin-
..
mendation for pacing in patients with CSS from class I (as in the 2013 .. hibitory reflex is dominant in some patients, as there is no role for
ESC Pacing Guidelines294) to class IIa.
.. pacing in the preventing vasodilatation and hypotension. In a substudy
..
.. of the ISSUE-3 trial,302 an asystolic response during tilt testing pre-
Despite the lack of large RCTs, there is sufficient evidence that
.. dicted a similar asystolic form during spontaneous ILR-documented
..
dual-chamber cardiac pacing should be considered to reduce .. syncope, with a positive predictive value of 86%. In the tilt subgroup
syncopal recurrences in patients affected by dominant cardi-
.. of the SUP 2 study,292 among 38 patients with dominant cardioinhibi-
..
oinhibitory CSS. .. tory reflex (with a mean asystolic pause of 22 ± 16 s) the estimated
.. rates of syncope recurrence with pacing were 3% at 1 year, 17% at 2
..
Two variables are well known to hamper the efficacy of pacing ther- .. years, and 23% at 3 years; these figures were significantly lower than
..
apy in CSS: the mixed forms93,98 (see also Web Practical Instructions .. the corresponding rates observed in untreated controls, and were
section 5) and the association with positivity of tilt testing. Patients .. similar to those observed in patients with CSS or with ECG-
..
who have positive tilt tests have a three-fold greater probability of .. documented asystole. In a recent multicentre crossover RCT per-
syncope recurrence after dual chamber pacing than those with nega- .. formed in 46 patients aged >40 years, affected by severely recurrent
..
tive tilt tests293,295; thus, when tilt testing is positive, caution must be .. (>5 episodes during life) cardioinhibitory VVS,303 during 24-month
recommended over pacemaker implantation. .. follow-up, syncope recurred in 4 (9%) patients treated with a dual-
..
chamber pacemaker with closed-loop stimulation compared with 21 .. dual-chamber cardiac pacing significantly reduced the 2-year syncope
(46%) patients who had received a sham pacemaker programmed off .. recurrence rate from 69% in the control group to 23% in the active
..
(P=0.0001). .. group.
Adding video recording to tilt testing, Saal et al.205 recently ..
..
showed, in patients with asystole, that asystole occurred 3 s .. There is weak evidence that dual-chamber cardiac pacing
before syncope or later in one-third of patients, in whom cardioinhi- .. may be useful in reducing recurrences of syncope in patients
..
bition was too late to have primarily caused syncope; in the other .. with the clinical features of adenosine-sensitive syncope.
two-thirds of asystolic tilt responses, the cause must have been .. The documentation of possible bradyarrhythmia in sponta-
..
mainly cardioinhibition or a combination of cardioinhibition and .. neous syncope remains the preferred eligibility criterion for
vasodepression.
.. pacing.
..
The clinical presentation is probably as important as tilt test ..
positivity when selecting patients who can benefit from cardiac
.. 5.2.6.5 Choice of pacing mode
..
pacing. The SUP 2 study population was characterized by higher .. In CSS, a few small controlled studies304,305 and one registry306
mean age, history of recurrent syncope beginning in middle or
.. showed that dual-chamber pacing is better than the single chamber
..
older age, and frequent injuries, probably due to presentation .. ventricular mode in counteracting BP fall during CSM and in prevent-
..
without warning.292 .. ing symptom recurrences. Even if the quality of evidence is weak,
... dual-chamber pacing is widely preferred in clinical practice.
Owing to the contrasting results of the randomized trials, the .. In patients with VVS, dual-chamber pacing was used mostly with
..
estimated benefit of dual-chamber pacing in cardioinhibitory .. a rate drop response feature that instituted rapid dual-chamber
tilt-positive patients is weak. Divergence of opinion exists .. pacing if the device detected a rapid decrease in HR. A compari-
..
among experts. Further research is very likely to have an .. son between dual-chamber closed-loop stimulation and conven-
important impact on recommendations. Conversely, there is .. tional dual-chamber pacing has been performed by means of a
..
strong consensus that pacing cannot be offered to patients .. crossover design in two small studies; these studies showed fewer
with non-cardioinhibitory tilt-positive response, and further .. syncope recurrences with closed-loop stimulation, both in the
..
tests (e.g. ILR) are warranted to document the mechanism of .. acute setting during repeated tilt testing307 and during 18-month
the spontaneous reflex. .. clinical follow-up.308
..
..
5.2.6.4 Evidence from trials in patients with adenosine-sensitive syncope .. 5.2.6.6 Selection of patients for pacing and proposed algorithm
..
Under this term, classified as a non-classical form of reflex syn- .. The fact that pacing is effective does not mean that it is always neces-
cope in Table 3, different clinical conditions are included, which .. sary. In patients with reflex syncope, cardiac pacing should be the last
..
have a supposed role of adenosine in the genesis of syncope in .. choice and should only be considered in highly selected patients, i.e.
common.
.. those >_40 years of age (mostly >60 years), affected by severe forms
..
A new clinical entity, called idiopathic AV block, has recently .. of reflex syncope with frequent recurrences associated with a
been described in patients with a long history of syncope and in
.. high risk of injury, often due to the lack of prodrome.186 While there
..
whom paroxysmal AV block could be recorded at the time of syn- .. is growing scepticism over the diagnostic accuracy of tilt testing for
cope recurrence.5 These patients had an otherwise normal heart
.. syncope diagnosis, emerging evidence supports the use of tilt testing
..
and no sign of conduction disease on ECG and EPS; they had very .. for the assessment of reflex hypotensive susceptibility132, which may be
low plasma adenosine levels and a high induction rate of transient
.. considered to identify patients with an associated hypotensive
..
complete heart block during exogenous injections of adenosine. .. response who would be less likely to respond to permanent cardiac
..
No syncope recurrence was observed after permanent cardiac .. pacing (see section 4.2.2.2). In a meta-analysis309 of individual patient
pacing over very long periods of follow-up and there was no per- .. data from four studies performed in patients with asystolic reflex
..
manent AV block. .. syncope documented by an ILR, the estimated 3-year recurrence
Similarly, the entity of ‘low-adenosine syncope’ has recently .. rate of syncope was 2% (95% CI ± 4%) in tilt-negative patients and
..
been described in patients who have an otherwise unexplained .. 33% (95% CI ± 20%) in tilt-positive patients; a positive tilt test
syncope with sudden onset without prodrome, a normal heart, .. response was the only significant predictor of syncope recurrence
..
and normal ECG.4 The clinical, laboratory, and biological features .. with a hazard ratio of 4.3. Patients with hypotensive susceptibility
of these patients are similar to those observed in patients .. should need measures directed to counteract hypotensive suscepti-
..
affected by idiopathic paroxysmal AV block. Unlike in VVS, tilt .. bility in addition to cardiac pacing, e.g. the discontinuation/reduction
testing is usually negative.4,226 No syncope recurrence was .. of hypotensive drugs and the administration of fludrocortisone or
..
observed after permanent cardiac pacing in 10 patients who had .. midodrine.
ECG documentation of asystolic pause due to sinus arrest or AV .. The algorithm shown in Figure 11 has recently been prospectively
..
block.286 .. validated in a multicentre pragmatic study, which showed a low
In a small multicentre trial227 performed in 80 highly selected eld-
.. recurrence rate of syncope with pacing of 9% at 1 year and 15% at 2
..
erly patients with unexplained unpredictable syncope who had a pos- .. years, significantly lower than the 22% and 37%, respectively,
itive response to intravenous injection of a bolus of 20 mg of ATP,
.. observed in unpaced controls.186
Explanation of the diagnosis, the provision of reassurance, and explanation of the risk of recurrence and the avoidance of
I B
triggers and situations are indicated in all patients. Supplementary Data Table 10
Modification or discontinuation of hypotensive drug regimen should be considered in patients with vasodepressor syncope,
IIa B
if possible.260–262
Physical manoeuvres
Isometric PCM should be considered in patients with prodromes who are <60 years of age.119–121,263,264 IIa B
Tilt training may be considered for the education of young patients.265–272 IIb B
Pharmacological therapy
Fludrocortisone may be considered in young patients with the orthostatic form of VVS, low–normal values of arterial BP,
IIb B
and the absence of contraindication to the drug.275
Midodrine may be considered in patients with the orthostatic form of VVS.278 IIb B
279,280
Beta-adrenergic blocking drugs are not indicated. III A
Cardiac pacing
Cardiac pacing should be considered to reduce syncopal recurrences in patients aged >40 years, with spontaneous docu-
mented symptomatic asystolic pause(s) >3 s or asymptomatic pause(s) >6 s due to sinus arrest, AV block, or the combina- IIa B
tion of the two.184,185,200,292
Cardiac pacing should be considered to reduce syncope recurrence in patients with cardioinhibitory carotid sinus syn-
IIa B
drome who are >40 years with recurrent frequent unpredictable syncope.90,292,293
Cardiac pacing may be considered to reduce syncope recurrences in patients with tilt-induced asystolic response who are
IIb B
>40 years with recurrent frequent unpredictable syncope.292,297,298,303
Cardiac pacing may be considered to reduce syncope recurrences in patients with the clinical features of adenosine-sensi-
IIb B
tive syncope.5,227,286
Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex.299,300 III B
AV = atrioventricular; BP = blood pressure; PCM = physical counter-pressure manoeuvres; VVS = vasovagal syncope.
a
Class of recommendation.
b
Level of evidence.
No
No
Asystolic
tilt testing?
No
No
Figure 11 Decision pathway for cardiac pacing in patients with reflex syncope. CI-CSS = cardioinhibitory carotid sinus syndrome; CSM = carotid
sinus massage; DDD PM = dual-chamber pacemaker; ILR = implantable loop recorder.
..
5.3 Treatment of orthostatic hypotension .. chloride.310 Rapid ingestion of cool water is reported to be effective in
.. combating orthostatic intolerance and postprandial hypotension.311
and orthostatic intolerance syndromes ..
Current management strategies for OH are summarized in Figure 12. ..
..
..
.. 5.3.3 Discontinuation/reduction of vasoactive drugs
5.3.1 Education and lifestyle measures .. Several studies that have evaluated the association of vasoactive
Education regarding the nature of the condition in conjunction with the ..
.. drugs (i.e. any antihypertensive agents, nitrates, diuretics, neuroleptic
lifestyle advice outlined in section 5.2.1 can markedly improve ortho- .. antidepressants, or dopaminergic drugs) with OH and falls
static symptoms, even though the rise in BP is relatively small (10–15 ..
.. have yielded contrasting results.312 However, intensely prescribed
mmHg); raising standing BP to just within the autoregulatory zone can .. antihypertensive therapy can increase the risk of OH. Intensive anti-
make a substantial functional difference. Ambulatory BP recordings may
..
.. hypertensive treatment can be defined as higher doses of antihyper-
be helpful in identifying abnormal diurnal patterns. These recordings may .. tensive medications, an increased number of antihypertensive
also help identify supine or nocturnal hypertension in treated patients.
..
.. drugs, or lowering BP to a target <140/90 mmHg. The total
.. number of BP-lowering medications313 or the use of three or more
..
5.3.2 Adequate hydration and salt intake .. antihypertensive drugs may be a significant predictor of OH.314
The expansion of extracellular volume is an important goal. In the
.. Angiotensin-converting enzyme inhibitors, angiotensin receptors
..
absence of hypertension, patients should be instructed to have a sufficient .. blockers, and calcium channel blockers are less likely to be associated
salt and water intake, targeting 2–3 L of fluids per day and 10 g of sodium
.. with OH compared with beta-blockers and thiazide diuretics.315–318
..
.. 5.4.1.1 Sinus node disease
Treatment of orthostatic hypertension .. In general, cardiac pacemaker therapy is indicated and has proved
..
.. effective in intrinsic sinus node disease when intermittent sinus arrest
Recommendations Classa Levelb .. or sinoatrial block has been demonstrated to account for syncope by
..
.. means of ECG documentation during spontaneous syncope.334–338
Explanation of the diagnosis, the provision .. A frequent situation is that of patients who have prolonged sinus
of reassurance, and explanation of the risk ..
I C .. pause following the termination of tachycardia in bradycar-
of recurrence and the avoidance of triggers .. dia-tachycardia syndrome due to the abnormally prolonged time
and situations are indicated in all patients. ..
.. needed for the recovery of automaticity by a diseased sinus node.
.. Permanent pacing does not affect survival.
Adequate hydration and salt intake are
I C ..
indicated.310,311 ..
.. When the correlation between symptoms and ECG is estab-
Modification or discontinuation of hypoten-
..
.. lished, there is general consensus that cardiac pacing is effec-
sive drug regimens should be IIa B .. tive and useful for symptom relief.
considered.312–318
..
.. In the absence of the above situations, despite adequate pacing, syn-
.. cope recurs in approximately 15–28% of patients at 5 years339–341
Isometric PCM should be considered.319 IIa C ..
.. (see Supplementary Data Table 9). This is due to the frequent associa-
Abdominal binders and/or support stockings ..
.. tion of a vasodepressor reflex mechanism with sinus node disease. In
to reduce venous pooling should be IIa B .. patients with sinus node disease and syncope, carotid sinus hypersen-
considered.23,320,321 ..
.. sitivity and a positive response to tilt are present in <_50% of patients.
Head-up tilt sleeping (>10 degrees) to
.. Thus, an increased susceptibility to neurally mediated bradycardia/
..
increase fluid volume should be IIa C .. hypotension is often the cause of syncope.135,136 A reflex mechanism
considered.104,322,323
.. of syncope fits well with the unpredictable natural history of syncope
..
.. recurrence. Physicians should be aware that effectiveness of therapy is
Midodrine should be considered if symp-
IIa B
.. not well documented in such cases. From a practical perspective, car-
toms persist.324–326 ..
.. diac pacing may be a reasonable solution in patients affected by sinus
.. node disease, who have had documentation of an asymptomatic ven-
Fludrocortisone should be considered if
IIa C ..
symptoms persist.322,327,328 .. tricular pause >3 s (with exceptions for young trained persons, during
.. sleep, and medicated patients), when a competitive diagnosis, i.e.
Additional advice and clinical perspectives
..
.. hypotension, can be ruled out.294 An abnormal SNRT enhances the
• In individuals with established OH and risk factors for falls, .. probability of efficacy of cardiac pacing (see section 4.2.6.1).210–212
aggressive BP-lowering treatment should be avoided; their
..
..
treatment targets should be revised to a systolic BP value of .. When the correlation between symptoms and ECG is not
..
140–150 mmHg and medication withdrawal should be .. established, cardiac pacing may be reasonable in patients with
considered. .. intrinsic sinus node disease, syncope, and documentation of
..
• The BP-lowering agents (angiotensin-converting enzyme .. asymptomatic pause(s).
inhibitors, angiotensin receptor blockers, and calcium channel .. The elimination of drugs that may exacerbate or unmask an underly-
..
blockers) should be used preferentially, especially among .. ing susceptibility to bradycardia is an important element in preventing
patients at high risk of falls, as diuretics and beta-blockers are .. syncope recurrence. Percutaneous cardiac ablative techniques for
..
associated with OH and falls and should be avoided in at-risk .. the control of atrial tachyarrhythmia have become of increasing
individuals. ..
.. importance in selected patients with the bradycardia-tachycardia
.. form of sick sinus syndrome, but are infrequently used for the pre-
BP = blood pressure; OH = orthostatic hypertension; PCM = physical counter-
..
.. vention of syncope.
pressure manoeuvres. ..
a
Class of recommendation. ..
b
Level of evidence. .. 5.4.1.2 Atrioventricular conduction system disease
.. Cardiac pacing is the treatment of syncope associated with sympto-
..
lost after 8 weeks.333 Thus, current evidence is insufficient to confirm
.. matic AV block (Figure 13). Although formal RCTs of pacing in third-
.. or second-degree type 2 AV block have not been performed, some
the efficacy of droxidopa for long-term use. ..
.. observational studies suggest that pacing is highly effective in prevent-
.. ing syncope recurrences when AV block is documented. Langenfeld
5.4 Cardiac arrhythmias as the primary ..
.. et al.341 observed a decline in the rate of syncope from 44 to 3.4%
cause .. over 5-year follow-up in 115 patients paced for AV block; the recur-
..
5.4.1 Syncope due to intrinsic sinoatrial or .. rence rate was 7% in the subgroup with syncope before pacemaker
atrioventricular conduction system disease
.. implantation. More recently, Sud et al.200 reported no syncope recur-
..
Current management strategies in patients with syncope due to .. rence, and Aste et al.255 reported a recurrence of 1% at 5 years after
intrinsic cardiac bradycardia are summarized in Figure 13.
.. pacemaker implantation among 73 patients with documented
° °
Figure 13 Summary of indications for pacing in patients with syncope due to intrinsic cardiac bradycardia. AF = atrial fibrillation; asympt. = asymp-
tomatic; AV = atrioventricular; BBB = bundle branch block; ECG = electrocardiogram; EPS = electrophysiological study; HR = heart rate; ILR =
implantable loop recorder; SB = sinus bradycardia; SND = sinus node dysfunction; sympt. = symptomatic.
..
persistent or intermittent documented AV block (see Supplementary .. Even if the quality of evidence is moderate, there is strong con-
Data Table 9). .. sensus that in patients with bifascicular BBB with a positive EPS
..
.. or documentation of paroxysmal AV block during prolonged
5.4.1.3 Bundle branch block and unexplained syncope .. ECG monitoring, cardiac pacing is highly effective in preventing
..
The presence of bifascicular BBB suggests that the cause of syncope .. syncope recurrence. The evidence of efficacy of empirical pac-
may be complete heart block. Nevertheless, less than half of the
.. ing strategy is weak and the estimate of benefit is uncertain.
..
patients with bifascicular BBB and syncope will have a final diagnosis .. Although syncope is not associated with an increased incidence of sud-
of AV block, a similar percentage will have a final diagnosis of reflex
.. den death in patients with preserved cardiac function, a high incidence
..
syncope, and, in approximately 15%, the cause will remain unex- .. of total deaths (about one-third sudden) was observed in patients with
plained at the end of a complete workup.342 In addition, among
.. BBB and heart failure, previous myocardial infarction, or low ejection
..
patients receiving an ILR, approximately half remained free of syn- .. fraction.345–347 Indeed, the high total and sudden mortality seems to be
cope for >2 years after the implantation.187,188,342,343 Conversely,
.. mainly related to underlying structural heart disease and ventricular
..
implantation of a pacemaker without documentation of AV block .. tachyarrhythmias. In this latter situation, syncope is a risk factor, rather
..
(empirical pacing) exposed patients to the risk of recurrence of syn- .. than the cause, of death.218 Unfortunately, ventricular programmed
cope in about one-quarter of cases during long-term follow-up and .. stimulation does not seem to identify these patients correctly, and the
..
was unnecessary in another half.217,344 Thus, only one in four pace- .. finding of inducible ventricular arrhythmia (VA) should therefore be
makers will finally be appropriate. Finally, pacemaker treatment has .. interpreted with caution.345,346 Therefore, an implantable cardioverter
..
not been proven to have a survival benefit. The above considerations .. defibrillator (ICD) or a cardiac resynchronization therapy defibrillator is
justify a class IIb indication in the ESC Guidelines on pacing.294 .. indicated in patients with BBB, congestive heart failure, or previous
..
To overcome the above problems, ESC Guidelines on pacing294— .. myocardial infarction and depressed systolic function for the preven-
in patients with LVEF >35%—recommend a strategy of EPS followed .. tion of SCD, but may be unable to prevent the recurrence of syncope,
..
by ILR if the EPS findings are unremarkable. With this strategy, a pace- .. which is often due to non-arrhythmic causes such as OH or vasode-
maker was implanted in approximately half of the patients and these .. pressor reflex. The strategy for the management of patients with unex-
..
patients had syncope recurrence after pacemaker implantation in .. plained syncope and BBB is summarized in Figure 14.
0–7% of cases188,217. This strategy was safe; however, this Task Force ..
..
recognizes that in the ‘real world’, an empirical pacemaker may be ..
acceptable in selected patients at high risk of traumatic recurrence .. 5.4.2 Syncope due to intrinsic cardiac tachyarrhythmias
..
(e.g. elderly patients with unpredictable syncopes) and that an individ- .. Current management strategies in patients with syncope due to
ual risk–benefit evaluation is warranted (Figure 14).
.. intrinsic cardiac tachyarrhythmia are summarized in Figure 15.
Figure 14 Therapeutic algorithm for patients presenting with unexplained syncope and bundle branch block. BBB = bundle branch block; CRT-D
= cardiac resynchronization therapy defibrillator; EPS = electrophysiological study; ICD = implantable cardioverter defibrillator; ILR = implantable
loop recorder; PM = pacemaker.
Figure 15 Choice of therapy for patients presenting with syncope due to cardiac tachyarrhythmias as the primary cause. AA = antiarrhythmic;
ICD = implantable cardioverter defibrillator; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
..
5.4.2.1 Paroxysmal supraventricular tachycardia .. 5.4.2.2 Paroxysmal ventricular tachycardia
In patients with paroxysmal AV nodal re-entrant tachycardia, AV re- .. Syncope due to torsade de pointes is not uncommon and is, in its
..
entrant tachycardia, typical atrial flutter, and ectopic tachycardia .. acquired form, the result of drugs that prolong the QT interval.
associated with syncope, catheter ablation is the first-choice treat- .. Treatment is the immediate discontinuation of the suspected drug.
..
ment. In these patients, the role of drug therapy is limited to being a .. Catheter ablation or drug therapy is recommended in patients
bridge to ablation or being used when ablation has failed. In patients .. with syncope due to VT in the presence or absence of structural
..
with syncope associated with atrial fibrillation or atypical left atrial .. heart disease in order to prevent syncope recurrence (Figure 15).
flutter, the decision should be individualized.
.. Detailed guidelines regarding antiarrhythmic drug usage in patients
.
with VT can be found in the 2015 ESC Guidelines for VA and the pre-
.. patients with syncope and previous myocardial infarction who have
..
vention of SCD.46 .. VT induced during EPS346 (see section 4.2.6).
..
An ICD is indicated in patients with syncope and depressed cardiac .. In patients with preserved systolic function, the indication for ICD
function, and VT or VF without correctable cause. Although ICD .. is weaker because trials have not addressed this specific issue.
..
may not prevent syncope recurrence in these patients,31,348 it is indi- .. However, when VT causes syncope, this Task Force believes that an
cated to reduce the risk of SCD (refer to the 2015 ESC Guidelines .. ICD is warranted if catheter ablation and pharmacological therapy
..
for VA and the prevention of SCD46). An ICD is also indicated in . have failed or could not be performed (Figure 15).
Bradycardia (intrinsic)
Cardiac pacing is indicated when there is an established relationship between syncope and symptomatic bradycardia due to:
• Sick sinus syndrome.210–212,334–338 I B
200,255,341
• Intrinsic AV block. I B
Cardiac pacing is indicated in patients with intermittent/paroxysmal intrinsic third- or second-degree AV block (including
I C
AF with slow ventricular conduction), although there is no documentation of a correlation between symptoms and ECGs.
Cardiac pacing should be considered when the relationship between syncope and asymptomatic sinus node dysfunction is
IIa C
less established.135,136,210–212,339,340
Cardiac pacing is not indicated in patients when there are reversible causes for bradycardia. III C
Bifascicular BBB
Cardiac pacing is indicated in patients with syncope, BBB, and a positive EPS or ILR-documented AV block.188,217 I B
Cardiac pacing may be considered in patients with unexplained syncope and bifascicular BBB.217,255,344 IIb B
Tachycardia
Catheter ablation is indicated in patients with syncope due to SVT or VT in order to prevent syncope recurrence.46 I B
An ICD is indicated in patients with syncope due to VT and an ejection fraction <_35%.46 I A
218
An ICD is indicated in patients with syncope and previous myocardial infarction who have VT induced during EPS. I C
An ICD should be considered in patients with an ejection fraction >35% with recurrent syncope due to VT when catheter
IIa C
ablation and pharmacological therapy have failed or could not be performed.46
Antiarrhythmic drug therapy, including rate-control drugs, should be considered in patients with syncope due to SVT or VT. IIa C
AF = atrial fibrillation; AV = atrioventricular; BBB = bundle branch block; CSM = carotid sinus massage; ECG = electrocardiogram; EPS = electrophysiological study; ICD =
implantable cardioverter defibrillator; ILR = implantable loop recorder; SCD = sudden cardiac death; SVT = supraventricular tachycardia; VT = ventricular tachycardia.
a
Class of recommendation.
b
Level of evidence.
..
5.5 Treatment of syncope secondary to .. 5.6.2 Left ventricular systolic dysfunction
.. The benefit of an ICD to reduce the risk of death is established. Thus,
structural cardiac, cardiopulmonary, and ..
.. patients with unexplained syncope who have an established ICD indi-
great vessel disease .. cation per current Guidelines46 must receive an ICD before, and
Cardiac syncope is diagnosed when syncope presents in patients with ..
.. independently of, the evaluation of the mechanism of syncope, even if
severe aortic stenosis, acute myocardial infarction/ischaemia, HCM, .. the mechanism of syncope is unknown or uncertain at the end of a
cardiac masses (atrial myxoma, ball thrombus, etc.), pericardial dis- ..
.. complete workup. While this strategy may help to prolong life,
ease/tamponade, congenital anomalies of the coronary arteries, pros- .. patients often remain at risk of recurrent syncope, implying a need
thetic valve dysfunction, pulmonary embolus, acute aortic dissection, ..
.. for precise identification of the mechanism of syncope and specific
and pulmonary hypertension (see section 4.1.1). Structural cardiac or .. treatment when possible.
cardiopulmonary disease can be present in some patients with syn- ..
.. Few data exist concerning the prevalence and the prognostic impli-
cope, and its incidence increases in older patients. The mere presence .. cations of unexplained syncope in unselected patients with left ven-
of heart disease does not imply that syncope is related to the underly- ..
.. tricular dysfunction or non-ischaemic dilated cardiomyopathy with
ing cardiac disorder. Some of these patients have typical reflex syn- .
cope; in others, such as those with inferior myocardial infarction or
aortic stenosis, the underlying cardiac disease may play a role in trig- Implantable cardioverter defibrillator indications in
gering or potentiating a reflex mechanism, and—finally—the underly- patients with unexplained syncopea and left ventricular
ing cardiac disease may be the substrate for conduction disturbances, systolic dysfunction
supraventricular arrhythmia, or VA that causes syncope.
Recommendations Classb Levelc
Even in the absence of specific trials, there is strong consensus
that with syncope secondary to structural cardiac disease, the ICD therapy is recommended to reduce
goal of treatment is not only to prevent syncopal recurrence, but SCD in patients with symptomatic heart fail-
to treat the underlying disease and decrease the risk of death. ure (NYHA class II–III) and LVEF <_35% after
I A
>_3 months of optimal medical therapy, who
are expected to survive >_1 year with good
5.6 Treatment of unexplained syncope in
functional status.46
patients at high risk of sudden cardiac
death An ICD should be considered in patients
The underlying clinical situation is that of a patient being evaluated for with unexplained syncopea with systolic
ICD implantation because they are affected by syncope(s) supposedly impairment, but without a current indication IIa C
due to transient self-terminating ventricular tachyarrhythmias (fast VT or for ICD, to reduce the risk of sudden
VF), which have not yet been documented because of their short dura- death.27,28,359,360
tion.349 Syncope due to documented VT/VF is outside the scope of this Instead of an ICD, an ILR may be considered
section; please refer to section 5.4.2. General guidance may be sought in in patients with recurrent episodes of unex-
the 2015 ESC Guidelines for VA and the prevention of SCD.46 IIb C
plained syncopea with systolic impairment,
but without a current indication for ICD.
5.6.1 Definition
Additional advice and clinical perspectives
In general, a history of syncope in patients with structural heart
disease or inheritable arrhythmia syndromes is associated with a • The presence of syncope increases mortality regardless of its
cause.348 Thus, syncope is a risk factor for life-threatening
two- to four-fold increased risk of death,348,350–353 but varies
events.
between specific conditions.354–356 Moreover, there have been
very few studies on ICDs in patients with syncope associated with • The decision to implant an ICD or to complete the
investigation (e.g. ILR implantation) in patients with unex-
left ventricular dysfunction,31,348 cardiomyopathy, or inheritable
plained syncope depends on a global clinical evaluation
arrhythmia syndromes.357 In these Guidelines, we complement
of the patient’s conditions, the potential benefit and harm
previous ESC Guidelines for VA and the prevention of SCD46 by
of such therapy, and the presence of other risk factors
providing a precise definition of unexplained syncope, and making
for SCD.
recommendations for its investigation and management in differ-
ent clinical settings.
• For this section, ‘unexplained syncope‘ is defined as syncope that ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;
does not meet any class I diagnostic criterion defined in the LVEF = left ventricular ejection fraction; NYHA = New York Heart Association;
tables of recommendations in section 4. In the presence of clini- SCD = sudden cardiac death.
a
cal features described in this section, unexplained syncope is con- Unexplained syncope is defined as syncope that does not meet a class I diagnos-
tic criterion defined in the tables of recommendations in section 4. In the pres-
sidered a ‘suspected arrhythmic syncope’. ence of clinical features described in this section, unexplained syncope is
considered a risk factor for ventricular tachyarrhythmias.
When the mechanism of syncope is non-arrhythmic, the manage- b
Class of recommendation.
c
ment of patients at high risk of SCD is the same as for patients with- Level of evidence.
out syncope.
less severe systolic impairment who do not meet the current indica- .. 5.6.4 Arrhythmogenic right ventricular
..
tion for ICD.358 Data from observational studies in selected cohorts .. cardiomyopathy
show a high rate of occurrence of ventricular arrhythmias, ICD dis- .. Although limited and diverse, current data suggest that unexplained syn-
..
charge, and death in patients with a history of unexplained syncope .. cope is a marker of arrhythmic risk in patients with ARVC.46,351,362,363
but, owing to a lack of control groups, are unable to show the benefit
.. The decision to implant an ICD should take into account the other
..
of an ICD.27,28,359,360 This Task Force believes that an ICD should be .. known risk factors for arrhythmic events46: frequent non-sustained VT,
considered in patients with unexplained syncope with systolic impair-
.. family history of premature sudden death, extensive right ventricular
..
ment but without a current indication for ICD to reduce the risk of .. disease, marked QRS prolongation, late gadolinium enhancement on
sudden death.
.. magnetic resonance imaging (MRI) (including left ventricular involve-
..
.. ment), left ventricular dysfunction, and VT induction during EPS.46
..
5.6.3 Hypertrophic cardiomyopathy
Unexplained syncope is an independent predictor for SCD and
appropriate ICD discharge. In a systematic review, the average haz- Implantable cardioverter defibrillator indications in
ard ratio of unexplained syncope (irrespective of definition) was 2.68 patients with unexplained syncopea and arrhythmogenic
right ventricular cardiomyopathy
(95% CI 0.97–4.38).361 In the largest multicentre study to date
(>3600 patients with HCM), syncope was an independent predictor
of the composite of SCD and ICD discharge (hazard ratio 2.05, 95% Recommendations Classb Levelc
CI 1.48–2.82).350 A prophylactic ICD is appropriate in individuals ICD implantation may be considered in
with other features indicative of a high risk of SCD that are used to patients with ARVC and a history of unex- IIb C
estimate the 5-year risk of SCD using the HCM Risk-SCD model245; plained syncope.a,46
they include: age, family history of SCD, maximum left ventricular
wall thickness, left atrial diameter, and non-sustained VT. Instead of an ICD, an ILR should be consid-
ered in patients with recurrent episodes of
unexplained syncope who are at low risk of
Implantable cardioverter defibrillator indications in IIa C
SCD, based on a multiparametric analysis
patients with unexplained syncopea and hypertrophic that takes into account the other known
cardiomyopathy
risk factors for SCD.
Recommendations Classb Levelc ARVC = arrhythmogenic right ventricular cardiomyopathy; ICD = implantable
cardioverter defibrillator; ILR = implantable loop recorder; SCD = sudden car-
It is recommended that decisions for ICD diac death.
a
implantation in patients with unexplained Unexplained (or uncertain) syncope is defined any syncope that does not meet
I B class I diagnostic criteria defined in the tables of recommendations in section 4. In
syncopea are made according to the ESC
the presence of clinical features described in this section, unexplained syncope is
HCM Risk-SCD score.d,245 considered a risk factor for ventricular tachyarrhythmias.
b
Class of recommendation.
Instead of an ICD, an ILR should be consid- c
Level of evidence.
ered in patients with recurrent episodes of
unexplained syncopea who are at low risk of IIa C
SCD, according to the HCM Risk-SCD
score.d,245 5.6.5 Patients with inheritable arrhythmogenic disorders
5.6.5.1 Long QT syndrome
Additional advice and clinical perspectives Syncopal events in long QT syndrome (LQTS) are associated with an
The decision to implant an ICD or to complete the investigation increased risk of subsequent cardiac arrest. The annual rate of SCD in
(e.g. ILR implantation) in patients with unexplained syncope patients with untreated LQTS is around 0.9% overall and 5% for those
depends on a global clinical evaluation of the patient’s condition, with syncope.352,364 Beta-blocker therapy substantially reduces the risk
the potential benefit and harm of such therapy, and the presence of syncope and SCD, but presentation with cardiac arrest and recur-
of other risk factors for SCD. rent syncope during beta-blocker therapy is associated with the same
risk of fatal events as in untreated patients.46 For this reason, ICD treat-
ESC = European Society of Cardiology; HCM = hypertrophic cardiomyopathy; ment should be considered in patients with LQTS and recurrent unex-
ICD = implantable cardioverter defibrillator; ILR = implantable loop recorder;
SCD = sudden cardiac death.
plained syncope despite beta-blocker therapy, especially in cases of
a
Unexplained syncope is defined as syncope that does not meet the class I diag- good treatment compliance, in the absence of precipitating factors,
nostic criterion defined in the tables of recommendations in section 4. In the and in LQT2 and LQT3 syndromes. Left cardiac sympathetic denerva-
presence of clinical features described in this section, unexplained syncope is con-
sidered a risk factor for ventricular tachyarrhythmias.
tion should also be considered in this situation, particularly in LQT1.46
b
Class of recommendation.
c
Level of evidence. 5.6.5.2 Brugada syndrome
d
A web-based calculator of the HCM risk score can be found at: http://www.
doc2do.com/hcm/webHCM.html. It can also be found in the ESC Pocket
A history of syncope may increase the risk of arrhythmic events up to
Guidelines App found in all app stores. two- to three-fold compared with that in asymptomatic patients. In
the largest registry (1029 patients), the incidence of arrhythmic events
..
(sustained VT or VF, appropriate ICD therapy, or sudden death) in .. risk factors for arrhythmic events, including spontaneous type 1 Brugada
patients with Brugada syndrome was 7.7% per year in those with a .. ECG pattern, family history of sudden death, VF inducibility with one or
..
history of sudden cardiac arrest, 1.9% per year with syncope, and .. two ventricular premature beats during EPS, fractionated QRS, early
0.5% per year in asymptomatic patients.353 However, in a second .. repolarization in the peripheral leads, increased Tpeak– Tend interval, and
..
study, the rate of appropriate ICD shocks was similar in asymptomatic .. long PR interval.220,367–371 A drug-induced type 1 ECG pattern has a
patients and in those with syncope, a difference possibly explained by .. lower risk of sudden death than a spontaneous type 1 response.
..
patient selection and a high rate of non-arrhythmic syncope.355
..
cardiovascular diagnoses such as aortic stenosis or atrial fibrillation377 .. 6.1.3 Cognitive assessment and physical performance tests
may not necessarily be the attributable cause of events.378–380 .. Age-related memory impairment or more established forms of cog-
..
The prescription of polypharmacy, cardiovascular medications, and .. nitive impairment are frequently associated with poor recall and
psychotropic (neuroleptics and antidepressants) and dopaminergic .. therefore the lack of an accurate history of events. In such circum-
..
drugs also increases the risk of syncope and falls.381–385 Conversely, .. stances, details of prodromal symptoms, whether or not LOC
the discontinuation or reduction of hypotensive therapy reduces such .. occurred, and symptoms after the event may be unre-
..
risk.260 Negative dromotropic and chronotropic medications should .. liable.373,389,391–394 Cognitive assessment to inform the accuracy of
be carefully evaluated in older patients presenting with syncope or falls. .. historical data, and general physical assessment to identify comorbid
..
Focal neurological events can occasionally occur due to hypoten- .. disorders that influence diagnosis and response to treatments (such
sion and syncope, even in patients without significant carotid artery .. as Parkinson’s disease, gait and balance abnormalities, previous
..
stenosis (so called ‘hypotensive TIA’). Although these neurological .. stroke, and polyneuropathies, etc.), are recommended.
events occur in only 6% of patients with recurrent syncope, their mis- ..
..
diagnosis is particularly important because they may lead to a lowering .. Despite the lack of large controlled trials and an overall modest
of BP with antihypertensive medications (e.g. if focal neurology is mis- .. quality of studies, there is strong consensus that the assessment
..
takenly attributed to vascular pathology rather than hypotension), and .. of older patients with syncope or unexplained falls may require
to a further increase of the risk of syncope and neurologic events.386
.. cognitive assessment and physical performance tests in addition
..
.. to syncope evaluation. Further research is likely to have an
Despite the lack of large controlled trials and an overall mod-
.. important impact on our confidence in the estimate of effect.
..
est quality of studies, there is strong consensus that reduction
or discontinuation of hypotensive drugs and psychotropic drugs
Syncope in patients with comorbidity and frailty
clearly outweighs the undesirable effects (e.g. complications)
of high BP. Further research is likely to have an important
Recommendations Classa Levelb
impact on our confidence in the estimate of effect.
Multifactorial evaluation and intervention is
recommended in older patients because more
I B
6.1.2 Falls than one possible cause for syncope and unex-
Syncopal events may be unwitnessed in over half of older patients plained fall may be present.33,372–374,376–380
meaning that collateral histories may not available, which makes discrim- Cognitive assessment and physical perform-
ination between falls and syncope challenging.387 If unwitnessed falls are ance tests are indicated in older patients with I C
not due to mechanical slips or trips (i.e. are unexplained or non- syncope or unexplained fall.373,389,391–394
accidental), it is likely that the patient experienced a syncopal event and
displayed lack of awareness for LOC (Figure 16).388,389 Management of Modification or discontinuation of possible culprit
falls in such circumstances is the same as that for syncope.191,194,390 medications, particularly hypotensive drugs and
IIa B
psychotropic drugs, should be considered in older
Despite the lack of controlled trials and an overall modest patients with syncope or unexplained fall.260,381–385
quality of studies, there is strong consensus that the manage- In patients with unexplained fall, the same
ment of unexplained falls should be the same as that for unex- assessment as for unexplained syncope should IIa C
plained syncope. be considered.191,194,387–390
..
6.2 Syncope in paediatric patients .. • Children with a history suggesting VVS, a normal ECG, and no
6.2.1 Diagnostic evaluation
.. family history of arrhythmia should not undergo further cardiac
.. investigations.
Diagnostic evaluation in paediatric patients is similar to that in adults. ..
... • The cornerstone of therapy for young patients with reflex syn-
Two specific conditions399 occur in early childhood: cope includes education and reassurance.
..
• Infantile reflex syncopal attacks (also called pallid breath-holding ..
..
spells or reflex anoxic seizures), elicited by a brief unpleasant ..
stimulus, caused by vagally mediated cardiac inhibition. .. 7. Psychogenic transient loss of
..
• Cyanotic breath-holding spells, characterized by stopping .. consciousness and its evaluation
breathing during crying, leading to cyanosis and usually ..
TLOC. ..
.. In psychogenic TLOC there is no gross somatic brain dysfunction,
..
Careful taking of personal and family history and a standard .. but the attacks fulfil the criteria for TLOC (see section 3.1). There
ECG are the most important methods of distinguishing benign .. are two types: PPS and PNES. In PPS movements are absent, so
..
reflex syncope (also including reflex anoxic seizure or breath- .. PPS resembles syncope or longer-lasting LOC, whereas in PNES
holding spells) from other causes. If the family history is positive, .. impressive limb movements mean the attacks resemble epileptic
..
genetic causes of electrical disease of the heart should be consid- .. seizures. PPS and PNES differ pathophysiologically from the
ered first. Some children with reflex syncope also have a positive .. TLOC forms that they resemble: in PPS, BP and HR are normal or
..
family history.400 Tilt testing seems to have high false-negative and .. high rather than low, and the EEG is normal instead of showing
false-positive rates and should be used with caution for the pri- .. the slowing or flattening typical of syncope; in contrast to epileptic
..
mary identification of reflex syncope. Since tilt protocols com- .. seizures, the EEG in PNES shows no epileptiform brain activity
monly used in adults may lack specificity in teenagers, in one study, .. during an attack.9,116
..
a shorter tilt test duration of 10 min at 60 or 70 degrees was used .. The frequency of PPS and PNES probably depends on the
and showed a specificity of >85%.401
.. setting. The rate of PPS varies from 1% of patients referred to
..
In young patients, syncope can rarely be the initial manifestation of .. general syncope clinics94 to 8% of patients referred to specialist
unusual but life-threatening conditions such as LQTS, Kearns–Sayre
.. neurological clinics,116 but PPS is probably insufficiently
..
syndrome (external ophthalmoplegia and progressive heart block), .. recognized.154
Brugada syndrome, catecholaminergic polymorphic VT,
..
..
Wolff-Parkinson-White syndrome, ARVC, HCM, pulmonary arterial .. 7.1 Diagnosis
hypertension, myocarditis, arrhythmia after repaired congenital heart
..
.. 7.1.1 Historical criteria for attacks
disease, and anomalous origin of a coronary artery. .. The presence of a psychological trauma is not a prerequisite for a
..
Some aspects of the history can suggest a cardiac origin, and .. diagnosis of conversion. The diagnosis of PPS rests on positive clues
should prompt cardiac evaluation. ..
.. taken from the patient’s history and from documenting normal EEG
.. results, HR, or BP during an attack. History taking in PPS usually
• Family history: premature SCD at age <40 years and/or familial ..
heart disease. .. reveals a combination of the following features116,154,403:
• Known or suspected heart disease. ..
.. (1) In most cases, the duration of PPS is as short as in syncope, but a
• Event triggers: loud noise, fright, and/or extreme emotional ..
stress. .. much longer duration is a useful diagnostic finding: patients may lie
• Syncope during exercise, including swimming.
.. immobile on the floor for 15–30 min.
..
• Syncope without prodromes, while supine or sleeping, or pre- .. (2) The eyes are usually open in epileptic seizures and syncope but are
ceded by chest pain or palpitations. .. usually closed in psychogenic TLOC.
..
.. (3) The attack frequency is high, with several attacks occurring over a
6.2.2. Therapy .. week or in a day.
..
The therapeutic approach is the same as in adults. However, it should .. (4) There is usually no recognisable trigger, and no sweating, pallor, or
be stressed that the effectiveness of pharmacological agents and tilt
.. nausea beforehand.
..
training for recurrent reflex syncope is undetermined in the absence .. (5) Injury does not exclude PNES or PPS.
of well-designed paediatric trials. Furthermore, even in the presence
..
.. These features should occur together in most attacks. The pres-
of VVS with prolonged asystole, pacemakers should be avoided due ..
to the relatively transient and benign nature of the syndrome.402
.. ence of another pattern of features suggesting a true syncope type,
.. usually VVS, does not argue against a diagnosis of PPS.
In summary, the key points for the evaluation of syncope in paedi- ..
atrics are as follows:
..
..
.. 7.1.2 Documentation of key features during an attack
• Syncope in childhood is common, the majority being of reflex .. The following features are relevant during an attack:
origin, with only a minority having a potentially life-threatening ..
..
cause. .. • Video recording or clinical observation, including provocation of
• Discriminating benign from serious causes is made primarily by .. an attack during tilt testing. Primary features: sleep-like body posi-
history, physical examination, and ECG results.
.. tion with closed eyes and lack of response to speech or touch, if
..
tested. Secondary features: subtle signs incompatible with LOC .. 8. Neurological causes and mimics
such as eyelid flicker, eyeball movements, swallowing, intact ..
muscle tone, normal movements absent in true unconsciousness, .. of syncope
..
and resistance to eye opening. ..
• BP: normal or elevated during TLOC. .. This section discusses neurological disorders causing syncope or
.. resembling it, and tests to be performed in patients with syncope.
• EEG: normal waking eye-closed EEG pattern, i.e. usually with ..
alpha activity, during TLOC. ..
.. 8.1 Clinical conditions
The gold standard for PPS is documenting an attack with a home ..
.. 8.1.1 Autonomic failure
video recorder or with a tilt testing during which BP, HR, and EEG .. Neurological evaluation should be considered in OH due to auto-
are normal.116,204,404 The gold standard for PNES is documenting an
..
.. nomic failure. Warning signs are early impotence, disturbed micturi-
attack with video-EEG monitoring.204,404 ..
.. tion, hyposmia, rapid eye movement, sleep behaviour
.. disorders,408,409 Parkinsonism, ataxia, cognitive impairment, and sen-
7.1.2.1 Management of psychogenic pseudosyncope ..
Announcing a psychological diagnosis to patients may be considered
.. sory deficits. A multidisciplinary approach may be required in secon-
.. dary autonomic failure and in drug-induced OH, depending on the
difficult, but is necessary for reasons of honesty and as the first step of ..
treatment.404 It should be done by the somatic specialist who diagnoses
.. underlying disease.
..
PPS.116,404 Important aspects are to assure patients that they are taken ..
.. 8.1.2 Epilepsy and ictal asystole
seriously and that attacks are as involuntary as syncope or an epileptic ..
seizure. Acceptance of the diagnosis by patients may be critical for ther- .. Table 10 provides a number of clues that aid the differentiation of
.. syncope from epileptic seizures.9,50,410,411 Epilepsy and syncope
apy. In one observational study,405 communicating and explaining the ..
diagnosis resulted in an immediate reduction of attack frequency, with .. may evoke one another on rare occasions, resulting in epileptic
.. seizures triggering syncope as well as syncope triggering an epilep-
39% of patients being asymptomatic during a mean follow-up period of ..
4 years. Some advice on how to inform the patient is provided in Web .. tic seizure. The first form concerns ictal asystole. Whereas approx-
.. imately 90% of all epileptic seizures are accompanied by
Practical Instructions section 10: European Society of Cardiology information ..
sheet for patients affected by psychogenic pseudosyncope. .. tachycardia, ictal bradycardia and asystole occur in 0.3–0.5% of
.. seizures.412,413 Bradycardia precedes asystole and AV block may
Cognitive behavioural therapy is the usual treatment of PNES and ..
PPS, if attacks remain present after explanation. One pilot random- .. occur, resembling the ECG pattern of reflex syncope.412,414
.. Epileptic asystole occurs during partial complex seizures, not dur-
ized treatment trial, conducted in PNES,406 showed that psychologi- ..
cal therapy provided more attack reduction than no treatment or .. ing generalized seizures. Epileptic asystole occurs in only a fraction
.. of the seizures of one person, and then occurs after a variable
treatment with sertraline. There are currently no trials on PPS. ..
.. interval of 5–100 s from seizure onset.415,416 If asystole lasts for
.. more than about 8 s, syncope ensues.416 A typical history is for a
..
.. partial complex seizure to progress as usual for that patient, and
Diagnosis and management of psychogenic .. then the patient suddenly falls flaccidly, with or without brief myo-
pseudosyncope ..
.. clonic jerking.416,417 Ictal bradycardia, asystole, and ictal AV block
.. are likely self-terminating,412 and are due to vagal activation
Recommendations Classa Levelb
..
.. brought about by the seizure. Cessation of cortical activity due to
..
Diagnosis .. syncopal cerebral hypoperfusion will end the seizure. Therapy
.. requires anti-epileptic drugs and possibly a pacemaker.418
The recording of spontaneous attacks with ..
.. Ictal asystole is probably not involved in sudden death in epilepsy,
a video by an eyewitness should be consid- IIa C .. as this typically occurs in patients after unwitnessed nocturnal
ered for diagnosis of PPS.116,154 ..
.. generalized tonic-clonic seizures, i.e. another type of epi-
Tilt testing, preferably with concurrent EEG
.. lepsy.414,419 Note that most cases of sudden cardiac arrest in
..
recording and video monitoring, may be IIb C .. patients with epilepsy are due to cardiovascular disease and not to
considered for diagnosis of PPS.116,403,407
.. ictal asystole.420
..
.. The second form concerns a syncopal epileptic seizure.
Management .. Hypoxia can trigger epileptic seizures.208,421 Such syncopal epilep-
..
Doctors who diagnose PPS should present .. tic seizures have been described in infants with reflex syncope
IIa C .. or cyanotic breath-holding spells. A typical syncopal spell
the diagnosis of PPS to the patient.116,404 ..
.. suddenly transforms into prolonged clonic movements that
Cognitive behavioural therapy may be con- .. last for minutes; note that shorter epileptic seizures may remain
..
sidered in the treatment of PPS if attacks IIb C .. unnoticed.
persist after explanation. ..
..
.. 8.1.3 Cerebrovascular disorders
EEG = electroencephalogram; PPS = psychogenic pseudosyncope.
..
a
Class of recommendation.
.. In general, a TIA concerns a focal neurological deficit without LOC,
b
.. and syncope the opposite. Subclavian steal refers to the rerouting of
Level of evidence. ..
. blood flow to the arm through the vertebral artery due to proximal
Useful features
Nature of trigger Differs between types: pain, standing, emo- Flashing lights is best known; also range of rare
tions for VVS; specific trigger for situational triggers
syncope; standing for OH
Prodromes Often presyncope (autonomic activation in Epileptic aura: repetitive, specific for each patient.
reflex syncope, light-headedness in OH, palpi- Includes déja vu. Rising sensation in the abdomen
tations in cardiac syncope) (epigastric aura) and/or an unusual unpleasant
smell
Detailed characteristics of • <10, irregular in amplitude, asynchronous, • 20–100, synchronous, symmetrical, hemilateral
myoclonus asymmetrical • The onset mostly coincides with LOC
• Starts after the onset of LOC • Clear long-lasting automatisms as chewing or lip
smacking at the mouth
Confusion after attack No understanding of situation for <10 seconds Memory deficit, i.e. repeated questions without
in most syncope, full alertness and awareness imprinting for many minutes
afterwards
Presence of myoclonus (see below Very often 60%, dependent on accuracy of observation
for nature of myoclonus)
..
stenosis or occlusion of the subclavian artery. A TIA may occur when .. A TIA of the vertebrobasilar system can cause LOC, but there are
flow through the vertebral artery cannot supply both the arm and .. always focal signs, usually limb weakness, gait and limb ataxia, vertigo,
..
part of the brain during forceful use of the arm. Steal most often .. diplopia, nystagmus, dysarthria, and oropharyngeal dysfunction.
affects the left side. When detected with ultrasound, steal is asympto- .. Fewer than 1% of patients with vertebrobasilar ischaemia present
..
matic in 64% of cases.422 A TIA is likely due to steal only when it is .. with a single presenting symptom.425
vertebrobasilar (see below) and associated with exercise of one arm. ..
..
There are no reliable reports of isolated LOC without focal neuro- ..
logical symptoms and signs in subclavian steal. .. 8.1.4 Migraine
..
A TIA related to a carotid artery does not usually cause TLOC. An .. Syncope, presumable VVS, and orthostatic intolerance occur more
exception concerns orthostatic TIAs, concerning a combination of
.. often in patients with migraine, who have a higher lifetime prevalence
..
multiple stenoses of cerebral arteries and OH. This may rarely result .. of syncope and often frequent syncope.426 In migraineurs, syncope
in repetitive, orthostatic, short-lasting, and stereotyped TIAs.423,424
.. and migraine attacks rarely occur simultaneously.
8.1.5 Cataplexy
.. 8.2.3 Neurovascular studies
..
Cataplexy concerns paresis or paralysis triggered by emotions, usu- .. No studies suggest that carotid Doppler ultrasonography is valuable
..
ally laughter, but also by a range of other triggers.427 Patients are con- .. in patients with typical syncope.
scious even when considered unconscious by eyewitnesses, and ..
..
there is no amnesia. Cataplexy is a key feature of narcolepsy; other ..
cardinal symptoms are excessive daytime sleepiness, sleep-onset .. 8.2.4 Blood tests
.. An acute or subacute onset of multidomain autonomic failure sug-
paralysis, and hypnagogic hallucinations. Cataplexy may be mistaken ..
for syncope, but also for PPS: a partial awareness of events may be .. gests a paraneoplastic or autoimmune cause. Screening for specific
.. paraneoplastic antibodies is recommended: the most common para-
present in PPS, and the falls of cataplexy are partly controlled because ..
paralysis need not be immediately complete. .. neoplastic antibodies are anti-Hu, while others are anti-Purkinje cell
.. cytoplasmic autoantibody type 2 and anti-collapsin response media-
..
.. tor protein 5.431 Seropositivity for any of the above-mentioned anti-
8.1.6 Drop attacks ..
.. bodies may therefore prompt further investigation for occult
The term drop attacks is confusing as it is variably used for
.. malignancy (e.g. whole-body fluorodeoxyglucose-positron emission
Menière’s disease, atonic epileptic seizures, and unexplained .. tomography).432
falls.387 A specific condition also labelled drop attacks concerns ..
.. Seropositivity for antiganglionic acetylcholine receptor
middle-aged women (rarely men) who suddenly find themselves .. antibodies is the serological hallmark of autoimmune autonomic
falling.428 They usually remember hitting the floor and can stand ..
. ganglionopathy.433,434
up immediately afterwards.
Neurological evaluation
Neurological tests
Figure 17 Diagnostic work-up of cardiovascular autonomic failure (adapted from Fanciulli et al.429). CNS = central nervous system; CRMP-5 =
collapsin response mediator protein 5; DAT = dopamine active transporter; HbA1c = haemoglobin A1c; HIV = human immunodeficiency virus; 123I-
MIBG = 123I-metaiodobenzylguanidine; MRI = magnetic resonance imaging; PCA-2 = Purkinje cell cytoplasmic autoantibody type 2; SPECT = single-
photon emission computed tomography; SS-A = Sjogren’s syndrome-associated antigen A; SS-B = Sjogren’s syndrome-associated antigen B.
• The syncope unit should take the lead in service delivery for syncope, and in education and training of healthcare professionals who encounter syncope.
• The syncope unit should be led by a clinician with specific knowledge of TLOC and additional necessary team members (i.e. clinical nurse special-
ist) depending on the local model of service delivery.
• The syncope unit should provide minimum core treatments for reflex syncope and OH, and treatments or preferential access for cardiac syn-
cope, falls, psychogenic pseudosyncope, and epilepsy.
• Referrals should be directly from family practitioners, EDs, in-hospital and out-hospital services, or self-referral depending on the risk stratifica-
tion of referrals. Fast-track access, with a separate waiting list and scheduled follow-up visits, should be recommended.
• Syncope units should employ quality indicators, process indicators, and desirable outcome targets.
Therapy
Patients with syncope will receive their therapy under the care of the syncope unit unless expertise outside that of the unit is required.
Database management
The syncope unit is required to keep medical records that should also include follow-up when appropriate. The database will also offer the possibil-
ity of collaborative research with other syncope units.
BP = blood pressure; ECG = electrocardiogram; ED = emergency department; EPS = electrophysiological study; ILR = implantable loop recorder;
TLOC = transient loss of consciousness.
a
Implantation of loop recorders may be performed either by syncope unit physicians or by external cardiologists at the request of the syncope unit physicians.
Initial assessment
Blood tests Electrolytes, haemoglobin, troponin, B-type natriuretic peptide, glucose, D-dimer, haemogas anal-
ysis/oxygen saturation
Monitoring External loop recording, implantable loop recording, ambulatory 1–7 days ECG monitoring,
24–48-hour BP monitoring
Autonomic function tests Standing test, Valsalva manoeuvre, deep-breathing test, cold pressor test, and/or established pro-
cedures for access to other autonomic function tests
Cardiac evaluation Established procedures for access to echocardiogram, stress test, electrophysiological study, cor-
onary angiography
Neurological evaluation Established procedures for access to neurological tests (computed tomography, magnetic reso-
nance imaging, EEG, video-EEG)
Geriatric evaluation Established procedures for access to fall risk assessment (cognitive, gait and balance, visual, envi-
ronmental) and for gait and balance retraining
Psychological or psychiatric evaluation Established procedures for access to psychological or psychiatric consultancy (mental health
problem or psychogenic syncope)
BP = blood pressure; CSM = carotid sinus massage; ECG = electrocardiogram; EEG = electroencephalogram.
a
Postural orthostatic tachycardia may require longer period of standing.
..
9.1.5 Access and referrals to a syncope unit .. 9.2 The clinical nurse specialist in the
Referral can be direct from family practitioners, EDs, in-hospital and ..
.. syncope unit
out-hospital services, or self-referral from the patient. Fast-track .. 9.2.1 Definition
access with a separate waiting list and scheduled follow-up visits is ..
.. The syncope unit clinical nurse specialist is defined as an experienced
recommended. In particular, patients at low/intermediate risk admit- .. practitioner who has sufficient knowledge of history features and
ted to the ED should benefit from such fast-track facilities (so-called ..
.. physical findings to recognize all major forms of TLOC, as well as syn-
protected discharge or advanced access with an appointment for .. dromes of orthostatic intolerance. The clinical nurse specialist should
early assessment) to reduce hospitalization rates, directly from the ..
.. work in close collaboration with the syncope specialist. The core
ED or after a short stay in the short observation unit of the ED (see .. competencies of the clinical nurse specialist include a specialized clini-
section 4.1.2). ..
.. cal focus, patient advocacy, education and training, auditing, research,
.. and inter- and intradisciplinary consultations.
...
9.1.6 Outcomes and quality indicators ..
.. 9.2.2 Role and skills of the clinical nurse specialist
The EHRA Task Force63 has developed the following preliminary ..
quality indicators, based on consensus, as a rough guide for .. The clinical nurse specialist should be skilled in the performance and
.. interpretation of structured history taking, 12-lead ECG and routine
practitioners: ..
.. blood test results, tilt testing, active stand tests, autonomic function
(1) Absolute rate of undiagnosed TLOC should be reduced by 20%; .. tests, ECG monitoring (Holter and/or external loop recorder),
..
(2) Less than 20% of low-/intermediate-risk TLOC patients should be .. ABPM, ILR monitoring, and subsequent triaging of patients and moni-
admitted from the ED; .. toring responses to therapy. Other skills will depend on the service
..
(3) The syncope unit should have a 20% reduction in costs relative .. model, e.g. pacemaker interrogation. The clinical nurse specialist may
to usual practice and improved outcomes (i.e. <5% readmissions
.. have responsibility for follow-up clinics for cardiovascular risk factor
..
for syncope and <20% of paced patients with recurrence at .. management, autonomic function testing and monitoring, manage-
1 year).
.. ment (including education in PCM) of VVS and OH, and follow-up
Table 14 The role of physicians and staff in performing procedures and tests
History taking X
12-lead ECG X
Blood tests X
CSM X
ILR X (X)b
Remote monitoring X
Follow-up X X
BP = blood pressure; CSM = carotid sinus massage; ECG = electrocardiogram; EEG = electroencephalogram; EPS = electrophysiological study; ICD = implantable cardioverter
defibrillator; ILR = implantable loop recorder; PCM = physical counter-pressure manoeuvres.
a
Physician need not be in the room, but a physician adequately trained in resuscitation needs to be in the vicinity of the test.
b
Current practice limited to a few countries.
c
Biofeedback means that the PCM training session consists of biofeedback training using a continuous BP monitor. Each manoeuvre is demonstrated and explained. The manoeu-
vres are practised under supervision, with immediate feedback of the recordings to gain optimal performance.
..
of external and internal loop and Holter monitors and ABPM63 .. 10. Key messages
(Table 14). ..
.. The ESC Task Force has selected 19 simple rules to guide the diagno-
The clinical nurse specialist should be key in developing and deliv- ..
ering communication strategies and processes for the syncope unit .. sis and management of syncope patients with TLOC according to the
..
for all stakeholders—patients and practitioners—and play a pivotal .. 2018 ESC Guidelines on syncope:
role in education and training together with the syncope specialist. ..
.. Diagnosis: initial evaluation
The clinical nurse specialist should be involved in regular auditing and ..
collection of data to inform quality indicators. See the video in Web .. (1) At the initial evaluation answer the following four key questions:
.. Was the event TLOC?
Practical Instructions section 11. ..
.. In cases of TLOC, are they of syncopal or non-syncopal origin?
.. In cases of suspected syncope, is there a clear aetiological diagnosis?
Although the skill mix of a clinical nurse specialist has not been ..
exposed to rigorous scientific or economic scrutiny, the consen- .. Is there evidence to suggest a high risk of cardiovascular events or
.. death?
sus is that the clinical nurse specialist should have the neces- ..
sary skills to deliver assessment and treatment for syncope and
.. (2) At the evaluation of TLOC in the ED, answer the following three
.. key questions:
TLOC. Further research is required to establish the benefits. ..
.. Is there a serious underlying cause that can be identified?
Therefore, there is a need for: .. Therefore, there is strong urgent need for RCTs on the efficacy of:
..
..
2) Large clinical studies that test the superiority of management in a dedicated .. 4) Pharmacological therapies targeted to specific subgroups of reflex syncope.
syncope facility vs. conventional management .. 5) Pacemaker therapy targeted to specific subgroups of cardioinhibitory reflex
..
.. syncope.
.. 6) Pharmacological therapies of OH-mediated syncope.
Diagnosis: the need for new diagnostic ..
.. 7) ICD therapy targeted to specific subgroups of patients with unexplained syn-
tests and devices .. cope at risk of SCD.
BP recording is crucial for the majority of clinical TLOC situations ..
..
and will yield important information for the treatment of syncope. ..
Unfortunately, current long-term BP (or surrogate) recording sys- ..
..
tems are not optimal for diagnostic use in the syncope evaluation .. Treatment: the need for new therapies
setting. ..
.. There is a need to move towards personalized medicine. Improving
Therefore, there is a need for: .. our knowledge of the biochemical mechanisms underlying specific
..
3) Development and validation of new diagnostic multiparametric devices that .. forms of reflex syncope will allow the development of new therapies
.. in such specific settings. For example, a low adenosine phenotype
can record heart rhythm and BP (and possibly other physiological parameters ..
such as cerebral saturation or EEG) at the time of a syncopal event. .. and a low norepinephrine phenotype have been recently identified.
..
.. Therefore, there is a need for:
..
Treatment: lack of evidence of efficacy of .. 8) Randomized clinical trials on the efficacy of theophylline (and other xantine
..
most available therapies .. antagonists) for low adenosine syncope and norepinephrine transport inhibi-
Only a few small RCTs have been conducted on treatment of syncope. .. tors for low epinephrine syncope.
..
In addition, syncopal recurrences are unpredictable and often decrease .. Syncope is a transient phenomenon. The ideal therapy should be
spontaneously after medical assessment, even in the absence of a specific ..
.. one that is administered only when needed.
therapy. The consequence of the spontaneous decrease is that any ther- .. Therefore, there is a need for:
apy for syncope prevention appears to be more effective than it actually ..
..
is, making the results of observational data on therapy questionable in .. 9) Randomized clinical trials of on-demand administration of specific therapy
the absence of a control group. No therapy can be effective for all
.. based on specific sensors similar to adrenalin injectors in asthma or nasal
..
patients. Any therapy should be assessed in homogeneous subgroups. . spray for paroxysmal SVT.
12. ‘What to do’ and ‘what not to do’ messages from the Guidelines
VVS is highly probable if syncope is precipitated by pain, fear, or standing, and is associated with typical progressive pro-
I C
drome (pallor, sweating, and/or nausea).8,13–17
Situational reflex syncope is highly probable if syncope occurs during or immediately after specific triggers listed in Table 3.8,13–17 I C
Syncope due to OH is confirmed when syncope occurs while standing and there is concomitant OH.18–24 I C
It is recommended that patients with low-risk features, likely to have reflex or situational syncope or syncope due to OH,
I B
are discharged from the ED.27,35,36,49–54,58,62,69
It is recommended that patients with high-risk features receive an early intensive prompt evaluation in a syncope unit or in
I B
an ED observation unit (if available), or are hospitalized.26,27,35,36,44–46,50,55–57,59,60,70–76
It is recommended that patients who have neither high- nor low-risk features are observed in the ED or in a syncope unit
I B
instead of being hospitalized.40,63–65,77
CSM
CSM is indicated in patients >40 years of age with syncope of unknown origin compatible with a reflex mechanism.92–94 I B
CSS is confirmed if CSM causes bradycardia (asystole) and/or hypotension that reproduces spontaneous symptoms, and
I B
patients have clinical features compatible with a reflex mechanism of syncope.89,90,92,93,98–102
Active standing
Intermittent determination by sphygmomanometer of BP and HR while supine and during active standing for 3 min are indi-
I C
cated at initial syncope evaluation.20,103,104
Syncope due to OH is confirmed when there is a fall in systolic BP from a baseline value >_20 mmHg, diastolic BP >_10
I C
mmHg, or a decrease in systolic BP to <90 mmHg that reproduces spontaneous symptoms.6,20,103,104
ECG monitoring
Immediate in-hospital monitoring (in bed or by telemetry) is indicated in high-risk patients (defined in Table 6). I C
ILR is indicated in an early phase of evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk
criteria (listed in Table 6), and a high likelihood of recurrence within the battery life of the device.175,176,181–184,202, I A
Supplementary Data Table 5
ILR is indicated in high-risk (criteria listed in Table 6) patients in whom a comprehensive evaluation did not demonstrate a
cause of syncope or lead to a specific treatment, and who do not have conventional indications for primary prevention ICD I A
174,180,187,188,195
or pacemaker indication. , Supplementary Data Tables 5 and 6
Arrhythmic syncope is confirmed when a correlation between syncope and an arrhythmia (bradyarrhythmia or tachyar-
I B
rhythmia) is detected.172,184–186,188,200
EPS
In patients with syncope and previous myocardial infarction or other scar-related conditions, EPS is indicated when syncope
I B
remains unexplained after non-invasive evaluation.218
In patients with unexplained syncope and bifascicular BBB, a pacemaker is indicated in the presence of either a baseline H-V
interval of >_70 ms, second- or third-degree His-Purkinje block during incremental atrial pacing, or with pharmacological I B
challenge.188,214–217,221
In patients with unexplained syncope and previous myocardial infarction or other scar-related conditions, it is recom-
I B
mended that induction of sustained monomorphic VT is managed according to the current ESC Guidelines for VA.46
In patients without structural heart disease with syncope preceded by sudden and brief palpitations, it is recommended that
the induction of rapid SVT or VT, which reproduces hypotensive or spontaneous symptoms, is managed with appropriate I C
therapy according to the current ESC Guidelines.46,222
Echocardiography
Echocardiography is indicated for diagnosis and risk stratification in patients with suspected structural heart disease.235,236 I B
Exercise testing
Exercise testing is indicated in patients who experience syncope during or shortly after exertion. I C
Syncope due to second- or third-degree AV block is confirmed when the AV block develops during exercise, even without
I C
syncope.253–257
Reflex syncope is confirmed when syncope is reproduced immediately after exercise in the presence of severe hypotension.250–252 I C
Continued
Explanation of the diagnosis, provision of reassurance, and explanation of the risk of recurrence and the avoidance of trig-
I B
gers and situations are indicated in all patients. Supplementary Data Table 10
Treatment of OH
Explanation of the diagnosis, provision of reassurance, and explanation of the risk of recurrence and the avoidance of trig-
I C
gers and situations are indicated in all patients.
Cardiac pacing is indicated when there is an established relationship between syncope and symptomatic
I B
bradycardia.200,210–212,255,334–338,341
Cardiac pacing is indicated in patients with intermittent/paroxysmal intrinsic third- or second-degree AV block (including
I C
AF with slow ventricular conduction), although there is no documentation of a correlation between symptoms and ECG.
Cardiac pacing is not indicated in patients when there are reversible causes for bradycardia. III C
Cardiac pacing is indicated in patients with syncope, BBB, and a positive EPS or ILR-documented AV block.188,217 I B
Catheter ablation is indicated in patients with syncope due to SVT or VT in order to prevent syncope recurrence. I C
An ICD is indicated in patients with syncope due to VT and ejection fraction <_35%.46 I A
An ICD is indicated in patients with syncope and previous myocardial infarction who have VT induced during EPS.218 I C
ICD indications in patients with unexplained syncope and left ventricular systolic dysfunction
ICD therapy is recommended to reduce SCD in patients with symptomatic heart failure (NYHA class II–III) and LVEF
<_35% after >_3 months of optimal medical therapy, who are expected to survive for >_1 year with good functional status.46 I A
systolic dysfunction
A multifactorial evaluation and intervention is recommended in older patients because more than one possible cause for
I B
syncope and unexplained fall may be present.33,372–374,376–380
Neurological evaluation
Neurological evaluation is indicated when syncope is suspected to be epilepsy or due to autonomic failure to evaluate the
I C
underlying disease.
AF = atrial fibrillation; AV = atrioventricular; BBB = bundle branch block; BP = blood pressure; b.p.m. = beats per minute; CSM = carotid sinus massage; CSS = carotid sinus syn-
drome; ECG = electrocardiogram; ED = emergency department; EPS = electrophysiological study; ESC = European Society of Cardiology; HR = heart rate; ICD = implantable
cardioverter defibrillator; ILR = implantable loop recorder; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; OH = orthostatic hypotension;
SCD = sudden cardiac death; SVT = supraventricular tachycardia; VA = ventricular arrhythmia; VT = ventricular tachycardia; VVS = vasovagal syncope.
..
13. Supplementary Data and Web ..
..
14. Appendix
Practical Instructions ..
.. ESC Committee for Practice Guidelines (CPG): Stephan
.. Windecker (Chairperson) (Switzerland), Victor Aboyans (France),
Supplementary Data with additional Web Tables complementing the ..
full text, and an additional Web Practical Instructions document— .. Stefan Agewall (Norway), Emanuele Barbato (Italy), Héctor Bueno
.. (Spain), Antonio Coca (Spain), Jean-Philippe Collet (France), Ioan
with a glossary containing definitions of syncope and related concepts ..
with tracings, videos, flow charts, and checklists—are available on the .. Mircea Coman (Romania), Veronica Dean (France), Victoria Delgado
.. (The Netherlands), Donna Fitzsimons (UK), Oliver Gaemperli
European Heart Journal website and via the ESC Website at www. ..
escardio.org/guidelines. .. (Switzerland), Gerhard Hindricks (Germany), Bernard Iung
.. (France), Peter Jüni (Canada), Hugo Albert Katus (Germany), Juhani
.
Cardiology, Aurica Raducan; Montenegro: Montenegro Society .. 20. Naschitz JE, Rosner I. Orthostatic hypotension: framework of the syndrome.
.. Postgrad Med J 2007;83:568–574.
of Cardiology, Mihailo Vukmirovic; Morocco: Moroccan Society of .. 21. Consensus statement on the definition of orthostatic hypotension, pure auto-
Cardiology, Salima Abdelali; The Netherlands: Netherlands
.. nomic failure, and multiple system atrophy. J Neurol Sci 1996;144:218–219.
.. 22. Wieling W, Krediet CT, van Dijk N, Linzer M, Tschakovsky ME. Initial ortho-
Society of Cardiology, Martin E.W. Hemels; Norway: Norwegian .. static hypotension: review of a forgotten condition. Clin Sci (Lond)
Society of Cardiology, Kristina H. Haugaa; Poland: Polish Cardiac
..
.. 2007;112:157–165.
Society, Rafał Baranowski; Portugal: Portuguese Society of .. 23. Podoleanu C, Maggi R, Brignole M, Croci F, Incze A, Solano A, Puggioni E,
68. Krahn AD, Klein GJ, Yee R, Skanes AC, REVEAL Investigators. Predictive value
.. Canadian Syncope Risk Score to predict serious adverse events after emer-
..
of presyncope in patients monitored for assessment of syncope. Am Heart J .. gency department assessment of syncope. CMAJ 2016;188:E289–E298.
2001;141:817–821. .. 89. Kerr SR, Pearce MS, Brayne C, Davis RJ, Kenny RA. Carotid sinus hypersensitiv-
69. Huff JS, Decker WW, Quinn JV, Perron AD, Napoli AM, Peeters S, Jagoda AS, .. ity in asymptomatic older persons: implications for diagnosis of syncope and
American College of Emergency Physicians. Clinical policy: critical issues in the .. falls. Arch Intern Med 2006;166:515–520.
evaluation and management of adult patients presenting to the emergency .. 90. Puggioni E, Guiducci V, Brignole M, Menozzi C, Oddone D, Donateo P, Croci F,
department with syncope. Ann Emerg Med 2007;49:431–444. .. Solano A, Lolli G, Tomasi C, Bottoni N. Results and complications of the caro-
70. Thiruganasambandamoorthy V, Hess EP, Alreesi A, Perry JJ, Wells GA, Stiell IG.
.. tid sinus massage performed according to the “method of symptoms”. Am J
..
External validation of the San Francisco Syncope Rule in the Canadian setting. .. Cardiol 2002;89:599–601.
Ann Emerg Med 2010;55:464–472. .. 91. Wieling W, Krediet CT, Solari D, de Lange FJ, van Dijk N, Thijs RD, van Dijk
71. Brignole M, Menozzi C, Bartoletti A, Giada F, Lagi A, Ungar A, Ponassi I, Mussi .. JG, Brignole M, Jardine DL. At the heart of the arterial baroreflex: a physiologi-
C, Maggi R, Re G, Furlan R, Rovelli G, Ponzi P, Scivales A. A new management .. cal basis for a new classification of carotid sinus hypersensitivity. J Intern Med
of syncope: prospective systematic guideline-based evaluation of patients .. 2013;273:345–358.
referred urgently to general hospitals. Eur Heart J 2006;27:76–82. .. 92. Solari D, Maggi R, Oddone D, Solano A, Croci F, Donateo P, Brignole M.
72. Del Greco M, Cozzio S, Scillieri M, Caprari F, Scivales A, Disertori M.
.. Clinical context and outcome of carotid sinus syndrome diagnosed by means of
..
Diagnostic pathway of syncope and analysis of the impact of guidelines in a dis- .. the ‘method of symptoms’. Europace 2014;16:928–934.
trict general hospital. The ECSIT study (epidemiology and costs of syncope in .. 93. Solari D, Maggi R, Oddone D, Solano A, Croci F, Donateo P, Wieling W,
Trento). Ital Heart J 2003;4:99–106. .. Brignole M. Assessment of the vasodepressor reflex in carotid sinus syndrome.
73. McCarthy F, McMahon CG, Geary U, Plunkett PK, Kenny RA, Cunningham CJ, .. Circ Arrhythm Electrophysiol 2014;7:505–510.
European Society of Cardiology. Management of syncope in the Emergency .. 94. Brignole M, Ungar A, Casagranda I, Gulizia M, Lunati M, Ammirati F, Del Rosso
Department: a single hospital observational case series based on the application of .. A, Sasdelli M, Santini M, Maggi R, Vitale E, Morrione A, Francese GM, Vecchi
European Society of Cardiology Guidelines. Europace 2009;11:216–224.
.. MR, Giada F, Syncope Unit Project (SUP) investigators. Prospective multicentre
..
74. Numeroso F, Mossini G, Spaggiari E, Cervellin G. Syncope in the emergency .. systematic guideline-based management of patients referred to the Syncope
department of a large northern Italian hospital: incidence, efficacy of a short- .. Units of general hospitals. Europace 2010;12:109–118.
stay observation ward and validation of the OESIL risk score. Emerg Med J .. 95. Munro NC, McIntosh S, Lawson J, Morley CA, Sutton R, Kenny RA. Incidence
2010;27:653–658. .. of complications after carotid sinus massage in older patients with syncope.
75. Lin M, Wolfe RE, Shapiro NI, Novack V, Lior Y, Grossman SA. Observation vs .. J Am Geriatr Soc 1994;42:1248–1251.
admission in syncope: can we predict short length of stays? Am J Emerg Med .. 96. Ungar A, Rivasi G, Rafanelli M, Toffanello G, Mussi C, Ceccofiglio A, McDonagh
2015;33:1684–1686.
.. R, Drumm B, Marchionni N, Alboni P, Kenny RA. Safety and tolerability of Tilt
..
76. Grossman AM, Volz KA, Shapiro NI, Salem R, Sanchez LD, Smulowitz P, .. Testing and Carotid Sinus Massage in the octogenarians. Age Ageing
Grossman SA. Comparison of 1-day emergency department observation and .. 2016;45:242–248.
inpatient ward for 1-day admissions in syncope patients. J Emerg Med .. 97. Davies AJ, Kenny RA. Frequency of neurologic complications following carotid
2016;50:217–222. .. sinus massage. Am J Cardiol 1998;81:1256–1257.
77. Ungar A, Tesi F, Chisciotti VM, Pepe G, Vanni S, Grifoni S, Balzi D, Rafanelli M, .. 98. Brignole M, Menozzi C, Lolli G, Bottoni N, Gaggioli G. Long-term outcome of
Marchionni N, Brignole M. Assessment of a structured management pathway .. paced and nonpaced patients with severe carotid sinus syndrome. Am J Cardiol
for patients referred to the Emergency Department for syncope: results in a .. 1992;69:1039–1043.
tertiary hospital. Europace 2016;18:457–462.
.. 99. Claesson JE, Kristensson BE, Edvardsson N, Wahrborg P. Less syncope and
..
78. Serrano LA, Hess EP, Bellolio MF, Murad MH, Montori VM, Erwin PJ, Decker .. milder symptoms in patients treated with pacing for induced cardioinhibitory
WW. Accuracy and quality of clinical decision rules for syncope in the emer- .. carotid sinus syndrome: a randomized study. Europace 2007;9:932–936.
gency department: a systematic review and meta-analysis. Ann Emerg Med .. 100. Menozzi C, Brignole M, Lolli G, Bottoni N, Oddone D, Gianfranchi L, Gaggioli
2010;56:362–373.e1. .. G. Follow-up of asystolic episodes in patients with cardioinhibitory, neurally
79. Dipaola F, Costantino G, Perego F, Borella M, Galli A, Cantoni G, Barbic F, .. mediated syncope and VVI pacemaker. Am J Cardiol 1993;72:1152–1155.
Casella F, Duca PG, Furlan R, STePS investigators. San Francisco Syncope Rule, .. 101. Maggi R, Menozzi C, Brignole M, Podoleanu C, Iori M, Sutton R, Moya A, Giada
Osservatorio Epidemiologico sulla Sincope nel Lazio risk score, and clinical
.. F, Orazi S, Grovale N. Cardioinhibitory carotid sinus hypersensitivity predicts
..
judgment in the assessment of short-term outcome of syncope. Am J Emerg .. an asystolic mechanism of spontaneous neurally mediated syncope. Europace
Med 2010;28:432–439. .. 2007;9:563–567.
80. Sheldon RS, Morillo CA, Krahn AD, O’Neill B, Thiruganasambandamoorthy V, .. 102. Thomas JE. Hyperactive carotid sinus reflex and carotid sinus syncope. Mayo
Parkash R, Talajic M, Tu JV, Seifer C, Johnstone D, Leather R. Standardized .. Clin Proc 1969;44:127–139.
approaches to the investigation of syncope: Canadian Cardiovascular Society .. 103. Smit AA, Halliwill JR, Low PA, Wieling W. Pathophysiological basis of ortho-
position paper. Can J Cardiol 2011;27:246–253. .. static hypotension in autonomic failure. J Physiol 1999;519:1–10.
81. Perego F, Costantino G, Dipaola F, Scannella E, Borella M, Galli A, Barbic F,
.. 104. Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology,
..
Casella F, Solbiati M, Angaroni L, Duca P, Furlan R. Predictors of hospital admis- .. prognosis, and treatment. J Am Coll Cardiol 2015;66:848–860.
sion after syncope: relationships with clinical risk scores. Int J Cardiol .. 105. Kenny RA, Ingram A, Bayliss J, Sutton R. Head-up tilt: a useful test for investigat-
2012;161:182–183. .. ing unexplained syncope. Lancet 1986;1:1352–1355.
82. Schladenhaufen R, Feilinger S, Pollack M, Benenson R, Kusmiesz AL. Application .. 106. Bartoletti A, Alboni P, Ammirati F, Brignole M, Del Rosso A, Foglia Manzillo G,
of San Francisco Syncope Rule in elderly ED patients. Am J Emerg Med .. Menozzi C, Raviele A, Sutton R. ‘The Italian Protocol‘: a simplified head-up tilt
2008;26:773–778. .. testing potentiated with oral nitroglycerin to assess patients with unexplained
83. Sun BC, Mangione CM, Merchant G, Weiss T, Shlamovitz GZ, Zargaraff G,
.. syncope. Europace 2000;2:339–342.
..
Shiraga S, Hoffman JR, Mower WR. External validation of the San Francisco .. 107. Kenny RA, O’Shea D, Parry SW. The Newcastle protocols for head-up tilt table
Syncope Rule. Ann Emerg Med 2007;49:420–427, 427.e1–4. .. testing in the diagnosis of vasovagal syncope, carotid sinus hypersensitivity, and
84. Reed MJ, Henderson SS, Newby DE, Gray AJ. One-year prognosis after syn- .. related disorders. Heart 2000;83:564–569.
cope and the failure of the ROSE decision instrument to predict one-year .. 108. Benditt DG, Ferguson DW, Grubb BP, Kapoor WN, Kugler J, Lerman BB, Maloney
adverse events. Ann Emerg Med 2011;58:250–256. .. JD, Raviele A, Ross B, Sutton R, Wolk MJ, Wood DL. Tilt table testing for assessing
85. Birnbaum A, Esses D, Bijur P, Wollowitz A, Gallagher EJ. Failure to validate the .. syncope. American College of Cardiology. J Am Coll Cardiol 1996;28:263–275.
San Francisco Syncope Rule in an independent emergency department popula- .. 109. Morillo CA, Klein GJ, Zandri S, Yee R. Diagnostic accuracy of a low-dose iso-
tion. Ann Emerg Med 2008;52:151–159.
.. proterenol head-up tilt protocol. Am Heart J 1995;129:901–906.
..
86. Costantino G, Casazza G, Reed M, Bossi I, Sun B, Del Rosso A, Ungar A, .. 110. Forleo C, Guida P, Iacoviello M, Resta M, Monitillo F, Sorrentino S, Favale S.
Grossman S, D’Ascenzo F, Quinn J, McDermott D, Sheldon R, Furlan R. .. Head-up tilt testing for diagnosing vasovagal syncope: a meta-analysis. Int J
Syncope risk stratification tools vs clinical judgment: an individual patient data .. Cardiol 2013;168:27–35.
meta-analysis. Am J Med 2014;127:1126.e13–25. .. 111. Parry SW, Gray JC, Newton JL, Reeve P, O’Shea D, Kenny RA. ‘Front-loaded‘
87. Canzoniero JV, Afshar E, Hedian H, Koch C, Morgan DJ. Unnecessary hospital- .. head-up tilt table testing: validation of a rapid first line nitrate-provoked tilt pro-
ization and related harm for patients with low-risk syncope. JAMA Intern Med .. tocol for the diagnosis of vasovagal syncope. Age Ageing 2008;37:411–415.
2015;175:1065–1067.
.. 112. Verheyden B, Gisolf J, Beckers F, Karemaker JM, Wesseling KH, Aubert AE,
..
88. Thiruganasambandamoorthy V, Kwong K, Wells GA, Sivilotti ML, Mukarram M, .. Wieling W. Impact of age on the vasovagal response provoked by sublingual
Rowe BH, Lang E, Perry JJ, Sheldon R, Stiell IG, Taljaard M. Development of the .. nitroglycerine in routine tilt testing. Clin Sci (Lond) 2007;113:329–337.
.
..
239. Bogaert AM, De Scheerder I, Colardyn F. Successful treatment of aortic rupture .. 263. Kim KH, Cho JG, Lee KO, Seo TJ, Shon CY, Lim SY, Yun KH, Sohn IS, Hong YJ,
presenting as a syncope: the role of echocardiography in diagnosis. Int J Cardiol .. Park HW, Kim JH, Kim W, Ahn YK, Jeong MH, Park JC, Kang JC. Usefulness of
1987;16:212–214. .. physical maneuvers for prevention of vasovagal syncope. Circ J
240. Acikel M, Yekeler I, Ates A, Erkut B. A giant left atrial myxoma: an unusual .. 2005;69:1084–1088.
cause of syncope and cerebral emboli. Int J Cardiol 2004;94:325–326. .. 264. Tomaino M, Romeo C, Vitale E, Kus T, Moya A, van Dijk N, Giuli S, D’Ippolito
241. Nogueira DC, Bontempo D, Menardi AC, Vicente WV, Ribeiro PJ, Evora PR. .. G, Gentili A, Sutton R, International Study on Syncope of Uncertain Etiology 3
Left atrial myxoma as the cause of syncope in an adolescent. Arq Bras Cardiol
.. (ISSUE 3) Investigators. Physical counter-pressure manoeuvres in preventing
..
2003;81:206–209, 202–205. .. syncopal recurrence in patients older than 40 years with recurrent neurally
242. Sinha AK, Singh BP. LA myxoma presenting as recurrent syncope. Indian Heart J .. mediated syncope: a controlled study from the Third International Study on
2013;65:643. .. Syncope of Uncertain Etiology (ISSUE-3)†. Europace 2014;16:1515–1520.
243. Rahman MS, Michael H. A rare presentation of chest pain and syncope: massive .. 265. Reybrouck T, Heidbuchel H, Van De Werf F, Ector H. Long-term follow-up
right atrial myxoma. Postgrad Med J 2012;88:671–672. .. results of tilt training therapy in patients with recurrent neurocardiogenic syn-
244. Han H, Li Y, Guo S, Yu X. Right atrial myxoma-induced syncope. Postgrad Med J .. cope. Pacing Clin Electrophysiol 2002;25:1441–1446.
2011;87:438–439.
.. 266. Zeng H, Ge K, Zhang W, Wang G, Guo L. The effect of orthostatic training in
..
245. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, .. the prevention of vasovagal syncope and its influencing factors. Int Heart J
Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, .. 2008;49:707–712.
Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, .. 267. Jang WJ, Yim HR, Lee SH, Park SJ, Kim JS, On YK. Prognosis after tilt training in
Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and management of .. patients with recurrent vasovagal syncope. Int J Cardiol 2013;168:4264–4265.
hypertrophic cardiomyopathy: the Task Force for the Diagnosis and .. 268. Foglia-Manzillo G, Giada F, Gaggioli G, Bartoletti A, Lolli G, Dinelli M, Del
Management of Hypertrophic Cardiomyopathy of the European Society of .. Rosso A, Santarone M, Raviele A, Brignole M. Efficacy of tilt training in the
Cardiology (ESC). Eur Heart J 2014;35:2733–2779.
.. treatment of neurally mediated syncope. A randomized study. Europace
..
...
246. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, 2004;6:199–204.
Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a 269. Kinay O, Yazici M, Nazli C, Acar G, Gedikli O, Altinbas A, Kahraman H, Dogan
disease of left ventricular outflow tract obstruction. Circulation 2006;114:2232–2239. .. A, Ozaydin M, Tuzun N, Ergene O. Tilt training for recurrent neurocardiogenic
247. Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, Ward D, Kohli
.. syncope: effectiveness, patient compliance, and scheduling the frequency of
..
SK, Page SP, Demetrescu C, Sevdalis E, Keren A, Pellerin D, McKenna WJ, .. training sessions. Jpn Heart J 2004;45:833–843.
Elliott PM. Prevalence of exercise-induced left ventricular outflow tract .. 270. On YK, Park J, Huh J, Kim JS. Is home orthostatic self-training effective in pre-
obstruction in symptomatic patients with non-obstructive hypertrophic cardio- .. venting neurally mediated syncope? Pacing Clin Electrophysiol 2007;30:638–643.
myopathy. Heart 2008;94:1288–1294. .. 271. Duygu H, Zoghi M, Turk U, Akyuz S, Ozerkan F, Akilli A, Erturk U, Onder R,
248. Dimitrow PP, Bober M, Michalowska J, Sorysz D. Left ventricular outflow tract .. Akin M. The role of tilt training in preventing recurrent syncope in patients
gradient provoked by upright position or exercise in treated patients with .. with vasovagal syncope: a prospective and randomized study. Pacing Clin
hypertrophic cardiomyopathy without obstruction at rest. Echocardiography
.. Electrophysiol 2008;31:592–596.
..
2009;26:513–520. .. 272. Tan MP, Newton JL, Chadwick TJ, Gray JC, Nath S, Parry SW. Home ortho-
249. Marwick TH, Nakatani S, Haluska B, Thomas JD, Lever HM. Provocation of .. static training in vasovagal syncope modifies autonomic tone: results of a
latent left ventricular outflow tract gradients with amyl nitrite and exercise in .. randomized, placebo-controlled pilot study. Europace 2010;12:240–246.
hypertrophic cardiomyopathy. Am J Cardiol 1995;75:805–809. .. 273. Verheyden B, Liu J, van Dijk N, Westerhof BE, Reybrouck T, Aubert AE,
250. Sneddon JF, Scalia G, Ward DE, McKenna WJ, Camm AJ, Frenneaux MP. .. Wieling W. Steep fall in cardiac output is main determinant of hypotension dur-
Exercise induced vasodepressor syncope. Br Heart J 1994;71:554–557. .. ing drug-free and nitroglycerine-induced orthostatic vasovagal syncope. Heart
251. Sakaguchi S, Shultz JJ, Remole SC, Adler SW, Lurie KG, Benditt DG. Syncope
.. Rhythm 2008;5:1695–1701.
..
associated with exercise, a manifestation of neurally mediated syncope. Am J .. 274. Burklow TR, Moak JP, Bailey JJ, Makhlouf FT. Neurally mediated cardiac syn-
Cardiol 1995;75:476–481. .. cope: autonomic modulation after normal saline infusion. J Am Coll Cardiol
252. Colivicchi F, Ammirati F, Biffi A, Verdile L, Pelliccia A, Santini M. Exercise- .. 1999;33:2059–2066.
related syncope in young competitive athletes without evidence of structural .. 275. Sheldon R, Raj SR, Rose MS, Morillo CA, Krahn AD, Medina E, Talajic M, Kus T,
heart disease. Clinical presentation and long-term outcome. Eur Heart J .. Seifer CM, Lelonek M, Klingenheben T, Parkash R, Ritchie D, McRae M, POST 2
2002;23:1125–1130. .. Investigators. Fludrocortisone for the prevention of vasovagal syncope: a
253. Woelfel AK, Simpson RJ Jr, Gettes LS, Foster JR. Exercise-induced distal atrio-
.. randomized, placebo-controlled trial. J Am Coll Cardiol 2016;68:1–9.
ventricular block. J Am Coll Cardiol 1983;2:578–581.
.. 276. Salim MA, Di Sessa TG. Effectiveness of fludrocortisone and salt in preventing
..
254. Byrne JM, Marais HJ, Cheek GA. Exercise-induced complete heart block in a .. syncope recurrence in children: a double-blind, placebo-controlled, randomized
patient with chronic bifascicular block. J Electrocardiol 1994;27:339–342. .. trial. J Am Coll Cardiol 2005;45:484–488.
255. Aste M, Oddone D, Donateo P, Solano A, Maggi R, Croci F, Solari D, Brignole .. 277. Raviele A, Brignole M, Sutton R, Alboni P, Giani P, Menozzi C, Moya A. Effect
M. Syncope in patients paced for atrioventricular block. Europace .. of etilefrine in preventing syncopal recurrence in patients with vasovagal syn-
2016;18:1735–1739. .. cope: a double-blind, randomized, placebo-controlled trial. The Vasovagal
256. Sumiyoshi M, Nakata Y, Yasuda M, Tokano T, Ogura S, Nakazato Y, Yamaguchi .. Syncope International Study. Circulation 1999;99:1452–1457.
H. Clinical and electrophysiologic features of exercise-induced atrioventricular
.. 278. Izcovich A, Gonzalez Malla C, Manzotti M, Catalano HN, Guyatt G. Midodrine
..
block. Am Heart J 1996;132:1277–1281. .. for orthostatic hypotension and recurrent reflex syncope: a systematic review.
257. Wissocq L, Ennezat PV, Mouquet F. Exercise-induced high-degree atrioventricu- .. Neurology 2014;83:1170–1177.
lar block. Arch Cardiovasc Dis 2009;102:733–735. .. 279. Madrid AH, Ortega J, Rebollo JG, Manzano JG, Segovia JG, Sanchez A, Pena
258. Anderson LL, Dai D, Miller AL, Roe MT, Messenger JC, Wang TY. .. G, Moro C. Lack of efficacy of atenolol for the prevention of neurally medi-
Percutaneous coronary intervention for older adults who present with syncope .. ated syncope in a highly symptomatic population: a prospective, double-
and coronary artery disease? Insights from the National Cardiovascular Data .. blind, randomized and placebo-controlled study. J Am Coll Cardiol
Registry. Am Heart J 2016;176:1–9.
.. 2001;37:554–559.
..
259. El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and .. 280. Sheldon R, Connolly S, Rose S, Klingenheben T, Krahn A, Morillo C, Talajic M,
orthostatic tolerance in patients with unexplained syncope. Heart .. Ku T, Fouad-Tarazi F, Ritchie D, Koshman ML, POST Investigators. Prevention
1996;75:134–140. .. of Syncope Trial (POST): a randomized, placebo-controlled study of metopro-
260. Solari D, Tesi F, Unterhuber M, Gaggioli G, Ungar A, Tomaino M, Brignole M. .. lol in the prevention of vasovagal syncope. Circulation 2006;113:1164–1170.
Stop vasodepressor drugs in reflex syncope: a randomised controlled trial. .. 281. Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects
Heart 2017;103:449–455. .. of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refrac-
261. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK,
.. tory vasovagal syncope: a randomized, double-blind, placebo-controlled study.
..
Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel .. J Am Coll Cardiol 1999;33:1227–1230.
PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, .. 282. Theodorakis GN, Markianos M, Zarvalis E, Livanis EG, Flevari P, Kremastinos
Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood- .. DT. Provocation of neurocardiogenic syncope by clomipramine administration
Pressure Control. N Engl J Med 2015;373:2103–2116. .. during the head-up tilt test in vasovagal syndrome. J Am Coll Cardiol
262. Brignole M, Menozzi C, Gaggioli G, Musso G, Foglia-Manzillo G, Mascioli G, .. 2000;36:174–178.
Fradella G, Bottoni N, Mureddu R. Effects of long-term vasodilator therapy in .. 283. Marquez MF, Urias-Medina K, Gomez-Flores J, Sobrino A, Sotomayor-Gonzalez
patients with carotid sinus hypersensitivity. Am Heart J 1998;136:264–268.
.. A, Gonzalez-Hermosillo A, Cardenas M. [Comparison of metoprolol vs
clonazepam as a first treatment choice among patients with neurocardiogenic .. 303. Baron-Esquivias G, Morillo CA, Moya-Mitjans A, Martinez-Alday J, Ruiz-Granell
syncope]. Gac Med Mex 2008;144:503–507.
.. R, Lacunza-Ruiz J, Garcia-Civera R, Gutierrez-Carretero E, Romero-Garrido R.
..
284. Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP. Use of octreotide in the .. Dual-chamber pacing with closed loop stimulation in recurrent reflex vasovagal
treatment of refractory orthostatic intolerance. Am J Ther 2012;19:7–10. .. syncope: the SPAIN Study. J Am Coll Cardiol 2017;70:1720–1728.
285. Brignole M, Solari D, Iori M, Bottoni N, Guieu R, Deharo JC. Efficacy of theo- .. 304. Madigan NP, Flaker GC, Curtis JJ, Reid J, Mueller KJ, Murphy TJ. Carotid sinus
phylline in patients affected by low adenosine syncope. Heart Rhythm .. hypersensitivity: beneficial effects of dual-chamber pacing. Am J Cardiol
2016;13:1151–1154. .. 1984;53:1034–1040.
286. Brignole M, Guieu R, Tomaino M, Iori M, Ungar A, Bertolone C, Unterhuber M, .. 305. Brignole M, Sartore B, Barra M, Menozzi C, Lolli G. Is DDD superior to VVI
Bottoni N, Tesi F, Claude Deharo J. Mechanism of syncope without prodromes
.. pacing in mixed carotid sinus syndrome? An acute and medium-term study.
..
with normal heart and normal electrocardiogram. Heart Rhythm .. Pacing Clin Electrophysiol 1988;11:1902–1910.
2017;14:234–239. .. 306. Sutton R. Pacing in patients with carotid sinus and vasovagal syndromes. Pacing
287. Vaddadi G, Guo L, Esler M, Socratous F, Schlaich M, Chopra R, Eikelis N, .. Clin Electrophysiol 1989;12:1260–1263.
Lambert G, Trauer T, Lambert E. Recurrent postural vasovagal syncope: sympa- .. 307. Palmisano P, Dell’Era G, Russo V, Zaccaria M, Mangia R, Bortnik M, De Vecchi
thetic nervous system phenotypes. Circ Arrhythm Electrophysiol 2011;4:711–718. ... F, Giubertoni A, Patti F, Magnani A, Nigro G, Rago A, Occhetta E, Accogli M.
288. Schroeder C, Birkenfeld AL, Mayer AF, Tank J, Diedrich A, Luft FC, Jordan J. .. Effects of closed-loop stimulation vs. DDD pacing on haemodynamic variations
Norepinephrine transporter inhibition prevents tilt-induced pre-syncope. J Am .. and occurrence of syncope induced by head-up tilt test in older patients with
Coll Cardiol 2006;48:516–522. .. refrac\tory cardioinhibitory vasovagal syncope: the Tilt test-Induced REsponse
289. Sheldon RS, Ritchie D, McRae M, Raj S. Norepinephrine transport inhibition for .. in Closed-loop Stimulation multicentre, prospective, single blind, randomized
treatment of vasovagal syncope. J Cardiovasc Electrophysiol 2013;24:799–803. .. study. Europace; doi:10.1093/europace/eux015. Published online ahead of print
290. Pachon JC, Pachon EI, Cunha Pachon MZ, Lobo TJ, Pachon JC, Santillana TG.
.. 12 April 2017.
..
Catheter ablation of severe neurally meditated reflex (neurocardiogenic or vas- .. 308. Russo V, Rago A, Papa AA, Golino P, Calabro R, Russo MG, Nigro G.
ovagal) syncope: cardioneuroablation long-term results. Europace .. The effect of dual-chamber closed-loop stimulation on syncope recurrence
2011;13:1231–1242. .. in healthy patients with tilt-induced vasovagal cardioinhibitory syncope: a
291. Aksu T, Güler TE, Bozyel S, Ozcan € KS, Yalin K, Mutluer FO. .. prospective, randomised, single-blind, crossover study. Heart 2013;99:
Cardioneuroablation in the treatment of neurally mediated reflex syncope: a .. 1609–1613.
review of the current literature. Turk Kardiyol Dern Ars 2017;45:33–41. .. 309. Brignole M, Deharo JC, Menozzi C, Moya A, Sutton R, Tomaino M, Ungar A.
292. Brignole M, Arabia F, Ammirati F, Tomaino M, Quartieri F, Rafanelli M, Del
.. The benefit of pacemaker therapy in patients with neurally-mediated syncope
..
Rosso A, Rita Vecchi M, Russo V, Gaggioli G, Syncope Unit Project 2 (SUP 2) .. and documented asystole: a meta-analysis of implantable loop recorder studies.
investigators. Standardized algorithm for cardiac pacing in older patients .. Europace; doi:10.1093/europace/eux321. Published online ahead of print 15
affected by severe unpredictable reflex syncope: 3-year insights from the .. December 2017.
Syncope Unit Project 2 (SUP 2) study. Europace 2016;18:1427–1433. .. 310. Claydon VE, Hainsworth R. Salt supplementation improves orthostatic cerebral
293. Brignole M, Menozzi C. The natural history of carotid sinus syncope and the .. and peripheral vascular control in patients with syncope. Hypertension
effect of cardiac pacing. Europace 2011;13:462–464. .. 2004;43:809–813.
294. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt .. 311. Schroeder C, Bush VE, Norcliffe LJ, Luft FC, Tank J, Jordan J, Hainsworth R.
OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW,
.. Water drinking acutely improves orthostatic tolerance in healthy subjects.
..
Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC .. Circulation 2002;106:2806–2811.
Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task .. 312. Zia A, Kamaruzzaman SB, Tan MP. Blood pressure lowering therapy in older
Force on cardiac pacing and resynchronization therapy of the European Society .. people: does it really cause postural hypotension or falls? Postgrad Med
of Cardiology (ESC). Developed in collaboration with the European Heart .. 2015;127:186–193.
Rhythm Association (EHRA). Eur Heart J 2013;34:2281–2329. .. 313. Verwoert GC, Mattace-Raso FU, Hofman A, Heeringa J, Stricker BH, Breteler
295. Gaggioli G, Brignole M, Menozzi C, Devoto G, Oddone D, Gianfranchi L, .. MM, Witteman JC. Orthostatic hypotension and risk of cardiovascular disease
Gostoli E, Bottoni N, Lolli G. A positive response to head-up tilt testing pre-
.. in elderly people: the Rotterdam study. J Am Geriatr Soc 2008;56:1816–1820.
..
dicts syncopal recurrence in carotid sinus syndrome patients with permanent .. 314. Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between
pacemakers. Am J Cardiol 1995;76:720–722. .. orthostatic hypotension and medication use in the British Women’s Heart and
296. Connolly SJ, Sheldon R, Roberts RS, Gent M. The North American Vasovagal .. Health Study. Age Ageing 2010;39:51–56.
Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the .. 315. Valbusa F, Labat C, Salvi P, Vivian ME, Hanon O, Benetos A, PARTAGE investi-
prevention of vasovagal syncope. J Am Coll Cardiol 1999;33:16–20. .. gators. Orthostatic hypotension in very old individuals living in nursing homes:
297. Sutton R, Brignole M, Menozzi C, Raviele A, Alboni P, Giani P, Moya A. Dual- .. the PARTAGE study. J Hypertens 2012;30:53–60.
chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibi-
.. 316. Romero-Ortuno R, O’Connell MD, Finucane C, Soraghan C, Fan CW, Kenny
..
tory syncope: pacemaker versus no therapy: a multicenter randomized study. .. RA. Insights into the clinical management of the syndrome of supine
The Vasovagal Syncope International Study (VASIS) Investigators. Circulation .. hypertension–orthostatic hypotension (SH-OH): the Irish Longitudinal Study
2000;102:294–299. .. on Ageing (TILDA). BMC Geriatr 2013;13:73.
298. Ammirati F, Colivicchi F, Santini M, Syncope Diagnosis and Treatment Study .. 317. Canney M, O’Connell MD, Murphy CM, O’Leary N, Little MA, O’Seaghdha CM,
Investigators. Permanent cardiac pacing versus medical treatment for the pre- .. Kenny RA. Single agent antihypertensive therapy and orthostatic blood pressure
vention of recurrent vasovagal syncope: a multicenter, randomized, controlled .. behaviour in older adults using beat-to-beat measurements: the Irish
trial. Circulation 2001;104:52–57.
.. Longitudinal Study on Ageing. PLoS One 2016;11:e0146156.
..
299. Connolly SJ, Sheldon R, Thorpe KE, Roberts RS, Ellenbogen KA, Wilkoff BL, .. 318. Fogari R, Zoppi A, Mugellini A, Corradi L, Lazzari P, Preti P, Derosa G. Efficacy
Morillo C, Gent M, VPS II Investigators. Pacemaker therapy for prevention of .. and safety of two treatment combinations of hypertension in very elderly
syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal .. patients. Arch Gerontol Geriatr 2009;48:401–405.
Pacemaker Study (VPS II): a randomized trial. JAMA 2003;289:2224–2229. .. 319. van Lieshout JJ, ten Harkel AD, Wieling W. Physical manoeuvres for combating
300. Raviele A, Giada F, Menozzi C, Speca G, Orazi S, Gasparini G, Sutton R, .. orthostatic dizziness in autonomic failure. Lancet 1992;339:897–898.
Brignole M, Vasovagal Syncope and Pacing Trial Investigators. A randomized, .. 320. Smit AA, Wieling W, Fujimura J, Denq JC, Opfer-Gehrking TL, Akarriou M,
double-blind, placebo-controlled study of permanent cardiac pacing for the .. Karemaker JM, Low PA. Use of lower abdominal compression to combat
treatment of recurrent tilt-induced vasovagal syncope. The Vasovagal Syncope
.. orthostatic hypotension in patients with autonomic dysfunction. Clin Auton Res
..
and Pacing Trial (SYNPACE). Eur Heart J 2004;25:1741–1748. .. 2004;14:167–175.
301. Sud S, Massel D, Klein GJ, Leong-Sit P, Yee R, Skanes AC, Gula LJ, Krahn AD. .. 321. Fanciulli A, Goebel G, Metzler B, Sprenger F, Poewe W, Wenning GK, Seppi K.
The expectation effect and cardiac pacing for refractory vasovagal syncope. Am .. Elastic abdominal binders attenuate orthostatic hypotension in Parkinson’s dis-
J Med 2007;120:54–62. .. ease. Mov Dis Clin Practice 2015;3:156–160.
302. Brignole M, Donateo P, Tomaino M, Massa R, Iori M, Beiras X, Moya A, Kus T, .. 322. Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypoten-
Deharo JC, Giuli S, Gentili A, Sutton R, International Study on Syncope of .. sion with sleeping in the head-up tilt position, alone and in combination with
Uncertain Etiology 3 (ISSUE-3) Investigators. Benefit of pacemaker therapy in
.. fludrocortisone. J Intern Med 1992;232:139–145.
..
patients with presumed neurally mediated syncope and documented asystole is .. 323. Omboni S, Smit AA, van Lieshout JJ, Settels JJ, Langewouters GJ, Wieling W.
greater when tilt test is negative: an analysis from the third International Study .. Mechanisms underlying the impairment in orthostatic tolerance after nocturnal
on Syncope of Uncertain Etiology (ISSUE-3). Circ Arrhythm Electrophysiol .. recumbency in patients with autonomic failure. Clin Sci (Lond) 2001;101:
2014;7:10–16. . 609–618.
324. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M,
.. 346. Morady F, Higgins J, Peters RW, Schwartz AB, Shen EN, Bhandari A, Scheinman
..
Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double-blind, placebo- .. MM, Sauve MJ. Electrophysiologic testing in bundle branch block and unex-
controlled study with midodrine. Am J Med 1993;95:38–48. .. plained syncope. Am J Cardiol 1984;54:587–591.
325. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of .. 347. Tabrizi F, Rosenqvist M, Bergfeldt L, Englund A. Long-term prognosis in patients
midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, .. with bifascicular block–the predictive value of noninvasive and invasive assess-
double-blind multicenter study. Midodrine Study Group. JAMA 1997;277: .. ment. J Intern Med 2006;260:31–38.
1046–1051. .. 348. Ruwald MH, Okumura K, Kimura T, Aonuma K, Shoda M, Kutyifa V, Ruwald
326. Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng
.. AC, McNitt S, Zareba W, Moss AJ. Syncope in high-risk cardiomyopathy
..
KN, Low PA. A double-blind, dose-response study of midodrine in neurogenic .. patients with implantable defibrillators: frequency, risk factors, mechanisms, and
orthostatic hypotension. Neurology 1998;51:120–124. .. association with mortality: results from the multicenter automatic defibrillator
327. van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the .. implantation trial-reduce inappropriate therapy (MADIT-RIT) study. Circulation
head-up position limit the postural decrease in cardiac output in autonomic fail- .. 2014;129:545–552.
ure. Clin Auton Res 2000;10:35–42. .. 349. Sacher F, Probst V, Maury P, Babuty D, Mansourati J, Komatsu Y, Marquie C,
328. Finke J, Sagemuller I. [Fludrocortisone in the treatment of orthostatic hypoten- .. Rosa A, Diallo A, Cassagneau R, Loizeau C, Martins R, Field ME, Derval N,
sion: ophthalmodynamography during standing(author’s transl)]. Dtsch Med
.. Miyazaki S, Denis A, Nogami A, Ritter P, Gourraud JB, Ploux S, Rollin A,
..
Wochenschr 1975;100:1790–1792. .. Zemmoura A, Lamaison D, Bordachar P, Pierre B, Jais P, Pasquie JL, Hocini M,
329. Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, .. Legal F, Defaye P, Boveda S, Iesaka Y, Mabo P, Haissaguerre M. Outcome after
Feirtag M, Mathias CJ, NOH301 Investigators. Droxidopa for neurogenic ortho- .. implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a
static hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology .. multicenter study-part 2. Circulation 2013;128:1739–1747.
2014;83:328–335. .. 350. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, Biagini E,
330. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short- .. Gimeno JR, Limongelli G, McKenna WJ, Omar RZ, Elliott PM, Hypertrophic
term treatment of symptomatic neurogenic orthostatic hypotension in
.. Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model
..
Parkinson’s disease (nOH306B). Mov Disord 2015;30:646–654. .. for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur
331. Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa .. Heart J 2014;35:2010–2020.
302 Investigators. Randomized withdrawal study of patients with symptomatic .. 351. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward
neurogenic orthostatic hypotension responsive to droxidopa. Hypertension .. D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes NA
2015;65:101–107. .. III, Wichter T, McKenna WJ, Thiene G, Marcus FI. Prophylactic implantable
332. Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic .. defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/
orthostatic hypotension associated with Parkinson’s disease (NOH306A).
.. dysplasia and no prior ventricular fibrillation or sustained ventricular tachycar-
..
J Parkinsons Dis 2014;4:57–65. .. dia. Circulation 2010;122:1144–1152.
333. Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A. Meta- .. 352. Liu JF, Jons C, Moss AJ, McNitt S, Peterson DR, Qi M, Zareba W, Robinson JL,
analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypo- .. Barsheshet A, Ackerman MJ, Benhorin J, Kaufman ES, Locati EH, Napolitano C,
tension. Clin Auton Res 2016;26:171–180. .. Priori SG, Schwartz PJ, Towbin J, Vincent M, Zhang L, Goldenberg I,
334. Alboni P, Menozzi C, Brignole M, Paparella N, Gaggioli G, Lolli G, Cappato R. .. International Long QT Syndrome Registry. Risk factors for recurrent syncope
Effects of permanent pacemaker and oral theophylline in sick sinus syndrome .. and subsequent fatal or near-fatal events in children and adolescents with long
the THEOPACE study: a randomized controlled trial. Circulation .. QT syndrome. J Am Coll Cardiol 2011;57:941–950.
1997;96:260–266.
.. 353. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, Babuty D,
..
335. Breivik K, Ohm OJ, Segadal L. Sick sinus syndrome treated with permanent .. Sacher F, Giustetto C, Schulze-Bahr E, Borggrefe M, Haissaguerre M, Mabo P,
pacemaker in 109 patients. A follow-up study. Acta Med Scand .. Le Marec H, Wolpert C, Wilde AA. Long-term prognosis of patients diagnosed
1979;206:153–159. .. with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry.
336. Hartel G, Talvensaari T. Treatment of sinoatrial syndrome with permanent car- .. Circulation 2010;121:635–643.
diac pacing in 90 patients. Acta Med Scand 1975;198:341–347. .. 354. Spirito P, Autore C, Rapezzi C, Bernabo P, Badagliacca R, Maron MS,
337. Rasmussen K. Chronic sinus node disease: natural course and indications for .. Bongioanni S, Coccolo F, Estes NA, Barilla CS, Biagini E, Quarta G, Conte MR,
pacing. Eur Heart J 1981;2:455–459.
.. Bruzzi P, Maron BJ. Syncope and risk of sudden death in hypertrophic cardio-
..
338. Sasaki Y, Shimotori M, Akahane K, Yonekura H, Hirano K, Endoh R, Koike S, .. myopathy. Circulation 2009;119:1703–1710.
Kawa S, Furuta S, Homma T. Long-term follow-up of patients with sick sinus .. 355. Conte G, Sieira J, Ciconte G, de Asmundis C, Chierchia GB, Baltogiannis G, Di
syndrome: a comparison of clinical aspects among unpaced, ventricular inhibited .. Giovanni G, La Meir M, Wellens F, Czapla J, Wauters K, Levinstein M, Saitoh Y,
paced, and physiologically paced groups. Pacing Clin Electrophysiol .. Irfan G, Julia J, Pappaert G, Brugada P. Implantable cardioverter-defibrillator
1988;11:1575–1583. .. therapy in Brugada syndrome: a 20-year single-center experience. J Am Coll
339. Sgarbossa EB, Pinski SL, Jaeger FJ, Trohman RG, Maloney JD. Incidence and pre- .. Cardiol 2015;65:879–888.
dictors of syncope in paced patients with sick sinus syndrome. Pacing Clin
.. 356. Olde Nordkamp LR, Vink AS, Wilde AA, de Lange FJ, de Jong JS, Wieling W,
..
Electrophysiol 1992;15:2055–2060. .. van Dijk N, Tan HL. Syncope in Brugada syndrome: prevalence, clinical signifi-
340. Ng Kam Chuen MJ, Kirkfeldt RE, Andersen HR, Nielsen JC. Syncope in paced .. cance, and clues from history taking to distinguish arrhythmic from nonarrhyth-
patients with sick sinus syndrome from the DANPACE trial: incidence, predic- .. mic causes. Heart Rhythm 2015;12:367–375.
tors and prognostic implication. Heart 2014;100:842–847. .. 357. Olde Nordkamp LR, Wilde AA, Tijssen JG, Knops RE, van Dessel PF, de Groot
341. Langenfeld H, Grimm W, Maisch B, Kochsiek K. Course of symptoms and spon- .. JR. The ICD for primary prevention in patients with inherited cardiac diseases:
taneous ECG in pacemaker patients: a 5-year follow-up study. Pacing Clin .. indications, use, and outcome: a comparison with secondary prevention. Circ
Electrophysiol 1988;11:2198–2206.
.. Arrhythm Electrophysiol 2013;6:91–100.
..
342. Donateo P, Brignole M, Alboni P, Menozzi C, Raviele A, Del Rosso A, Dinelli .. 358. Spezzacatene A, Sinagra G, Merlo M, Barbati G, Graw SL, Brun F, Slavov D, Di
M, Solano A, Bottoni N, Croci F. A standardized conventional evaluation of the .. Lenarda A, Salcedo EE, Towbin JA, Saffitz JE, Marcus FI, Zareba W, Taylor MR,
mechanism of syncope in patients with bundle branch block. Europace .. Mestroni L, Familial Cardiomyopathy Registry. Arrhythmogenic Phenotype in
2002;4:357–360. .. Dilated Cardiomyopathy: Natural History and Predictors of Life-Threatening
343. Azocar D, Ruiz-Granell R, Ferrero A, Martinez-Brotons A, Izquierdo M, .. Arrhythmias. J Am Heart Assoc 2015;4:e002149.
Dominguez E, Palau P, Morell S, Garcia-Civera R. Syncope and bundle branch .. 359. Russo AM, Verdino R, Schorr C, Nicholas M, Dias D, Hsia H, Callans D,
block. Diagnostic yield of a stepped use of electrophysiology study and implant- .. Marchlinski FE. Occurrence of implantable defibrillator events in patients with
able loop recorders. Rev Esp Cardiol 2011;64:213–219.
.. syncope and nonischemic dilated cardiomyopathy. Am J Cardiol
..
344. Santini M, Castro A, Giada F, Ricci R, Inama G, Gaggioli G, Calo L, Orazi S, .. 2001;88:1444–1446, A1449.
Viscusi M, Chiodi L, Bartoletti A, Foglia-Manzillo G, Ammirati F, Loricchio ML, .. 360. Phang RS, Kang D, Tighiouart H, Estes NA III, Link MS. High risk of ventricular
Pedrinazzi C, Turreni F, Gasparini G, Accardi F, Raciti G, Raviele A. Prevention .. arrhythmias in patients with nonischemic dilated cardiomyopathy presenting
of syncope through permanent cardiac pacing in patients with bifascicular block .. with syncope. Am J Cardiol 2006;97:416–420.
and syncope of unexplained origin: the PRESS study. Circ Arrhythm Electrophysiol .. 361. Christiaans I, van Engelen K, van Langen IM, Birnie E, Bonsel GJ, Elliott PM,
2013;6:101–107. .. Wilde AA. Risk stratification for sudden cardiac death in hypertrophic cardio-
345. Englund A, Bergfeldt L, Rehnqvist N, Astrom H, Rosenqvist M. Diagnostic value
.. myopathy: systematic review of clinical risk markers. Europace
..
of programmed ventricular stimulation in patients with bifascicular block: a pro- .. 2010;12:313–321.
spective study of patients with and without syncope. J Am Coll Cardiol .. 362. Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, Bauce
1995;26:1508–1515. . B, Basso C, Brunckhorst C, Tsatsopoulou A, Tandri H, Paul M, Schmied C,
409. Siderowf A, Lang AE. Premotor Parkinson’s disease: concepts and definitions. .. 426. Thijs RD, Kruit MC, van Buchem MA, Ferrari MD, Launer LJ, van Dijk JG.
Mov Disord 2012;27:608–616.
.. Syncope in migraine: the population-based CAMERA study. Neurology
..
410. Hoefnagels WA, Padberg GW, Overweg J, van der Velde EA, Roos RA. .. 2006;66:1034–1037.
Transient loss of consciousness: the value of the history for distinguishing seiz- .. 427. Overeem S, van Nues SJ, van der Zande WL, Donjacour CE, van Mierlo P, Lammers
ure from syncope. J Neurol 1991;238:39–43. .. GJ. The clinical features of cataplexy: a questionnaire study in narcolepsy patients
411. Benbadis SR, Wolgamuth BR, Goren H, Brener S, Fouad-Tarazi F. Value of .. with and without hypocretin-1 deficiency. Sleep Med 2011;12:12–18.
tongue biting in the diagnosis of seizures. Arch Intern Med 1995;155:2346–2349. .. 428. Stevens DL, Matthews WB. Cryptogenic drop attacks: an affliction of women.
412. van der Lende M, Surges R, Sander JW, Thijs RD. Cardiac arrhythmias during or .. Br Med J 1973;1:439–442.
after epileptic seizures. J Neurol Neurosurg Psychiatry 2016;87:69–74.
.. 429. Fanciulli A, Indelicato E, Wenning GK. Autonomic history taking and key symp-
..
413. Rugg-Gunn FJ, Simister RJ, Squirrell M, Holdright DR, Duncan JS. Cardiac .. toms: where is the autonomic disease? In: A Fanciulli et al (eds). Bedside Approach
arrhythmias in focal epilepsy: a prospective long-term study. Lancet .. to Autonomic Disorders A Clinical Tutor. Cham: Springer Verlag; 2017, 15–36.
2004;364:2212–2219. .. 430. Abubakr A, Wambacq I. The diagnostic value of EEGs in patients with syncope.
414. Benditt DG, van Dijk G, Thijs RD. Ictal asystole: life-threatening vagal storm or .. Epilepsy Behav 2005;6:433–434.
a benign seizure self-termination mechanism? Circ Arrhythm Electrophysiol ... 431. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med
2015;8:11–14. .. 2008;358:615–624.
415. Rocamora R, Kurthen M, Lickfett L, Von Oertzen J, Elger CE. Cardiac asystole in .. 432. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles
epilepsy: clinical and neurophysiologic features. Epilepsia 2003;44:179–185. .. of patients seropositive for type 1 antineuronal nuclear autoantibodies.
416. Schuele SU, Bermeo AC, Alexopoulos AV, Locatelli ER, Burgess RC, Dinner .. Neurology 1998;50:652–657.
DS, Foldvary-Schaefer N. Video-electrographic and clinical features in patients .. 433. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA.
with ictal asystole. Neurology 2007;69:434–441.
.. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic
..
417. Ghearing GR, Munger TM, Jaffe AS, Benarroch EE, Britton JW. Clinical cues for .. neuropathies. N Engl J Med 2000;343:847–855.
detecting ictal asystole. Clin Auton Res 2007;17:221–226. .. 434. McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ. Ganglionic acetyl-
418. Bestawros M, Darbar D, Arain A, Abou-Khalil B, Plummer D, Dupont WD, Raj .. choline receptor autoantibody: oncological, neurological, and serological
SR. Ictal asystole and ictal syncope: insights into clinical management. Circ .. accompaniments. Arch Neurol 2009;66:735–741.
Arrhythm Electrophysiol 2015;8:159–164. .. 435. Dantas FG, Cavalcanti AP, Rodrigues Maciel BD, Ribeiro CD, Napy Charara
419. Lamberts RJ, Thijs RD, Laffan A, Langan Y, Sander JW. Sudden unexpected .. GC, Lopes JM, Martins Filho PF, Junior LA. The role of EEG in patients with syn-
death in epilepsy: people with nocturnal seizures may be at highest risk.
.. cope. J Clin Neurophysiol 2012;29:55–57.
..
Epilepsia 2012;53:253–257. .. 436. Kapoor WN, Karpf M, Maher Y, Miller RA, Levey GS. Syncope of unknown ori-
420. Lamberts RJ, Blom MT, Wassenaar M, Bardai A, Leijten FS, de Haan GJ, Sander .. gin. The need for a more cost-effective approach to its diagnosis evaluation.
JW, Thijs RD, Tan HL. Sudden cardiac arrest in people with epilepsy in the .. JAMA 1982;247:2687–2691.
community: Circumstances and risk factors. Neurology 2015;85:212–218. .. 437. Farwell DJ, Sulke AN. Does the use of a syncope diagnostic protocol
421. Horrocks IA, Nechay A, Stephenson JB, Zuberi SM. Anoxic-epileptic seizures: .. improve the investigation and management of syncope? Heart 2004;90:
observational study of epileptic seizures induced by syncopes. Arch Dis Child .. 52–58.
2005;90:1283–1287. .. 438. Mendu ML, McAvay G, Lampert R, Stoehr J, Tinetti ME. Yield of diagnostic tests
422. Hennerici M, Klemm C, Rautenberg W. The subclavian steal phenomenon: a com-
.. in evaluating syncopal episodes in older patients. Arch Intern Med
..
mon vascular disorder with rare neurologic deficits. Neurology 1988;38:669–673. .. 2009;169:1299–1305.
423. Melgar MA, Weinand ME. Thyrocervical trunk-external carotid artery bypass .. 439. Schnipper JL, Ackerman RH, Krier JB, Honour M. Diagnostic yield and utility of
for positional cerebral ischemia due to common carotid artery occlusion. .. neurovascular ultrasonography in the evaluation of patients with syncope. Mayo
Report of three cases. Neurosurg Focus 2003;14:e7. .. Clin Proc 2005;80:480–488.
424. Dobkin BH. Orthostatic hypotension as a risk factor for symptomatic occlusive .. 440. Kadian-Dodov D, Papolos A, Olin JW. Diagnostic utility of carotid artery duplex
cerebrovascular disease. Neurology 1989;39:30–34. .. ultrasonography in the evaluation of syncope: a good test ordered for the
425. Savitz SI, Caplan LR. Vertebrobasilar disease. N Engl J Med 2005;352:2618–2626.
.. wrong reason. Eur Heart J Cardiovasc Imaging 2015;16:621–625.
..
.